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Abstract 
 
 Subclinical mastitis remains the dominant form of mastitis affecting dairy cattle, 
and is responsible for the greatest economic losses associated with mastitis in dairy herds 
in the major dairy producing countries.  Mastitis control has relied on a series of well 
established management practices that have led to significant improvements in mastitis 
prevalence and milk quality measures over the past 3 decades.  Changes in pathogen 
prevalence, including the shift in absolute and relative importance of pathogens such as 
Escherichia coli, Klebsiella spp. and Streptococcus uberis combined with the ongoing 
importance of Staphylococcus aureus, highlight the need for continued research to 
evaluate mastitis control practices.  
 
 This dissertation examines targeted antimicrobial treatment of chronic subclinical 
mastitis during lactation as a control measure implemented in herds that have applied 
standard mastitis control practices.  Treatment of subclinical mastitis caused by the major 
gram-positive mastitis pathogens Staphylococcus aureus, Streptococcus uberis, and 
Streptococcus dysgalactiae in dairy herds is examined.  Methods include predictive 
modeling of the effects of lactation therapy using a deterministic state-transition model of 
pathogen transmission dynamics, and evaluation of lactation treatment in a negative 
controlled clinical field trial. Concepts put forward include the distinction between direct 
and indirect effects of mastitis control practices and the value of molecular diagnostics to 
improve our understanding of mastitis epidemiology and the impact of control programs. 
  
Results obtained from predictive modeling indicate that overall positive 
population level effects of lactation therapy would be realized for herds that have 
successfully implemented practices that reduce pathogen transmission.  A novel finding 
was the prediction that under management scenarios with high pathogen transmission 
rates treatment of subclinical mastitis will have little impact on the proportion of infected 
quarters and no positive population level effect in reducing new infection rates.  In a field 
trial, positive direct and indirect effects of treatment of S. aureus mastitis were observed 
suggesting benefits of lactation therapy targeting this pathogen.  Potential benefits were 
off-set by the frequent finding of post treatment infections which resulted in no 
improvement in somatic cell count of treated cows compared to untreated controls. 
Lactation therapy of S. uberis and S. dysgalactiae mastitis resulted in cure proportions 
and duration of infection did not differ from spontaneous cure of untreated controls and 
there was limited evidence of an effect of treatment on rates of new infection. A unique 
finding was the identification of an association between Coxiella burnetii shedding and 
subclinical mastitis in dairy cattle. 
 
It is concluded from this research that treatment of subclinical mastitis during 
lactation may be justified under specific conditions, and it is recommended that dairy 
farm managers and their advisors should not routinely implement lactation therapy of 
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Subclinical mastitis: Identification, causes and significance for dairy herds 
Mastitis continues to be recognized as the most common and costly disease 
affecting dairy cattle (DeGraves and Fetrow, 1993; Fetrow et al., 2000).  Mastitis is an 
inflammation of the mammary gland, and while it may have a variety of causes, bacterial 
infections are the predominant cause of mastitis among dairy cattle (Philpot and Pankey, 
1975; Watts, 1988; Wellenberg et al., 2002).  To be clear, the term mastitis is a non-
specific descriptor of inflammatory changes of the mammary gland for which there are 
numerous etiologies. From a practical perspective, mastitis of dairy cattle is the response 
of the gland to an infection typically acquired by invasion of bacterial pathogens through 
the teat orifice and teat canal (streak canal). Infectious organisms may also enter the 
gland by hematogenous or percutaneous routes (Kennedy and Miller, 1993), although 
these routes are considered significantly less important in the context of practical mastitis 
control.  The stages of the infection process, (from contamination of the teat end with a 
potential pathogen, to penetration of the teat duct by the pathogen, and establishment of 
the pathogen in the gland), have been described with references to the value of specific 
mastitis control practices (Bramley and Dodd, 1984). 
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The term intramammary infection (IMI) is not strictly synonymous with the term 
mastitis, as IMI is more commonly used in the context of a defined etiology following 
completion of diagnostic culture procedures.  IMI refers to infection of ductal and 
secretory glandular tissues (mammary gland parenchyma) and/or lumenal spaces (i.e. 
alveolar and ductal lumen, gland cistern, teat cistern).  In perhaps the most 
comprehensive review of bacterial organisms associated with bovine mastitis, Watts 
(1988) listed 137 species. In comparison Philpot and Pankey (1975) reported on a broader 
range of 86 species and groups of microorganisms associated with bovine mastitis that 
included eukaryotes (e.g. yeast, fungi, and algae), many of the bacterial species described 
by Watts, and viruses.  Wellenberg et al. (2002)  have reviewed the viruses that either 
have been associated with mammary inflammation or isolated from mammary secretions. 
Similar to some of the viruses, a number of the bacterial species that have been isolated 
from bovine milk are associated with minimal inflammatory changes (e.g. 
Mycobacterium spp., including M. bovis, M. tuberculosis, and M. paratuberculosis, 
Brucella spp., Salmonella spp., and Listeria spp.) and are frequently found in cases of 
concurrent systemic infection caused by these organisms (Watts, 1988; Kennedy and 
Miller, 1993). In some cases the mammary gland may act as source of exposure for 
transfer of organisms to neonates or other potential hosts, as also occurs for some of the 
helminth parasites (Watts, 1988; Kennedy and Miller, 1993).  Philpot and Pankey (1975) 
have suggested some organisms included in their review “are not true pathogens of the 
bovine udder,” but may be present as secondary invaders.  These authors advise that 
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individual case reports describing isolation of organisms from mammary secretions often 
do not provide conclusive evidence of an association with mastitis.   
The most common bacteria associated with mastitis include species of the 
Staphylococcaceae, Streptococcaceae, Enterococcaceae, Enterobacteriaceae and 
Corynebacteriaceae families. The organisms commonly isolated from cases of mastitis 
have been categorized as ‘major’ or ‘minor’ pathogens based on the extent of clinical 
symptoms, effect on inflammatory response, milk yield and milk composition (Griffin et 
al., 1977). Minor pathogens include the coagulase-negative staphylococci and the 
corynebacteria. Major pathogens include Staphylococcus aureus, the streptococci, and 
various gram-negative coliform bacteria (Griffin et al., 1977). Two of the most important 
species of bacteria that cause mastitis in dairy cattle are the gram-positive pathogens 
Staphylococcus aureus and Streptococcus uberis (Bramley and Dodd, 1984; Hillerton et 
al., 1995; Hillerton and Berry, 2005).  Infections of the mammary gland, including those 
caused by S. aureus or S. uberis, may be symptomatic (clinical) or asymptomatic 
(subclinical).  Further, individual infections can be of short (transient) or extended 
(persistent or chronic) duration. Frequently the definition of short versus long duration 
IMI is one of convenience driven by the sampling frequency of surveillance studies, 
although it appears to be commonly accepted that IMI of < 1 month (i.e. 28 to 30 days) 
may be regarded as a short duration, and an IMI of ≥ 1 month would be defined as 
chronic (Schukken et al., 2003; St Rose et al., 2003). Finally, clinical cases may be 
characterized by the degree of severity, ranging from mild to severe based on both local 
and/or systemic signs (Wenz et al., 2006). Thus IMI may range in character from short 
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duration mild to severe clinical cases, or from short to long duration subclinical cases, 
and the categories of clinical and subclinical are not exclusive (Dodd and Neave, 1970) 
(figure 1.1).  Persistent intramammary infections can be characterized by extended 
periods of subclinical mastitis punctuated by one or more clinical episodes (Dodd and 
Neave, 1970; Zadoks et al., 2002a). Chronic subclinical infections are known to persist 
for as long as the duration of a lactation and may persist across multiple lactations 
(Hillerton and Berry, 2003).  
 
 























Figure 1.1  The pattern of intramammary infection status.  Uninfected susceptible quarters become infected 
and infection is first observed as either clinical or subclinical (A).  Infected quarters may transition into and 
out of the clinical and subclinical states (B), with subclinical mastitis being the dominant form. 
Spontaneous recovery is possible from either infected state to an uninfected susceptible state (C). 
Antimicrobial treatment of a clinical quarter may result in either clinical cure (D1) shifting the infection to 
a subclinical state, or bacteriologic cure (D2) moving the quarter to an uninfected state.  The successful 
treatment of subclinically infected quarters shifts the quarter to an uninfected state (E). Adapted from Dodd 




In most herds, subclinical mastitis is the dominant form, and is responsible for the 
greatest economic losses due to reduced milk production (Fetrow et al., 2000).  Chronic 
subclinical infections have long been recognized as a major barrier in the control of 
mastitis on dairy farms (Bramley, 1984; Hillerton and Berry, 2005).  Although 
subclinical mastitis is the dominant form affecting cows, it frequently goes undetected or 
untreated for extended periods by most dairy producers (Bramley and Dodd, 1984; 
Hillerton and Berry, 2003; Oliver et al., 2004).  Subclinical mastitis can be detected by 
increases in milk somatic cell count (SCC).  Milk somatic cells include lymphocytes, 
macrophages, polymorphonuclear leukocytes (neutrophils), and epithelial cells. Changes 
in the relative and absolute leukocyte (white blood cell) counts of milk can be used to 
distinguish infected and uninfected mammary glands or quarters (Leitner et al., 2000; 
Detilleux, 2004).  Increases in milk SCC are associated with reduced milk production, 
and SCC has been used as a measure of herd or regional milk quality and mastitis 
prevalence.  The recent USDA-APHIS National Animal Health Monitoring System 
(NAHMS) Dairy 2007 report, indicates that only 6.7% of U.S. dairy producers surveyed 
achieve a bulk tank milk SCC (BTSCC) of < 200,000 cells/ml.  BTSCC was between 
200,000 and 400,000 cells/ml for 37.1% of producers, with 83% of all milk shipped being 
less than 400,000 cells/ml (United States Department of Agriculture, 2008).  Ott and 
Novak (2001) reported that herds with bulk tank milk SCC <200,000 cells/ml generated 
between $100 and $300 per cow per year more then herds in higher BTSCC categories, 
consistent with previous estimates of mastitis costs (DeGraves and Fetrow, 1993). The 
high prevalence of subclinical mastitis among dairy cattle is a critical health issue 
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resulting in significant losses in productivity.  Many U.S. dairy producers have an 
opportunity to enhance milk quality and profitability by minimizing subclinical mastitis. 
This will become even more important when the U.S. decides to implement milk quality 
limits (e.g. BTSCC < 400,000 cells/ml) that are in line with most developed countries. 
The introduction of cow level SCC testing at regular intervals provides information that 
can be used by producers or their advisors to identify subclinically infected cows 
(Bramley and Dodd, 1984).  A threshold of 200,000 cells/ml has been recommended to 
distinguish between uninfected and infected quarters or cows (Dohoo, 1991; Smith et al., 
2001; Schukken et al., 2003; Hillerton and Berry, 2005) and results of sequential monthly 
SCC testing can be used to identify cows with chronic subclinical mastitis (Schukken et 
al., 2003).   
 
Mastitis control on dairy farms: current practices 
Current mastitis control recommendations are designed to reduce the duration of 
infections and prevent new infections (Neave et al., 1969; Dodd et al., 1977). A series of 
large field trials conducted by the National Institute for Research in Dairying (NIRD) and 
the Central Veterinary Laboratory of the UK (Dodd and Neave, 1970; Kingwill et al., 
1970) demonstrated the efficacy of the “Five Point Mastitis Control Plan” in reducing 
incidence and duration of the most common mastitis pathogens of that period.  Specific 
components of this program include: 1) appropriate treatment and record keeping of 
clinical mastitis cases, 2) application of post-milking teat disinfectants (PMTD), 3) use of 
long acting intramammary antibiotic preparations in all cows at the end of lactation (i.e. 
 7 
“dry-cow therapy” at “dry-off”), 4) culling or segregation of ‘chronically’ infected cows, 
and 5) annual milking machine evaluation and repair.  Bramley and Dodd (1984) have 
reviewed how specific components of this plan influence the risk for infection.  The 
widespread adoption of the five-point mastitis control plan is likely in great part because 
farmers are able to apply the practices with limited increases in labor and no need to rely 
on diagnostic procedures (Dodd et al., 1977). The adoption of these control practices has 
led to the successful control of contagious pathogens, especially Streptococcus 
agalactiae, and the significant reduction in Staphylococcus aureus and Streptococcus 
dysgalactiae.  This has resulted in reduced incidence of clinical mastitis and overall 
reductions in BTSCC on a national scale in the major dairy producing countries in both 
the Northern and Southern hemispheres over the past decades (Myllys et al., 1998; 
Bradley and Green, 2001; Forshell and Østerås, 2001; McDougall, 2002; van Schaik et 
al., 2002; Pitkälä et al., 2004; Hillerton and Berry, 2005; Piepers et al., 2007).  
Concurrent with these changes, a number of authors have recognized a shift in the 
dominant species of bacteria causing clinical and subclinical mastitis over the past 40 
years (Myllys et al., 1994; Bradley and Green, 2001; Forshell and Østerås, 2001; Bradley, 
2002; Pitkälä et al., 2004; Hillerton and Berry, 2005; Sampimon et al., 2005; Piepers et 
al., 2007).  Two important trends are worth note. First, while the prevalence of S. aureus 
has declined, this pathogen remains an important cause of mastitis, in many surveys 
representing the most frequently isolated major pathogen (Wilson et al., 1997; Makovec 
and Ruegg, 2003; Pitkälä et al., 2004; Sampimon et al., 2005; Østerås et al., 2006; 
Piepers et al., 2007). Second, the streptococcal species, especially S. uberis, and the 
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coliform bacteria, especially Escherichia coli and Klebsiella spp., have increased in 
relative importance as a cause of both clinical and subclinical mastitis (Bramley, 1984; 
Bradley and Green, 2001; Bradley, 2002; McDougall, 2002; Makovec and Ruegg, 2003; 
Hillerton and Berry, 2005; Dogan et al., 2006).  Clearly there is continued opportunity to 
improve mastitis control, warranting investigations of practices that may be readily 
integrated with established control programs.  The detection and treatment of subclinical 
mastitis cases during lactation has received some attention in this regard, although has 
been assumed not to be cost effective (McDermott et al., 1983; Hillerton and Berry, 
2003). Recent work has suggested that treatment of subclinical mastitis cases during 
lactation may be economically beneficial under some management scenarios (Swinkels et 
al., 2005a; Swinkels et al., 2005b; Salat et al., 2008). 
 
Mastitis treatment in dairy cattle and treatment of subclinical mastitis during lactation 
Treatment of mastitis accounts for a major use of antimicrobials in dairy cattle 
and many current protocols for clinical mastitis may be ineffective (Hillerton and Kliem, 
2002; Zwald et al., 2004; Sawant et al., 2005; Pol and Ruegg, 2007). Clinical mastitis is 
readily observed, and is frequently treated with the goal of returning milk to a normal 
marketable consistency (clinical cure) but often treatment is given without specific 
information on the cause of infection (Bramley and Dodd, 1984). Appropriate 
antimicrobial selection based on pharmacokinetic and pharmacodynamic principles must 
be considered when selecting drug, dose concentration, and dosing frequency to achieve 
minimum inhibitory concentrations at the site of infection.  Commercially available 
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intramammary antimicrobial formulations are administered as an infusion through the 
teat canal using single dose syringes with specially designed applicator tips.  
Appropriately selected systemic therapies may be as efficacious as intramammary 
preparations (Sérieys et al., 2005; Salat et al., 2008; Sandgren et al., 2008), and lipid 
solubility appears to be a key factor affecting distribution to the mammary gland for 
drugs given systemically (Baggot, 2006). In the United States, only intramammary 
antimicrobial infusion formulations are currently approved for treatment of either clinical 
or subclinical mastitis.   
For S. uberis, bacteriologic cure rates following treatment of clinical mastitis 
appear to be higher compared to treatment of subclinical mastitis (Zadoks, 2007), while 
for S. aureus subclinical treatments have shown similar efficacy compared to treatment of 
clinical cases (Barkema et al. 2006). Comparison of different studies evaluating treatment 
of clinical and subclinical IMI should be made with caution due to differences in 
enrollment criteria, infection definitions, and cure definitions.   
Positive results associated with early treatment of cows infected with the major 
mastitis pathogens S. aureus and S. uberis (Sol et al., 1997; Sol et al., 2000; Hillerton and 
Kliem, 2002), have led to recommendations for intensive antimicrobial treatment 
protocols for subclinical mastitis in dairy herds. A number of studies have demonstrated 
the efficacy of treating subclinical mastitis caused by S. aureus or streptococcal species 
during lactation (Sol et al., 1997; Gillespie et al., 2002; Oliver et al., 2003; St Rose et al., 
2003; Oliver et al., 2004; Deluyker et al., 2005).  Increased proportions of quarters with 
chronic subclinical mastitis are cured following extended therapy of 5 to 8 days 
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compared to either spontaneous cure of untreated quarters, or cure following label 
recommended 2-day duration of therapy.  In many cases, cure rates for extended therapy 
exceeded 90% and were significantly improved over either the no-treatment rates of 
spontaneous cure (< 30%) or the two-day treatment cure rates (67-77%).  These studies 
provide evidence of the potential efficacy of extended therapy for treatment of chronic 
subclinical mastitis caused by S. aureus or Streptococcus spp., however the decision to 
implement such a regimen needs careful consideration of the potential benefits and costs 
(Hillerton and Berry, 2003).  
 
Factors associated with the decision to implement subclinical mastitis therapy during 
lactation 
The circumstances that impact a decision to treat subclinical mastitis are similar to 
those that have been described for clinical mastitis (figure 1.2).  However, the decision to 
treat subclinical mastitis is perceived as being less urgent and may be considered optional 
or discretionary.  Historically, treatment of subclinical mastitis has been delayed until 
dry-off.  The high efficacy of dry cow therapy for bacteriologic cure, and the reduced 
cost of dry cow therapy compared to the costs of discarded milk for lactation therapy, 
have influenced subclinical mastitis treatment decisions.  Yet, as has been pointed out in 
a recent review, “the balance has changed where milk quality is often a significant 
component of price, and it may be that in some circumstances treating subclinical 
infections has a value, but these circumstances should be properly evaluated first” 





Direct benefits (cow effects) 
• Increased cure rate and decreased 
duration of infection 
• Reduced clinical mastitis cases  
• Reduced individual SCC 
• Increased welfare 
 
Indirect benefits (herd effects) 
• Reduced transmission and new 
infection rates 
• Reduced herd SCC and improved milk 
quality 
 
Costs of no treatment 
• Delayed return to higher quality milk 
• Increased risk of exposure to herd 
resulting in new or recurrent IMI 
• Increased culling 
• Decreased welfare 
Costs of treatment 
• Increased treatment costs 
       (includes labor and diagnostics) 
• Increased discarded milk  
• Unnecessary discarded milk if 
treatment not needed for cure 
Data needed to understand the balance (Swinkels et al. 2005) 
• Probability of cure following therapy 
• Probability of spontaneous cure, chronic IMI, and clinical 
mastitis 
• Probability of transmission to other cows  
• Potential for increased revenue (e.g. increased milk 
production, or increased milk quality premium payments) 
• Potential for reduced costs (e.g. prevention of repeated or 
recurrent clinical mastitis, prevention of new IMI, reduced 
culling, reduced production losses) 
• Reduced income (e.g. increased discarded milk) 
• Additional costs, including labor, diagnostic and treatment 
costs 
 




Early detection and cure of subclinical mastitis cases may be beneficial in the 
individual as cure may reduce duration of infection and prevent subsequent clinical 
episodes, as well as be associated with a reduction in SCC, although there is currently 
limited evidence supporting this hypothesis.  Two recent studies found a siginificant 
reduction in SCC following treatment of subclinical mastitis (St Rose et al., 2003; 
Sandgren et al., 2008), but only one of these two studies found a reduction in clinical 
mastitis rates among treated cows compared to an untreated control group (St Rose et al., 
2003).  The prevention of recurrent clinical episodes and associated clinical treatments 
may offset the additional antimicrobial use associated with treating subclinical cases 
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Figure 1.3  Time line of Mastitis dynamics and potential influence of early detection and treatment of 
chronic cases.  A mastitis case begins when a susceptible cow or quarter becomes infected.  An individual 
infection persists for a variable duration of time dependent on pathogen, cow, and treatment factors.  Each 
infection may include either a subclinical stage or a clinical stage or both clinical and subclinical periods. 
Treatment of subclinical mastitis (for example at 1) may have the greatest value if the overall effect of 
treatment includes a reduction in duration of infection and an associated reduction in somatic cell count, 
prevention of subsequent clinical episodes, and reduction of exposure of other susceptible individuals in a 




An important concern in treatment of clinical and subclinical mastitis is selection 
of individual cases for therapy to avoid inappropriate or unwarranted use of antibiotics.  
This may be especially true for Escherichia coli infections given their transient nature 
(high spontaneous cure rate) (Hogan and Smith, 2003) and where there are no approved 
intramammary formulations indicated for treatment of subclinical gram-negative 
pathogens.  Similarly, the short duration of many infections caused by gram-positive 
pathogens (Grommers et al., 1985; Todhunter et al., 1995; Watt, 1999; Zadoks et al., 
2003), suggests that treatment should be delayed for a newly acquired subclinical 
infection in the absence of evidence of persistence.  This, in combination with knowledge 
about the impact of chronic subclinical mastitis on milk production and SCC levels, 
suggests that chronic subclinical mastitis cases caused by major gram-positive pathogens 
(e.g. S.  aureus and Streptococcus spp.) are leading candidates for lactation therapy. This 
also suggests that an accurate diagnosis is required for the appropriate and prudent use of 
lactation therapy. 
There are few field studies examining the potential cost effectiveness of treating 
subclinical mastitis in dairy herds.  Diagnosis and treatment of cows with Streptococcus  
agalactiae infections offers the clearest example of circumstances where the benefits of 
lactation therapy for subclinical mastitis have been described at the population level 
(Yamagata et al., 1987; Erskine and Eberhart, 1990).  Successful treatment of subclinical 
S. agalactiae infections can be achieved using commercially available intramammary 
formulations at labeled dosing intervals, [e.g. 2 infusions of penicillin/novobiocin 
administered 24 hours apart (Erskine and Eberhart, 1990)].  The benefits of these ‘blitz’ 
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treatment programs are attributed to high cure rates and prevention of contagious mastitis 
transmission, resulting in herd level reductions in SCC and increases in milk production  
(Erskine and Eberhart, 1990).  The value of blitz therapy for control of other major 
pathogens has been described as being limited based on circumstances in field studies 
where the objective was to reduce herd level SCC from >700,000 cells/ml to below 
400,000 cells/ml (Kingwill et al., 1970).  In these studies the long-term reductions in 
mastitis prevalence were attributed to the effect of post milking teat disinfection and 
blanket dry-cow therapy consistently applied over a 12 to 24-month period.  Further, in 
most scenarios any benefit of ‘blitz’ treatment is likely to be short-lived in the absence of 
consistent PMTD and blanket dry-cow therapy. 
 McDermott et al. (McDermott et al., 1983) provide results that argue against 
treatment of subclinical mastitis during lactation using SCC as the trigger for treatment 
without regard to bacteriologic diagnostics. These authors selected cows for treatment 
based on a single SCC measure exceeding a threshold of 400,000 cells/ml and observed 
no differences in milk production and SCC between treated and untreated control cows. 
The majority (58%) of the cost of this program was due to the discarded milk associated 
with treatment, representing a net loss which was presumed to be increased due to 
treatment of 49 (48%) culture negative cows.  Recent economic models of lactation 
therapy of subclincal mastitis have included bacteriologic culture results as a criterion for 
treatment and have suggested treatment be limited to chronic IMI to avoid treatment of 
transient infections that spontaneously cure (Swinkels et al., 2005a; Swinkels et al., 
2005b).  These studies have suggested that targeted therapy of chronic subclincal mastitis 
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caused by S. aureus, S. uberis, or S. dysgalactiae may be beneficial under some 
scenarios, especially where contagious transmission risk is high and the benefit of 
treatment includes reduced costs by preventing new infections (Swinkels et al., 2005a; 
Swinkels et al., 2005b).   
    
Further rationale for subclinical mastitis control:  Indirect effects of therapy  
Cases of subclinical mastitis caused by major gram positive pathogens may 
constitute a reservoir of bacteria that are an important source of infection for other cattle 
in a herd (Dodd et al., 1969; Bramley and Dodd, 1984; Zadoks et al., 2002a; White et al., 
2006). Hence, successful bacteriologic cure of subclinical mastitis has a direct effect on 
the individual animal, but may also have an indirect effect on other members of a herd, in 
that it reduces exposure to pathogenic organisms.  A number of authors have identified 
strategies to control subclinical mastitis on dairy farms, and many of these strategies 
target treatment of chronic subclinical mastitis in individual quarters or cows (Dodd et 
al., 1969; Bramley and Dodd, 1984; Hillerton and Berry, 2003; St Rose et al., 2003; 
Oliver et al., 2004; Deluyker et al., 2005; Swinkels et al., 2005a).  As described in a 
previous section, the efficacy of lactation therapy for treatment of individual cows with 
subclinical mastitis has been demonstrated in both experimental challenge studies and 
clinical field trials (Sol et al., 1997; Gillespie et al., 2002; Oliver et al., 2003; St Rose et 
al., 2003; Oliver et al., 2004; Deluyker et al., 2005), and may be referred to as the direct 
effect of therapy which is most commonly measured in individual level study designs 
(Halloran and Struchiner, 1991; Hayes et al., 2000; Farrington, 2003).  However, the 
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incidence of disease for pathogens which may be transmitted between hosts may depend 
on the prevalence of disease in a population (Halloran and Struchiner, 1991). Therefore, 
interventions that target control of contagious or transmissible infectious disease may 
have indirect or population level effects (Halloran et al., 1997; Hayes et al., 2000; 
Farrington, 2003). In dairy herds these indirect effects of mastitis treatment strategies 
may include the reduced risk of pathogen transmission in the population following 
bacteriologic cure of infected individuals (Zadoks et al., 2002a; Swinkels et al., 2005a; 
Swinkels et al., 2005b).  However, no field trials have evaluated the potential population 
level effects of lactation therapy for subclinical mastitis caused by the major gram-
positive pathogens other than Streptococcus agalactiae. One reason for this lack of 
research may be that study designs that assess indirect effects of interventions on mastitis 
transmission dynamics are labor intensive and expensive. Another reason may be that the 
presumed variability in pathogen transmission dynamics across farms would require that 
large numbers of farms be enrolled in multi-location field trials to evaluate the impact of 
interventions under a variety of management conditions.  
 
Evaluating interventions at the population level: Use of deterministic models 
As early as 1969, Dodd and others recognized the importance of population level 
measures and mathematical models in evaluating mastitis control strategies (Dodd et al., 
1969). However, it has only been recently that a small number of studies have 
incorporated population level mathematical models to describe the dynamics of pathogen 
transmission and the overall effects of interventions such as post milking teat disinfection 
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or other control strategies (Lam et al., 1996; Allore and Erb, 1999; Zadoks et al., 2002a; 
White et al., 2006). The use of deterministic state-transition compartmental models to 
describe pathogen transmission dynamics (SEIR models, where S, E, I, and R represent 
the infection status compartments susceptible, latent, infectious, and recovered, 
respectively) allows for the estimation of population level measures such as the basic 
reproductive number (R0) for a pathogen (Anderson and May, 1991; Lam et al., 1996; 
Zadoks et al., 2002a).  Essentially, R0 describes the tendency of a pathogen to spread in a 
population of susceptible hosts, and is defined as the average number of secondary 
infections resulting from the introduction of one infectious individual into a fully 
susceptible population (Anderson and May, 1991; Vynnycky and Fine, 1998). R0 
describes the tendency of a pathogen to spread in a population of hosts, and is a function 
of the probability per unit time that one infectious individual will infect a susceptible 
individual (the transmission parameter, ß), and of the duration of infection. The 
transmission parameter, ß, is the coefficient that relates the transmission rate and type of 
transmission function to the frequencies or densities of infectious and susceptible hosts in 
a population (Anderson and May, 1991; Lam et al., 1996; McCallum et al., 2001). An 
effective or net reproductive number (Rt) can be determined as the expected number of 
secondary cases per infectious case where a fraction of the population is susceptible, or in 
other words, as the number of secondary infections arising from each infectious case in a 
given population (Anderson and May, 1991; Vynnycky and Fine, 1998; Zadoks et al., 
2002a). R0 and Rt are useful summary measures to examine the potential impact of 
control programs or to compare the transmission potential of pathogens in different 
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populations having different epidemiologic conditions (Lam et al., 1996; Cherry et al., 
1998; Vynnycky and Fine, 1998; Zadoks et al., 2002a; White et al., 2006). In summary, a 
primary advantage of SEIR models is they incorporate the effect of population level 
variables including numbers of susceptible and infectious individuals and thus these 
models have use in quantifying the overall impact of interventions such as vaccination, 
quarantine or removal, or antibiotic treatment programs (Cherry et al., 1998; Longini et 
al., 1998; Bonten et al., 2001; Pourbohloul et al., 2003). The use of quantitative 
epidemiologic methods that rely on cow-level data to estimate group or population level 
parameters of pathogen transmission offer advantages over previous methods of analysis 
as they incorporate the dependent effect of population-level pathogen prevalence and the 
transmission parameters of pathogens (Lam et al., 1996).  The collection of data from a 
longitudinal field trial in a population of dairy cattle managed under typical commercial 
conditions provides the opportunity to test relevant herd level clinical outcomes 
associated with implementation of a mastitis control program (Zadoks et al., 2002a).  
While antibiotic treatment is a common practice implemented in mastitis control, few 
studies have applied mathematical models of pathogen transmission to estimate the 
efficacy of antibiotic based mastitis control programs. 
 
Evaluating interventions at the molecular level: Use of molecular epidemiology in field 
trials 
Zadoks and Schukken (2006) have reviewed the value and use of molecular strain 
typing in the evaluation of transmission dynamics of veterinary pathogens.  The potential 
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significance of strain typing in mastitis control research has also been described 
(Barkema et al., 2006).  As indicated in these reviews, identification of strain types within 
and between farms may provide evidence of associations between strain type and 
infection outcome.  For example, Haveri et al. (2005)and Zadoks et al. (2000; 2003) have 
described associations between bacterial genotype and infection severity and duration for 
S. aureus and S. uberis mastitis.  In some cases these associations have been expanded to 
include identification of potential virulence genes that may be linked to S. aureus strain 
types causing specific clinical manifestations in bovine mastitis (Haveri et al., 2007).  In 
the broader context of understanding host specificity and strain adaptation, recent studies 
have characterized genes unique to S. aureus isolates recovered from cases of bovine 
mastitis, providing genetic evidence of host specialization and virulence factors of S. 
aureus clonal groups associated with cattle (Herron-Olson et al., 2007).  One study 
discovered that the reference S. aureus strain Newbould 305 (NCIMB 702892) frequently 
used in experimental challenge and in vitro experiments may be more closely associated 
with cattle skin isolates than naturally occurring intramammary isolates (Smith et al., 
2005b), although this finding may not be a great surprise to the researchers who 
pioneered use of this strain, as a less virulent strain has significant advantages in 
experimental challenge models and this strain may have been originally selected based on 
its less virulent phenotype.  A number of recent studies utilizing molecular typing 
methods [e.g. (Haveri et al., 2007; Herron-Olson et al., 2007)] have corroborated the 
potential importance of some previously recognized host and virulence factors associated 
with bovine S. aureus mastitis (Devriese, 1984; Bramley et al., 1989).  For example, 
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bovine ecovars appear to be staphylokinase negative and beta-hemolysin (Hlb) positive, 
while  staphylokinase positive and Hlb positive S. aureus strains are primarily human-
specific ecovars (Devriese, 1984).  Recent work has demonstrated that the Hlb-
converting bacteriophages, which integrate specifically in the Hlb gene, and upon 
integration convert isolates to an Hlb-negative phenotype, carry a cluster of genes 
associated with innate immune system invasion and modulation in humans (Goerke et al., 
2006; van Wamel et al., 2006).  These phage mediated virulence factors appear to be 
positively selected for and are more frequently found among human isolates associated 
with chronic infections (e.g. lung infections in cystic fibrosis patients and cases of 
bacteremia) versus nose isolates colonizing healthy individuals.  An analogous situation 
may be identified among bovine isolates, where isolates associated with skin colonization 
appear to be distinct from those associated with mastitis (Zadoks et al., 2002b; Smith et 
al., 2005b). These examples illustrate how molecular methods may be used in an 
epidemiologic context to provide a finer level of detail in our understanding of disease 
processes in populations.  On the purpose of molecular epidemiology, Bruce Levin et al. 
(1999) provide this summary, “The practical goals of molecular epidemiology are to 
identify the microparasites (viruses, bacteria, fungi, and protozoa) responsible for 
infectious diseases and determine their physical sources, their biological (phylogenetic) 
relationships, and their routes of transmission and those of the genes (and accessory 
elements) responsible for their virulence, vaccine-relevant antigens, and drug resistance.”  
These authors consider molecular epidemiology the logical adjunct (or perhaps 
descendant) to earlier typing schemes (such as serologic, phenotypic, or phage typing), 
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which were applied to understand “variation in the incidence and severity of infections 
with microbes classified as members of the same species” (Levin et al., 1999).   
In the context of intervention studies, such as mastitis treatment efficacy trials, 
molecular strain typing has been proposed as a method to refine our understanding of 
transmission dynamics at the farm or treatment group level and of pathogen cure and 
reinfection rates (Barkema et al., 2006; Zadoks and Schukken, 2006).   
Zadoks et al. (Zadoks et al., 2001a) and Phuektes et al. (Phuektes et al., 2001b) 
provide clear examples of the use of molecular epidemiologic methods that provided 
fresh insight to the potential of cow to cow transmission of  S. uberis mastitis within 
dairy herds. This has led Zadoks to propose a conceptual framework for S. uberis 
epidemiology which hypothesizes that strains of this species might be separated into host-
adapted and non-host-adapted ecotypes (Zadoks, 2007).  Characteristics of the host-
adapted ecotype were proposed to include low strain heterogeneity and subclinical 
presentations with a long duration of infection.  A contagious source of exposure would 
dominate for the host-adapted ecotype leading to a higher risk of infection during 
lactation.  In comparison, characteristics of a non-host-adapted ecotype were suggested to 
include high strain heterogeneity and a short duration of infection more frequently with 
clinical manifestations.  The source of exposure for the non-host adapted ecotype would 
be the environment, leading to new infections in both lactating and non-lactating cattle 
(Zadoks, 2007).  Based on evidence of host specificity for S. aureus (Devriese, 1984; 
Zadoks et al., 2000; Zadoks et al., 2002b; Smith et al., 2005b; Herron-Olson et al., 2007), 
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a similar ecotype hypothesis seems appropriate for this species, and may be expanded to 
include bovine host-adapted, human host-adapted, and non-host adapted ecotypes.   
In a practical application, it has been suggested that molecular typing can be used 
in conjunction with epidemiologic and clinical data to differentiate between contagious 
and environmental sources of exposure for pathogens causing bovine mastitis (Zadoks 
and Schukken, 2006; Zadoks, 2007). The finding of multiple bacterial strains of a single 
species causing mastitis in a population of cows suggests these infections arise from one 
or more sources of exposure that are populated with many strains (e.g. the environment). 
Such findings have been used to infer environmental sources of exposure for S. uberis 
mastitis in dairy herds where the environment is populated with a diverse number of 
strain types (Wieliczko et al., 2002; Zadoks et al., 2003; Pullinger et al., 2006; Pullinger 
et al., 2007).  In comparison, the finding of a limited number of strains within a herd 
experiencing a mastitis outbreak over a defined time period may be consistent with cow 
to cow transmission as has also been suggested for S. uberis in some herds or 
management scenarios (Phuektes et al., 2001b; Zadoks et al., 2001a). In these later cases 
it is possible that clusters of infection with a limited number of strains in space or time 
can also arise from a common environmental source populated with a dominant strain, or 
from the enhanced virulence of some individual environmental strains (Phuektes et al., 
2001b). Because indirect effects of mastitis treatment strategies may include the reduced 
risk of pathogen transmission in the population following bacteriologic cure of infected 
individuals, the ability to demonstrate these effects is likely driven by the contagious 
transmission potential of individual strains of a pathogen within a herd.  Therefore it 
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follows that identification of indirect effects of a subclinical mastitis treatment program 
would be improved by characterization of strain diversity for the targeted species of 
pathogens in a clinical field trial.  
The ability to differentiate strains by molecular typing may also improve 
estimates of infection duration and the proportion of bacteriologic cure in studies of 
direct effects of mastitis therapy (Luby and Middleton, 2005; Barkema et al., 2006; 
Zadoks and Schukken, 2006).  Few veterinary intervention studies appear to have 
incorporated molecular strain typing methods in studies of treatment efficacy, although 
the importance of including molecular genotyping to distinguish recrudescent and new 
Plasmodium falciparum infections following treatment has been described for human 
anti-malarial trials (Mugittu et al., 2007).    
Luby and Middleton (2005) provided improved estimates of cure proportions by 
strain typing pre-treatment and post-treatment isolates for infected quarters that did not 
appear to cure. These authors identified one of 10 chronic S. aureus infections where the 
post-treatment isolate differed from the pre-treatment isolate in DNA digest pattern on 
pulsed-field gel electrophoresis (PFGE). They used this data to define this quarter as 
cured of the first strain type and reinfected with a different strain type.  Other authors 
have suggested that some differences in the PFGE fingerprint identified during chronic S. 
aureus infections in cystic fibrosis patients are due to genomic alterations of a single 
infecting strain over time (Goerke et al., 2004).  Interestingly, the extent of DNA digest 
banding pattern differences observed in these two studies appears to be similar. In both 
publications there appear to be one to three identifiable differences in fragment patterns 
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suggesting the isolates are closely related and consistent with a single genetic event (i.e. a 
mutation, insertion, or deletion) (Tenover et al., 1995).  Goerke et al. (Goerke et al., 
2006) identified shifts in band sizes among S. aureus isolates from chronically infected 
cystic fibrosis patients that were attributed to phage mobilization, and these authors 
suggested the changes were a result of selective pressure on the pathogen due to the host 
response or regular antibiotic exposure during chronic infections, but not associated with 
a new infection caused by a different strain.  In contrast, Luby and Middleton (Luby and 
Middleton, 2005), suggested that what appeared to be a single change in band size was 
attributed to a infection caused by a different strain.  These authors did not address the 
possibility that the difference in PFGE pattern observed over the course of this infection 
could be attributed to a genetic change in the infection strain type in response to 
treatment.  Additional research appears warranted to evaluate the extent of genetic 
variation in chronic S. aureus bovine mastitis cases associated with treatment or host 
responses, or the frequency of potential post treatment reinfections that may lead to 
underestimation of cure rates associated with therapy.  
 
Molecular methods of bacterial strain typing 
The extensive number of molecular typing methods available for discriminating 
among bacterial strain types is beyond the scope of this review, and has been briefly 
addressed by other authors (Zadoks and Schukken, 2006), and more extensively reviewed 
elsewhere (Maslow et al., 1993; Riley, 2004).  
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 PFGE and multilocus sequence typing (MLST) are two molecular typing methods 
that meet the performance criteria described by Maslow (1993) for discriminating among 
S. aureus isolates, including those obtained from dairy cattle milk, skin and the farm 
environment.  Although other methods may have some advantages such as reduced costs 
or labor, both PFGE and MLST have been demonstrated to be highly suitable for 
epidemiologic analysis of bovine S. aureus isolates (Fitzgerald et al., 1997; Zadoks et al., 
2000; Zadoks et al., 2002b; Sabour et al., 2004; Jorgensen et al., 2005; Smith et al., 
2005a; Smith et al., 2005b; Anderson and Lyman, 2006; Anderson et al., 2006; Dingwell 
et al., 2006; Aires-de-Sousa et al., 2007; Haveri et al., 2007; Rabello et al., 2007).  
Comparison of the two methods appears favorable, with strong concordance of results for 
bovine S. aureus isolates, although PFGE may provide a higher level of discrimination 
and thus may be more appropriate for investigations conducted within herds (Jorgensen et 
al., 2005; Smith et al., 2005b; Aires-de-Sousa et al., 2007).  
Random amplified polymorphic DNA (RAPD) appears to have good 
discriminatory power for studies of S. uberis epidemiology within dairy herds (Gillespie 
et al., 1998; Oliver et al., 1998; Wieliczko et al., 2002; Zadoks et al., 2003).  The 
identification and typing of streptococcal species may prove to be more of a challenge 
given the high level of recombination found in this group (Lefebure and Stanhope, 2007), 
and S. uberis has been described as having a high extent of recombination compared to 




Outline of this Dissertation 
 
 Following this general introduction (Chapter 1), the theoretical basis of 
population level effects of lactation therapy is explored through development of a 
deterministic mathematical model in Chapter 2.  In this chapter, the potential indirect and 
overall effects of treatment of chronic cases of subclinical mastitis on the dynamics of 
mastitis transmission for pathogens that can spread from cow to cow are estimated under 
a range of transmission scenarios.  In Chapter 3, the hypothesis that treatment of chronic 
subclinical Staphylococcus aureus mastitis in a population of dairy cattle results in the 
reduction of duration of S. aureus infection (direct effect of therapy) and reduction of 
incidence of new S. aureus intramammary infection (indirect effect of therapy) is tested. 
Pulsed field gel electrophoresis (PFGE) is used to assess the effect of the treatment 
program on strain specific dynamics of S. aureus infection. In addition the effect of the 
treatment program on somatic cell count following treatment is described.  In Chapter 4, 
the direct and indirect effects of treating chronic subclinical mastitis caused by 
streptococcal species are explored, with a focus on treatment of chronic subclinical 
Streptococcus uberis infections.  In this chapter, the molecular epidemiology of S. uberis 
infections is examined for two herds using random amplified polymorphic DNA (RAPD) 
methods.  In addition, the association between response to therapy and pretreatment 
antimicrobial resistance phenotypes is described. Chapter 5 introduces an unexpected 
finding that emerged from these studies, by examining the association between Coxiella 
burnetti shedding in milk and subclinical mastitis.  These findings are used in Chapter 6, 
to support conclusions regarding the the potential benefits and limitations of lactation 
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therapy for subclinical mastitis.  In Chapter 6 additional data on strain typing S. aureus 
using multilocus sequence type (MLST) methods is presented and compared to results of 
PFGE and antimicrobial susceptibility typing.  Finally, Chapter 6 provides suggestions 
for future research in subclinical mastitis control. 
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A deterministic state-transition model for mastitis transmission was developed to 
explore population level effects of antibiotic treatment regimens targeting chronic 
subclinical mastitis caused by major gram-positive pathogens in lactating dairy cows. 
Behavior and sensitivity of model outputs to changes in key parameters were explored.  
Outcomes included the size of the state variables describing proportions of infected 
quarters and basic and effective reproductive numbers. Treatment effects were estimated 
by calculating proportional reductions in state variables at equilibrium for populations 
implementing a treatment program relative to populations with no intervention. In general 
the relationships between parameters were complex and non-linear, although the model 
was especially sensitive to changes in the value of the transmission rate parameter.  
Interaction between the parameters resulted in large variations in treatment effect 
estimates. Effect estimates calculated from model outputs showed a quadratic curve with 
a clear optimum at low, but not the lowest, transmission rates. These results indicate that 
overall positive population level effects of lactation therapy would be realized for herds 
that have successfully implemented practices that reduce the transmission rate of 
pathogens. A key finding is that in herds with high transmission rates, treatment of 
chronically infected quarters was predicted to have little impact on the proportion of 
infected quarters and no positive population level effect in reducing the force of infection 
and new infection rates. Results of this study suggest that field trials to evaluate efficacy 
of antimicrobial treatment should include estimates of indirect treatment effects. 




Subclinical mastitis is the dominant form of mastitis affecting dairy cattle yet 
often goes undetected or is left untreated (Bramley and Dodd, 1984; Hillerton and Berry, 
2003; Oliver et al., 2004). Cases of subclinical mastitis caused by major gram positive 
pathogens constitute a reservoir of bacteria that are an important source of infection for 
other cattle in a herd (Dodd et al., 1969; Bramley and Dodd, 1984; Zadoks et al., 2002a; 
White et al., 2006). Subclinical mastitis may be of short duration (transient infections 
which spontaneously cure) or extended duration (chronic or persistent infections of more 
than one or two months) (Zadoks et al., 2003; Swinkels et al., 2005a; Swinkels et al., 
2005b). A number of authors have identified strategies to control subclinical mastitis on 
dairy farms, including antibiotic treatment of chronic cases during lactation (Dodd et al., 
1969; Bramley and Dodd, 1984; St Rose et al., 2003; Zadoks et al., 2003; Oliver et al., 
2004; Swinkels et al., 2005a; Swinkels et al., 2005b).  The direct effect of lactation 
therapy for subclinical mastitis has been described in both experimental challenge studies 
and clinical field trials (Gillespie et al., 2002; Oliver et al., 2003; St Rose et al., 2003; 
Oliver et al., 2004; Deluyker et al., 2005). Interventions targeting control of infectious 
disease may also have indirect or population level effects as incidence may depend on 
prevalence of disease in a population (Halloran et al., 1997; Hayes et al., 2000; 
Farrington, 2003). In dairy herds the indirect effects of mastitis treatment strategies may 
include the reduced risk of pathogen transmission in the population following 
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bacteriologic cure of infected individuals (Zadoks et al., 2002a; Swinkels et al., 2005a; 
White et al., 2006).   
As early as 1969, Dodd and others recognized the importance of population level 
measures and mathematical models in evaluating mastitis control strategies (Dodd et al., 
1969). However, it has only been recently that a small number of studies have used 
population level mathematical models to describe the dynamics of mastitis transmission 
and the overall effects of interventions (Lam et al., 1996; Allore and Erb, 1999; Zadoks et 
al., 2002a; White et al., 2006). The use of deterministic state-transition compartmental 
models to describe pathogen transmission dynamics (SEIR models, where S, E, I, and R 
represent the infection status compartments susceptible, latent, infectious, and recovered, 
respectively) allows for the estimation of population level measures such as the basic 
reproductive number (R0) (Anderson and May, 1991; Lam et al., 1996; Zadoks et al., 
2002a).  Essentially, R0 describes the tendency of a pathogen to spread in a population of 
susceptible hosts, and is defined as the average number of secondary infections resulting 
from the introduction of one infectious individual into a fully susceptible population 
(Anderson and May, 1991; Diekmann and Heesterbeek, 2000). An effective or net 
reproductive number (Rt) can be determined as the expected number of secondary cases 
per infectious case where only a fraction of the population is susceptible (Anderson and 
May, 1991; Diekmann and Heesterbeek, 2000). R0 and Rt are useful summary measures 
to examine the potential impact of control programs or to compare the transmission 
potential of pathogens in different populations under different epidemiologic conditions 
(Lam et al., 1996; Cherry et al., 1998; Vynnycky and Fine, 1998; Zadoks et al., 2002a; 
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White et al., 2006). SEIR models incorporate population level variables in predicting 
disease transmission dynamics over time, and these models have been used to quantify 
the overall impact of interventions such as vaccination, quarantine or removal, or 
antibiotic treatment programs (Cherry et al., 1998; Bonten et al., 2001; Longini et al., 
2002; Pourbohloul et al., 2003).  
The primary objective of this research was to explore the potential effects of 
antibiotic treatment regimens targeting chronic subclinical mastitis caused by major 
gram-positive pathogens.  The main effect of interest was the indirect effect of treating 
chronic intramammary infections during lactation on new infection rates and the force of 
infection.  We describe the development and use of a deterministic state-transition model 
for subclinical mastitis transmission dynamics to quantify indirect effects of a targeted 
intervention. The impact of parameter estimate variation and the interaction between 
parameter estimates, including the transmission and cure rate estimates, on direct, 





 The model is a variant of the classic infectious disease epidemic models (SEIR) 
described by Anderson and May (1991), with modifications specific to mastitis 
transmission in dairy herds to account for 1) the apparent absence of a latent period, and 
2) recurrent infection due to the apparent absence of, or very short duration of, immunity 
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(Lam et al., 1996; Zadoks et al., 2002a; White et al., 2006).  The present model was 
developed for a population of lactating udder quarters divided into four states, susceptible 
(S), newly infected (IN), chronically infected (IC), and recovered-susceptible (RS), where 
the compartments represent the proportion of lactating quarters in the population in each 
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Figure 2.1  Flow diagram of the state-transition model of subclinical mastitis transmission for estimation of 
the impact of mastitis treatment strategies targeting chronic subclinical mastitis in a population of lactating 
quarters of dairy cattle.  The boxes represent the state variables and arrows represent the flow rates between 
naïve susceptible (S), newly infected (IN), chronically infected (IC), and recovered susceptible (RS) states. 
Lettering represents the variables and parameters in the mathematical model (equations [1 – 14]; table1). 
The superscript i represents the cure rate associated with populations that differ in application of a mastitis 
treatment strategy, where i=1 for herds implementing an intervention and i =0 for herds not implementing a 
subclinical mastitis treatment strategy (see table 2.1 for default values). 
 
 
The model was structured on the assumption that IMI status is strictly defined by serial 
bacteriologic culture results where the sample interval is approximately 1 month using 
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previously published definitions of infection (Hogan, 1990; Dohoo, 1991; Lam et al., 
1997b; Zadoks et al., 2001a). The model was defined by a set of four ordinary differential 
equations describing the change in proportion of quarters in each state over time 




bθ λ µ= − −                                                                                    [2.1] 
( ) (1 )N N S R S N N N N N N
dI b S R I I I
dt
θ λ λ µ α ρ ν ρν= + + − + − − −                    [2.2]   
( )C C N N C C C C
dI b I I I
dt
θ ρν µ α ν= + − + −                                                      [2.3]          
(1 ) ( )S R C C N N R S R S
dR b I I R R
dt
µ αθ ν ρ ν λ += + + − − −                                   [2.4] 
where 
1N C SN S I I R= + + + =                                                                               [2.1] 
1 ( )S N C Rθ θ θ θ= − + +                           [2.2]           
( )S S N CI Iλ β ε= +                                                                                        [2.3]                                                                                        
( )R R N CI Iλ β ε= +                                                                                        [2.4]                                                                              
N N C C R SN I Ib Rµ α α α+ + +=                                                                       [2.5] 
R Sβ δβ=                                                                                          [2.6] 
ˆ1/N Ndν =                                                                                          [2.7] 
ˆ1/C Cdν =                                                                                         [2.8] 
with the meaning of all symbols defined in table 2.1.   
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Table 2.1  Definitions of variables and initial parameter estimates for the subclinical mastitis model in a 
population of udder quarters 
 
  
        Symbol Units  Definition                           Estimate 1               
 
   Variables S Normalized Proportion of lactating population  initial = 0.90     
with no previous evidence of  
       IMI (naïve susceptible) 
  IN Normalized Proportion of lactating population  initial = 0.0075 
 with new subclinical IMI 
  IC Normalized Proportion of lactating population  initial = 0.0425 
 with chronic subclinical IMI 
  RS Normalized Proportion of lactating population  initial = 0.05 
 not currently infected with history of  
 previous IMI (recovered) 
λS day-1  Force of infection –  
 coefficient of transmission 
 between I and S individuals  
λR day-1  Force of infection –  
       coefficient of transmission  
 between I and R individuals 
 
Parameters µ day-1  Rate of turnover of quarters   0.0040 
 (cull, death, dry-off)  
αi day-1  Additional rate of turnover   αN 0.00401       
 of quarters in IN,  IC, or RS   αC 0.00261 
     αR 0.0009 
   
δ -  Transmission rate coefficient    3       
   for increased risk of previously  
infected quarter (see text) 
 
  dN day  Duration estimate in IN state  ˆNd        30 days 
  dC day  Duration estimate in IC state  ˆCd        95 days 
       
    
  ρ -  Proportion new IMI that progress   0.74 
     to chronic state 
βi capita-1day-1 Transmission rate   βS 0.008       
           βR = δβS   0.024 
   
νi day-1  Recovery or cure rate   νN 0.03333 2  
        νC
0
 0.010526 3  
        νC
1
 0.025 3 
 
  θi Normalized Proportion of individuals  
 entering the lactating herd   θN 0.0075    
θC  0.0425 
θR 0.05 
             θS =1-(θN+θC +θR) 0.90 
ε -  Coefficient that reflects potential difference   1 
 in transmissibility between new IMI and chronic IMI 
 
1. Initial variable estimates based on field observations from referenced studies with per capita rates expressed as events per 103 quarter days at 
risk.  References for source of estimates are described in methods section of text. 
2. Calculated from equation 11 where it was assumed the mean duration in the IN state is 30 days. 
3. Calculated from equation 12 where it was assumed the mean duration in the Ic state is 95 days in herds not implementing treatment of 
subclinical mastitis during lactation, and 40 days in herds implementing diagnosis and treatment of subclincal mastitis. 
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The total population size (N) was assumed to be constant, set to unity, and equals the sum 
of the proportion of quarters in each state [2.5].  Therefore all exits from the lactating 
herd were replaced by entries. Exits from the population were represented by the rate 
parameters µ and αi, where µ represents the general exit rate for any reason other than 
mastitis (including dry-off), and αi represents additional exit rates from the infected and 
recovered states.  Quarters were assumed to enter the population into all states at a rate 
equivalent to the sum of all exit rates (b) [2.9], where θi represents the proportion of 
quarters entering each state.  Parameters λS and λR are the force-of-infection probabilities 
that susceptible or recovered-susceptible quarters become newly infected, respectively.  
Each of the force-of-infection parameters are a function of the transmission parameter 
(βi) and the total proportion of infected quarters in the population (IN+IC) [2.7-2.8].  A 
transmissibility coefficient (ε) was included in the model to account for potential 
differences in transmissibility between new IMI and chronic IMI quarters; however, 
because there is limited evidence demonstrating that chronically infected quarters are 
more or less likely than new infections to transmit infection upon contact with susceptible 
quarters this coefficient was set to 1 in all iterations of the present analysis.  Additional 
assumptions regarding parameter estimates are described in the individual sections that 
follow. Realizations of the model were obtained using the computer software package 
Berkeley Madonna (Version 8.0.1, Macey & Oster, University of California, Berkeley, 
CA, 2000). Initial parameter estimates and their ranges were obtained from peer-
reviewed publications, are defined in table 2.1 and briefly described below. 
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Entry into the lactating herd 
The model was developed as a proportional model for a constant population size.  
This is consistent with a year-round calving system where herd size is stable.  Entries into 
the lactating herd may come from either primiparous or multiparous cows, with all 
multiparous cows assumed to have received dry cow therapy.  Potential heterogeneity in 
mastitis risk among replacement animals was ignored and entries were modeled in the 
simplest form, with a fixed proportion of quarters entering each state from a uniform 
population of replacements.  These entries were represented by the parameters θS, θN, θC, 
and θR, for the respective states S, IN, IC, RS, where θS + θN + θC + θR = 1. Each θi was 
then multiplied by the net replacement rate (b) [2.9] to replace all quarters that exit from 
the herd.  Fixed estimates for values of influx parameters were obtained from published 
field trial data (Lam et al., 1997b; Zadoks et al., 2002a; Zadoks et al., 2003; White et al., 
2006). These estimates were also used to set initial proportions of quarters in each state at 
time zero (table 2.1).  
 
Exits from the lactating herd 
 Quarters were assumed to exit the lactating herd as a result of dry-off, culling, 
sales, or death. Following White et al. (2001b) and Zadoks et al. (2002a), the average 
length of lactation was assumed to be 250 days, (i.e. efflux rate was 0.004 quarters per 
day), which is used as the fixed estimate for the parameter µ uniformly applied to all 
compartments. Additional exits from the herd were represented by αi, and separate rates 
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were recognized for each infected state (αN and αC) and for the recovered susceptible state 
(αR).  Zadoks et al. (2002a) observed additional rates of mastitis associated culling for 
clinical and subclinical mastitis caused by S. aureus to be 0.034 and 0.0021 quarters per 
day, and additional rates of culling among recovered quarters with a prior mastitis 
episode to be 0.0009 quarters per day. The present model assumed an increased rate of 
exit among quarters with clinical mastitis compared to subclinical IMI, and initial 
estimates of αN and αC are based on the rates observed by Zadoks et al. (2002a) while 
accounting for the average proportion of quarters likely to present with a clinical episode 
in each of the infected states.  Based on data obtained from the literature the current 
model assumed 30% of new and 25% of chronic major gram-positive IMI display clinical 
signs (Dodd et al., 1969; Todhunter et al., 1995; Lam et al., 1997b; Zadoks et al., 2003; 
and unpublished data of R.N. Zadoks). Fixed estimates of mastitis associated exit rate 
from the IN state was calculated as, (‘Exit rate for clinical mastitis’ * ‘proportion of days 
clinical in IN ’ * ‘proportion showing clinical signs in IN’) + (‘Exit rate for subclinical 
mastitis’) * (1-‘proportion of days clinical in IN’) * (‘proportion showing clinical signs in 
IN’) + (‘Exit rate for subclinical mastitis’) * (1-‘proportion showing clinical signs in IN’). 
Similarly exit rate from the IC state was calculated as (‘Exit rate for clinical mastitis’ * 
‘proportion of days clinical in IC ’ * ‘proportion showing clinical signs in IC’) + (‘Exit 
rate for subclinical mastitis’) * (1-‘proportion of days clinical in IC ’) * (‘proportion 
showing clinical signs in IC’) + (‘Exit rate for subclinical mastitis’) * (1-‘proportion 
showing clinical signs in IC’). Based on original data of Lam (1996) and Zadoks (2002), 
we assumed the average duration of a clinical mastitis event caused by major gram-
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positive pathogens to be 6 days, and the total average duration in the IN  and IC states to 
be 30 and 95 days respectively.  Therefore αN = (0.034 * 6/30 * 0.30) + (0.0021 * 24/30 * 
0.30) + (0.0021 * 0.70) = 0.00401, and αC = (0.034 * 6/95 * 0.25)+(0.0021 * 89/95 * 
0.25) + (0.0021 * 0.75) = 0.00261  (table 2.1).  
 
New infection rates 
Initial values for the transmission parameters were obtained from review of the 
literature, and were influenced by the observations of Zadoks et al. (2001a; 2002a) that 
transmission parameters for new infections from the naïve susceptible state are lower 
than those from the recovered state.  This difference has been attributed to increased 
susceptibility of recovered susceptible quarters compared to naïve uninfected quarters, 
and is in agreement with observational epidemiologic studies (Zadoks et al., 2001b). This 
epidemiologic study showed that increased susceptibility of recovered susceptible 
quarters is not species specific, i.e. recovery from S. aureus and from S. uberis were both 
associated with increased risk of subsequent new infection with either pathogen (Zadoks 
et al., 2001b). This implies that the increased risk of infection in recovered susceptible 
quarters is not due to undiagnosed chronic infections with episodes of very low bacterial 
shedding.  In the 3 herds studied by Zadoks et al. (2002a) the estimated transmission 
parameters for new S. aureus infections from RS were between 3 and 6 times greater than 
those for new infections from the susceptible state. Similarly during a S. uberis outbreak 
in one of these herds, the estimated transmission parameter for new infections among 
recovered susceptible quarters was approximately 7.5 times higher than naïve susceptible 
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quarters (Zadoks et al., 2001a). The current model structure allows input of a baseline 
transmission parameter for the susceptible state (βS), with βR expressed as a function of βS 
multiplied by an ‘inflation factor’ (δ) [2.10], with δ set to a value between 1 and 8.  In 
general, estimates of β for mastitis pathogens have been obtained from Poisson regression 
models of new infection incidence from longitudinal studies using data describing the 
change over time in the size of infected, susceptible and total population size (Lam et al., 
1996; Zadoks et al., 2001a) or from time series data fit to a mathematical transmission 
model (White et al., 2006).  Detailed longitudinal studies of subclinical mastitis incidence 
are labor intensive and infrequent, limiting the ability to obtain pathogen specific 
estimates of β, βS, and βR to a small number of publications (Lam et al., 1996; White et 
al., 2001a; Zadoks et al., 2001a; White et al., 2006). These few publications provide 
pathogen specific estimates of βS for Staphylococcus aureus transmission ranging from 
0.0028 under steady state conditions among teats with the use of post-milking teat 
disinfection (PMTD), to 0.046 during a S. aureus outbreak in the absence of PMTD 
where incorrect milking machine function was also suggested to play a role in 
transmission  (Lam et al., 1996; figure 2.2).  Estimates of β for S. uberis from a single 
herd were within the range of reported values for S. aureus (Zadoks et al., 2001a), 
although additional studies on S. uberis transmission dynamics are needed.  Most 
recently, White et al. (2006), using data obtained from the longitudinal studies of seven 
herds (Lam et al., 1997b), reported herd level summary estimates of β for major gram-
positive pathogens with or without PMTD, ranging from 0 to 0.089 (figure 2.2).  While 
numerous factors likely contribute to the variation observed for transmission parameter 
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estimates, analysis of the data from this series of references suggests that the distribution 
of β estimates from 10 different herds may be bimodal, with a lower range of estimates 
for herds using PMTD, compared to no PMTD use (figure 2.2).  From these data the 
mean (std. dev.) and median values of β were 0.00868 (0.000041) and 0.00684 for 
populations of quarters using PMTD and 0.0362 (0.00061) and 0.0295 for populations of 
quarters not using PMTD. The present model was initially formulated assuming PMTD 













































































Figure 2.2  Frequency distribution of transmission parameter (βS) estimates for major gram-positive 
mastitis pathogens, stratified by post milking teat disinfection (PMTD) conditions. Data from ten herds as 
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Spontaneous cure rate of subclinical IMI 
 Estimates for spontaneous cure rates are a function of the surveillance scheme and 
criteria for defining a chronic IMI.  In this model we assume that all new subclinical 
infections are observed as a single positive observation among sequential monthly 
observations. Therefore, assuming 30 day sampling intervals, the theoretical minimum 
and maximum duration in the IN compartment were assumed to be 1 and 59 days 
respectively, and the mean duration of new IMI ( ˆNd ) in the IN state was assumed to be 30 
days.   
Six references from five longitudinal studies were identified that provided 
numeric estimates of the proportion of new IMI caused by major gram-positive pathogens 
that persist more than 30 days (table 2.2).  Taking the numeric average of the five studies  
 
Table 2.2  Estimates of the parameter ρ, the proportion of new intramammary infections caused by major 
gram-positive pathogens that survive > 30 days obtained from literature review. 
 
 
that reported specific results for major gram-positive pathogens, initial estimates assumed 
74% of new IMI become chronic (ρ=0.74), with 1-ρ new IMI transitioning to the 
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recovered-susceptible state. This initial value of ρ is slightly less than the 78% persistent 
subclinical S. aureus IMI assumed by Swinkels et al. (Swinkels et al., 2005a) in one 
economic model, and slightly greater than the 70.7% proportion of S. uberis or S. 
dysgalactiae persistent IMI assumed in a separate model (Swinkels et al., 2005b).  
The arithmetic mean of estimates of duration of IMI reported by Zadoks et 
al.(2003)  and Watt (1999) for S. uberis is 100 days, and the arithmetic mean of S. aureus 
IMI duration from the reported values is 110 days (Grommers et al., 1985; Lam et al., 
1996; Lam et al., 1997b; Zadoks et al., 2002a; Swinkels et al., 2005a).  These estimates 
are similar to the mean duration of 100 days for IMI due to all major gram-positive 
pathogens obtained by White et al. (2006) using the data of Lam et al. (1996; 1997b)  
Therefore the initial duration estimate used for the present model for all major gram-
positive mastitis pathogens was 100 days, and based on the assumption that 74% of IMI 
become chronic then the total average duration of chronic IMI was assumed to be 125 
days. Given the first 30 days of a chronic IMI are in the IN state, the mean duration in the 
IC state is 95 days per quarter ( ˆCd =95) and υC0 = 0.010526. 
 
Cure rates associated with the treatment of chronic subclinical mastitis 
Twelve reports describing the effect of antibiotic treatment regimens targeting 
chronic subclinical mastitis caused by major gram-positive pathogens were identified 
(Bramley and Dodd, 1984; Owens et al., 1997; Sol et al., 1997; Cattell et al., 2001; 
Gillespie et al., 2002; Hillerton and Kliem, 2002; Oliver et al., 2003; St Rose et al., 2003; 
Oliver et al., 2004; Deluyker et al., 2005; Luby and Middleton, 2005; Milne et al., 2005).  
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Based on values from these references, reasonable estimates for cure proportions of 
chronic subclinical IMI caused by the major gram-positive pathogens appear to be 55, 65, 
and 75% for 2 day, 5 day, and 8 day treatment regimens respectively.  The 75% cure 
proportion estimate for 8 day regimens is approximately mid-way between the estimates 
of 60% for S. aureus and 88% for S. uberis used by Swinkels et al.(2005a; 2005b).  
Similarly, the short duration regimens approximate the cure estimate used by White et al. 
(2001b)  for major gram-positive pathogens (60%), which these authors based on data 
from Sol et al. (Sol et al., 1997). For the current analysis, we assumed all chronic 
subclinical infections were identified by a second positive observation in sequential 
monthly observations. Therefore the theoretical minimum and maximum total duration of 
chronic IMIs at the time of diagnosis was assumed to be 30 and 60 days respectively, and 
the average duration of a chronic IMI at the time of diagnosis was assumed to be 45 days, 
with the initial 30 days occurring in the IN compartment.  We assumed 6 additional days 
for bacteriologic culture, reporting of infection status, and initiation of treatment on the 
farm, thus the average duration of chronic IMIs at initiation of therapy would be a total of 
51 days, with 21 days duration in the IC compartment.  Based on a 75% cure proportion 
for an 8 day treatment regimen, the mean duration in the IC state of quarters in herds 
implementing an aggressive diagnosis and treatment program was calculated as (21 days 
x 0.75) + (95 days x 0.25) = 40 days.  Therefore, the initial estimate of υC1 in herds 
implementing an aggressive diagnosis and treatment program was 0.025 quarters per day.  
This is equivalent to reducing the total mean duration of chronic subclinical infections by 
55 days as a result of the treatment program.  
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Estimating the effect of treatment of chronic subclinical mastitis during lactation 
To explore the possible effects of treating chronic subclinical mastitis during 
lactation the model was numerically solved to equilibrium with parameter values in table 
2.1 set as initial conditions.  Following the recommendations of Halloran et al. (1991; 
1997), with slight modifications, the direct, indirect, and overall effects of the 
intervention were explored from model outcomes.  In the case of antimicrobial treatment 
of infected individuals in a population, the direct effect of successful treatment is to 
reduce duration of infection in the infected host, and the indirect effect of a treatment 
program is the reduction of risk of new infection among susceptible individuals in a 
population due to reduced infectiousness of infected hosts in the population. The direct 
effect of therapy in this model was strictly assumed to reduce duration of infection, and to 
have no effect on β.  As a result, the direct effect of treatment (DE) was estimated 
as 1 01 ( )DE d d= − , where d is the average total duration of chronic IMI and the 
subscripts 1 and 0 represent the population receiving the intervention and the population 
not receiving the intervention respectively. The indirect effect of the intervention in this 
model was assumed to be the reduction in risk of new infection.  The reduced risk of 
infection was realized in the model output from the proportion of quarters in the new IMI 
state at equilibrium, and the indirect effect of treatment (IE) was estimated 
as 1 01 ( )N NIE I I= − , where IN1 and IN0 are the steady state proportions of new IMI in 
populations receiving the intervention and not receiving the intervention, respectively.  
The overall effect (OE) of the intervention was defined to be the reduced prevalence of 
infection in populations of quarters receiving the intervention relative to populations not 
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receiving the intervention, and was determined from 1 – the ratio of the sum of quarters 
in the infected states at equilibrium; 1 01 (( ) ( ) )N C N COE I I I I= − + +  (Halloran et al., 
1997). 
 
Model behavior and scenario analysis 
To explore the possible effect of treating chronic subclinical mastitis during 
lactation the model was numerically solved to equilibrium using the initial parameter 
estimates (table 1.1), for two separate values of υCi, where υC1  represented herds treating 
subclinical mastitis during lactation, and υC0 represented herds not applying diagnosis and 
lactation therapy of subclinical mastitis. Outcomes evaluated included the size of the 4 
state variables, the sum prevalence of infected quarters (IT = IN + IC) and uninfected 
quarters (S+RS), the basic reproductive number (R0), and the effective reproductive 
number (Rt). R0 and Rt were derived using previously described methods (Diekmann and 
Heesterbeek, 2000) and are defined as:  
0
S N S
N N N N C C
R β ρν εβ
µ α ν µ α ν µ α ν
  
= +   
+ + + + + +  
                                              [2.9] 
and, 
( )S R N S R
t
N N N N C C
S Rs S RsR β β ρν ε β β
µ α ν µ α ν µ α ν
  + +
= +   
+ + + + + +  




  47 
Simulations, sensitivity and uncertainty analysis associated with key parameters 
Model behavior was explored for key parameters of interest, which were, the 
transmission parameter (β), transmission coefficient for increased transmission among 
quarters that were previously infected (δ), proportion of new IMI that progress to a 
chronic state (ρ), and cure rate (quarters per day) of chronic IMI associated with 
treatment (νCi).  The sensitivity of the model to changes in parameter estimates was 
examined using the ‘One At a Time’ (OAT) method of Morris (Saltelli et al., 2004).  
Sensitivity measures were obtained for each parameter from 10,000 iterations using 
randomly selected parameter values from a uniform distribution for each of the 
parameters, with all other parameters set at default values (table 2.1), or alternatively with 
the βS value randomly selected from a normal distribution with mean and variance as 
estimated from the literature for herds using PMTD or no PMTD.  The values for the 
transmission parameter βS, δ, and ρ ranged from 0 to 0.1015, 1 to 8, and 0.50 to 0.98, 
respectively. The values for νCi ranged from 0.06250 to 0.00455, which are equivalent to 
a range of 46 to 250 days average total duration of chronic IMIs.   
The impact of variability in parameter estimates on estimates of indirect and 
overall treatment effects was explored across the full range of potential values for the 
parameters βS, δ, and ρ.  Mean model outputs were obtained from 10,000 iterations for 
each of 30 discrete βS values in 0.0035 unit steps, with δ and ρ values randomly selected 
from uniform distributions at the start of each iteration. Using model outputs for the 
default values νC0 and νC1 the indirect and overall effect estimates were obtained for each 
discrete value of βS. 
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Results 
 
For the initial default parameter values (table 2.1) the model predicted low 
infection prevalence at equilibrium, across the full range of νCi values.  For example, a 
prevalence of 6% infected quarters (IT =IN+IC) at equilibrium was observed when νCi was 
set at the hypothetical extreme of 0.00455 (i.e. the average duration of chronic IMI is set 
at an extreme estimate of 250 days).  Comparing scenarios using the proposed default 
values of νC0 and νC1 (table 2.1), a reduction in the duration of chronic subclinical IMI 
from 125 (νC0) to 70 days (νC1) resulted in both a lower overall prevalence of infection, a 
lower prevalence of new IMI, as well as a reduction in both the basic and effective 
reproductive numbers (table 2.3 and figure 2.3).  The direct effect of the treatment 
regimen with the higher cure rate (νC1) relative to spontaneous cure (νC0) was 0.44. The 
 
 
Table 2.3   Model realization of outcome variables for fixed parameter estimates in table 2.1, for treated 
and control populations, where treatment reduces the mean duration of chronic subclinical infections to 70 
days (νC1) compared to an untreated population where the mean duration of chronic IMI is 125days (νC0). 
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indirect and overall effects of the higher cure rate were predicted to reduce the 
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Figure 2.3  Scenario analysis.  Numeric realization of proportion infected quarters over time at initial 
default parameter estimates (table1).  Black lines total IMI (IT =IN + IC), grey lines new IMI (IN), solid lines 
(──) duration of chronic IMI = 125 days (υC0 = 0.01053), dashed lines (----) duration of chronic IMI = 70 
days (υC1 = 0.025).  At initial parameter estimates, effect of reducing duration of chronic subclinical IMI 
from 125 days to 70 days is to reduce steady state proportion of all infected quarters in herd (IT) from 
0.02643 to 0.01140, and of new IMI (IN) from 0.00661 to 0.00330. 
 
 
The model was found to be sensitive to changes in the four parameters of interest, 
with βS generally ranked as first in order of importance based on the graphical 
representations of the sensitivity measures as described by Saltelli et al. (2004) (figure 
2.4).  However, the relative impact of the parameters was dependent on the outcome 
measure being considered and on the fixed value of other parameters during the OAT 
analysis.  For example, there is a larger mean and variance in outcomes associated with 
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variation in βS under conditions of low transmission (PMTD use scenarios) compared to 
the effect of varying other parameters across their range of values (figure 2.4a).  In 
comparison, under high transmission conditions (no PMTD scenarios) the effect of 
varying other parameters on outcomes appears to be approximately equivalent to the 
effect of changing βS, and the greatest variance in outcome measures is observed for 
changes in the duration of chronic infection parameter (figure 2.4b).  Sensitivity of the 
model to changes in one parameter was influenced by other parameter values in a 
complex non-linear fashion (figure 2.5).  Of particular interest were the complex 
interactions between βS, δ, andνC on the equilibrium value of IN and RS and how the size 
of the RS state strongly influenced rates of new infections under some scenarios. In 
general there was a range of values of βS where the model was most sensitive to changes 
in νC, with changes in the duration of chronic IMI between 40 and 100 days having 
greatest effect on IN at βS near 0.014 (figure 2.5b).  These results suggest that under some 
transmission scenarios increasing the cure rate of chronic IMI may have minimal impact 
on rates of new infection in a herd (figure 2.5a).  In addition under conditions where δ >1 
and high βS it appears that interventions resulting in a shorter duration of infection are 
associated with higher equilibrium values of IN (e.g. figure 2.5b top two lines). A key 
finding was that there was a non-linear relationship between changes in βS and model 
outputs demonstrating a range of βS values where the model was very sensitive to 
changes in βS across all other parameter combinations (figure 2.5a). 
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Figure 2.4  Sensitivity analysis.  Steady state outcome estimates for new infection (In), chronic infection 
(Ic), and recovered susceptible (Rs) states obtained from model simulations. Values of βS were randomly 
sampled from a random normal distribution with mean (std dev) 0.00868 (0.000041) for populations of 
quarters using PMTD and 0.0362 (0.00061) for populations of quarters not using PMTD, with other 
parameters set at default values (table 2.1).   Values of δ, νC (=1/ ˆCd ), and ρ were randomly selected from 
uniform distributions across the full range of values, with βS set to mean estimates for PMTD and no 
PMTD scenarios. Results are mean and standard deviation (error bar) values obtained from 10,000 
iterations, demonstrating increased relative sensitivity (increased variability) of the model to changes in the 
transmission parameter (βS) under conditions of post milking teat disinfection (PMTD) (a.) and relative 
sensitivity of the model to variation in the cure rate νC and βS under conditions of no PMTD (b.) Results 
were similar for an alternative set of simulations where values of βS were randomly sampled from a 
uniform distribution across the full range of parameter estimates (data not shown). 
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Figure 2.5  a. Impact of changes in transmission parameter (βS ) on equilibrium value of new IMI (IN) for 
two υCi values, solid line (─) duration of chronic IMI = 125 days (υC0 = 0.010526), dashed line (- -) duration 
of chronic IMI = 70 days (υC1 = 0.025).   b. Impact of changes in ˆCd  (=1/ υC), on equilibrium value of new 
IMI (IN) for 5 βS values, 0.007 (—), 0.014 (····), 0.021 (──), 0.028 (─ · ─), 0.035 (─ ·· ─).  
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The treatment effect estimates were determined from a series of iterative model 
realizations across the range of parameter values. The direct effect of treatment was 
constant across these iterations at 0.44.  The overall effect of the antibiotic therapy 
program targeting treatment of chronic subclinical mastitis was found to be positive 
across all combinations of parameters, although at high values of βS the overall effect 
estimate
 
approached 0 regardless of the values of δ or ρ (figure 2.6).  The maximum 
indirect and overall effects were 0.88 and 0.89, respectively, and were found to occur 
when βS was 0.014, δ was in the range of 4.5 to 5.5, and ρ was between 0.52 and 0.62.  At 
these parameter values the equilibrium proportions of quarters in IN, IC, and IT were 
approximately 11, 14, and 25%, respectively in the control population compared to 1.4, 
1.4, and 2.8%, in the treated population.  Changes in ρ across the range of values from 
0.50 to 0.98 had a minimum impact on overall effect estimates for any particular 
combination of βS and δ values.  In comparison, changes in δ had a large impact on 
overall and indirect effect estimates across value combinations of βS and ρ.   Changes in 
βS had the strongest impact on effect estimates at βS values < 0.042 (figure 2.6).   
Across the full parameter space of these model runs, where the direct effect is 
again constant, the indirect effect of treatment was found to range from -0.43 to 0.88 and 
the overall effect of treatment ranged from 0.01 to 0.89.  Additional model iterations 
were stratified by βS values and descriptive statistics calculated for each strata, where four 
strata were defined as low transmission (βS < 0.014), moderate transmission (βS 0.014 to 
0.021), high transmission (βS 0.0245 to 0.0315), and extreme transmission (βS > 0.0315)  
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Figure 2.6  Impact of changes in transmission parameter (βS ) on effect estimates across the full parameter 
space of  δ and ρ.   a. indirect effect estimates;   b. overall effect estimates. Points are mean values of the 
effect estimate for 10,000 simulations for each of 30 βS values, error bars are standard deviation. 
 
  55 
(table 2.4).  All indirect effect estimates were positive at values of βS ≤ 0.021, noting that 
as βS approaches zero so do the indirect effects (figure 2.6a).  In the range of βS values 
from 0.0035 to 0.014 the mean indirect effects across the full parameter space of δ and ρ 
was 0.516 (s.d. 0.22, min= -0.128 max= 0.882), and mean overall effect was 0.608 (s.d. 
0.158, min=0.219 max=0.890). At approximately βS > 0.028 the mean indirect effects are 
observed to become negative for any δ ≥ 2.   
 
 
Table 2.4  Indirect and overall effect estimate values observed for model realizations over the range of 
values for βS (0 to 0.1015), δ (1 to 8), and ρ (0.5 to 0.98) stratified by transmission parameter ranges, low 
transmission (βS < 0.014), moderate transmission (βS 0.014 to 0.021), high transmission (βS 0.0245 to 
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Discussion 
 
In simulating the impact of treating chronic subclinical mastitis during lactation 
using clinically relevant parameter estimates, the overall treatment effect was positive 
across all parameter values. However, under scenarios where transmission rates have 
been associated with mastitis outbreaks, in populations of quarters where teat end 
disinfection was not applied, the overall effect estimates were generally less than 0.20 
and approached zero (figure 2.6b). We defined these transmission rate scenarios as high 
and extreme in this study, and under these scenarios the indirect effect of the intervention 
was estimated to become negative.  Under high transmission scenarios it appears that 
increasing cure rates from the chronic state increases the size of the recovered susceptible 
pool, thus contributing to a higher proportion of new infections at equilibrium compared 
to scenarios with lower cure rates (figure 2.5b). 
Previously, Zadoks et al. (2002) reported the potential indirect benefit of 
increasing the cure rate of subclinical S. aureus infections through prompt diagnosis and 
treatment. In that study the transmission parameters (βS) and δ were 0.007 and 6, and 
0.014 and 3.7, for two herds respectively.  These parameter values were in the range of 
values where treatment was predicted to have a positive indirect effect in our current 
study, and simulation results in our current study were consistent with those of the 
previous report (compare figure 2.2 in this study to figure 5 in Zadoks et al. (2002)).   
Further, using herd specific parameter estimates obtained from peer-reviewed 
publications our current model was able to predict quarter level infection prevalence 
proportions that are approximately equivalent to the reported true prevalence for those 
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herds (data not shown). This is not surprising, as the current model structure is similar to 
the transmission models that were used to generate the herd specific estimates (Lam et 
al., 1996; Zadoks, 2002; White et al., 2006).    
In economic models Swinkels et al. (Swinkels et al., 2005a; Swinkels et al., 
2005b) recognized the potential economic impact of indirect effects of mastitis treatment.  
In those studies the authors estimated the indirect effect of treatment as a constant 
function across two transmission scenarios.  Data from our current study would suggest 
the proportion of prevented infections associated with treatment is not constant, but a 
complex function of cure rates, transmission rates, and the difference in the force of 
infection for naïve susceptible and recovered susceptible quarters.   Our results suggest 
that there may be a range of transmission rates where the indirect effect of lactation 
therapy of subclinical mastitis may be positive and this may be important for advisers to 
consider when designing treatment programs.  The practical implication of these findings 
is that the indirect benefit of treating chronic subclinical mastitis in high transmission 
scenarios may be limited. In such situations, producers would be better advised to first 
focus on mastitis control practices that reduce the transmission rate, or that remove 
chronically infected quarters without contributing to increasing the proportion of quarters 
in the recovered susceptible state (e.g. culling or drying of cows or quarters).  This is 
consistent with previous findings of White et al. (2006) who demonstrated that 
interventions had a reduced effect in herds with a high transmission rate, and suggested in 
these herds “determinants of transmission should be addressed before (or simultaneously 
with) application of other interventions.”  In contrast, at moderate to low transmission 
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scenarios (i.e. approximately βS ≤ 0.021), the indirect, and overall effect estimates are 
predominately strongly positive.  This suggests that dairy producers that have 
successfully implemented PMTD programs may benefit from the addition of targeted 
subclinical mastitis treatment programs to further control mastitis prevalence and 
transmission.  Based on our current findings, herds that may benefit the most from such 
programs are those with transmission parameter estimates in the range of 0.007 to 0.014.  
One issue that arises from these observations is the potential difficulty in 
estimating herd specific mastitis transmission rates in the absence of extensive 
longitudinal bacteriologic monitoring. The transmission parameter β is a function of the 
contact rate (c) between susceptible and infectious individuals, and the transmission 
probability (p) upon contact (Anderson and May, 1991). These parameters, c, p, and thus 
β, are conditional on our ability to measure exposure to infection, and are frequently 
difficult to measure directly (Halloran et al., 1997).  Estimates of β are obtained from 
longitudinal disease incidence data, and are likely herd specific within a range of values 
dependent upon milking hygiene practices (e.g. use of PMTD) and dominant species or 
strains of pathogens causing mastitis, among other potential factors.  Additional studies 
are needed to estimate the transmission parameters of mastitis pathogens and to quantify 
to what extent recovered susceptible quarters are at increased risk for intramammary 
infections compared to naïve susceptible quarters.  This is relevant to understanding the 
potential impact of interventions, as Safan et al. (2006) have recently proposed that the 
ratio (“r”) of susceptibility after primary infection and susceptibility after secondary 
infection is a key parameter in endemic steady state models where backward bifurcation 
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may occur.  Here we have presented an infectious disease model where under some 
scenarios implementation of an intervention may contribute to higher rates of new 
infections due to continual filling of the recovered susceptible state. 
To the best of our knowledge this is the first study describing a method to 
quantify the indirect effect of antibiotic treatment interventions for control of mastitis in 
dairy herds across a range of parameter values with complex interactions. Methods for 
estimating the direct and indirect effects of interventions have been developed mostly for 
vaccination trials and are based on ratios of disease risk or infection probabilities in 
populations receiving the intervention and control populations (Halloran et al., 1997; 
Haber, 1999; Hayes et al., 2000). Unlike vaccination or hygiene programs which act to 
reduce the transmission probability (β), the effect of a targeted antimicrobial treatment 
program is primarily through reduction in duration of infectiousness.  Furthermore, we 
assumed there to be no extended change in susceptibility of an individual host receiving a 
course of antibiotic treatment (except during the course of therapy, and for mastitis 
treatment this can be considered of minor length compared to the total time at risk in the 
population). However, this assumption ignores the potential that targeted therapy with a 
narrow spectrum antimicrobial may create an opportunity for infection caused by another 
species or strain of bacteria that is resistant to the therapeutic. Unlike ‘blanket’ dry cow 
treatment of all cows at the end of lactations or other mass treatment interventions [e.g. 
introduction of insecticide treated bed nets, or delivery of antibiotics in defined 
geographic regions (Hayes et al., 2000; Pourbohloul et al., 2003)], treatment in this model 
targeted only those individual quarters diagnosed as infected.  The indirect effect of the 
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intervention was assumed to be the reduced risk of infection among susceptible 
individuals, or as Farrington (2003) described “the efficacy against transmission” and in 
this study was calculated as the reduction in the proportion of quarters with new 
infections at equilibrium. Because the determination of indirect and overall effects of an 
intervention requires comparison of 2 populations, in this study we modeled two 
populations by duplicating simulations at each of two cure rates to represent a negative 
controlled field trial where all other factors (i.e. parameters) in the treated and control 
populations are equivalent.  We believe the model has clinical relevance in predicting the 
indirect and overall impacts of antibiotic treatment interventions during lactation.  An 
advantage to these methods is the ability to explore a large range of scenarios. Future 
work on evaluating the population level effects of lactation therapy should include 
completion of clinical field trials. Given our present results, such trials might be initially 
conducted in herds that, based on herd management practices, are expected to have 




Indirect and overall effects have been described as important measures in 
evaluations of the efficacy of mastitis treatment interventions in dairy cattle populations. 
This model provides evidence of the potential complex relationship between biologically 
relevant parameters that may impact indirect effect estimates, and the importance of 
variation in these parameters, especially the transmission parameter. A key conclusion is 
that positive population level effects of lactation therapy may be realized for herds that 
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have successfully implemented practices that reduce the transmission rate of pathogens, 
while in herds with high pathogen transmission rates, targeted treatment of chronically 
infected quarters may have little impact on the proportion of infected quarters and no 
positive effect in reducing new infection rates. 
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A split herd negative controlled field trial was conducted on 2 commercial dairy 
herds to evaluate the direct and indirect effects of a diagnosis and treatment program 
targeting Staphylococcus aureus subclinical mastitis. Monthly somatic cell count and 
bacteriologic culture were used to identify cows with chronic subclinical mastitis. The 
trial included a 3 month observation period followed by a 10 month intervention period. 
Pulsed-field gel electrophoresis (PFGE) was used to determine strain specific S. aureus 
infection dynamics in treated and control groups.  The direct effect of extended (8 days) 
intramammary lactation therapy with pirlimycin hydrochloride was demonstrated by an 
increased proportion of cure and an overall reduction in duration of infection in quarters 
receiving treatment compared to untreated controls.  A reduction in the incidence of 
clinical S. aureus mastitis in the treated group was observed on one farm, while no 
clinical S. aureus mastitis was observed on the second farm.  New post-treatment clinical 
and subclinical infections caused by different PFGE types of S. aureus, Streptococcus 
spp., or by coliform species were observed in 50% of quarters that received extended 
therapy.  These infections appeared to occur either during, within the week immediately 
following, or more than 3 weeks following treatment, and likely influenced the 
observation that there was no effect of treatment on cow level SCC at 45 days post 
treatment. The proportion of mastitis associated culls in treated and control groups was 
not different. The incidence of new S. aureus IMI in the treatment and control groups was 
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not significantly different when data was pooled over farms, PFGE types, and time. 
Elimination of new infections caused by the dominant strain type on one farm, and 
reduction in IMI incidence in the first 6 months of the intervention period on the other 
farm, were consistent with the presence of an indirect effect of therapy.  New infections 
in recovered susceptible quarters, and the emergence of a new PFGE type on one farm 
influenced incidence during the final 4 months of the intervention period. PFGE of pre- 
and post treatment isolates, as well as representative isolates taken over the duration of all 
IMI, provided more precise estimates of new infection, cure, and re-infection rates. This 
study provides evidence that treatment of subclinical S. aureus mastitis during lactation 
may be beneficial in some herds or for some strain types as a result of both direct and 
indirect treatment effects. The finding of frequent post-treatment infections is a concern 
and significantly limited the potential value of extended pirlimycin therapy on these 
farms. Application of lactation therapy programs may require bacteriologic monitoring to 
identify potential shifts in the dominant strain types, and infection of recovered 
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Introduction 
 
 Mastitis continues to be recognized as one of the most economically important 
health problems of dairy cattle (Allore and Erb, 1998; Ott and Novak, 2001).  Subclinical 
mastitis, characterized by an elevated milk somatic cell count (SCC), is the dominant 
form, and frequently goes undetected and untreated by dairy producers for extended 
periods (Bramley and Dodd, 1984; Hillerton et al., 1995; Oliver et al., 2004). Increased 
somatic cell count is associated with reduced milk production, increased risk of antibiotic 
residue violations, reduced fluid milk quality, and reduced cheese yield and quality 
(Reneau, 1986; van Schaik et al., 2002; Santos et al., 2003). Reduced productivity and 
lost milk quality payments associated with subclinical mastitis represent more than half 
of the estimated $1.8 billion in costs attributed to mastitis for U.S. dairy producers 
annually (Ott and Novak, 2001). The association between the increased somatic cell 
count due to subclinical mastitis, and reduced productivity and milk quality presents a 
potential economic opportunity for dairy producers through implementation of control 
programs targeting subclinical mastitis.   
 Current mastitis control recommendations are intended to reduce the duration of 
infections and prevent new infections. Management procedures to accomplish this 
include the use of long acting antibiotics in all quarters of all cows at the end of lactation 
(dry-cow therapy), and application of a post-milking teat disinfectant following each 
milking (Neave et al., 1969; Bramley and Dodd, 1984; Hillerton and Berry, 2005).  
Treatment of mastitis during lactation has been predominately limited to the treatment of 
clinical cases, as the economic value of lactation therapy to treat subclinical mastitis is 
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debated (McDermott et al., 1983; Reneau, 1986; Swinkels et al., 2005a; Swinkels et al., 
2005b).  A number of reports have described the direct effect of lactation therapy for 
subclinical mastitis caused by the major gram-positive pathogens Staphylococcus aureus 
and Streptococcus uberis [e.g. Deluyker et al., (2005) and Gillespie et al., (2002), and 
summarized in Barlow et al., (J. Barlow, unpublished data – manuscript submitted, 
Chapter 2 of this dissertation)].  Delaying treatment of subclinical mastitis until the end 
of lactation increases the duration of infection. An increased duration of infection reduces 
the probability of cure (reviewed in Barkema et al., 2006), and may increase the risk of 
exposure for uninfected quarters as cases of subclinical mastitis may constitute a 
reservoir of bacteria that are an important source of infection in a herd (Zadoks et al., 
2001a; Zadoks et al., 2002a).  Hence, curing cases of subclinical mastitis has a direct 
effect on the individual animal, but may also have an indirect effect on other animals in 
the same herd, as eliminating infections reduces transmission risk or the force of infection 
of contagious pathogens (Zadoks et al., 2002a; Barkema et al., 2006; White et al., 2006; 
J. Barlow unpublished data - manuscript submitted, Chapter 2 of this dissertation)].  
Other potential benefits of treating subclinical mastitis may include reduced clinical 
mastitis by prevention of clinical flare-ups, improved milk quality through SCC 
reduction, decreased mastitis associated culling, and increased milk production.  In a pair 
of partial budget models Swinkels et al. (2005a; 2005b) recently concluded that lactation 
therapy of subclinical mastitis may be economically justified in some situations, 
particularly in high transmission scenarios.  However, Barlow et al. showed that there 
was a curvi-linear effect of the transmission potential on the size of the indirect treatment 
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effect (J. Barlow, unpublished data – manuscript submitted, Chapter 2 of this 
dissertation).  Using a deterministic disease transmission model, it was suggested that 
under moderate transmission scenarios the indirect treatment effect was indeed high and 
important, however, perhaps paradoxically, under very high transmission scenarios the 
indirect effect of therapy may be close to or less than zero. Previously reported estimates 
regarding potential indirect effects of lactation therapy are based on observational studies 
and disease transmission and economic models derived from those studies (Lam et al., 
1996; Lam et al., 1997b; Zadoks et al., 2001a; Zadoks et al., 2002a; Swinkels et al., 
2005a; Swinkels et al., 2005b).  To date no controlled field trials have been conducted to 
test whether the predicted indirect effects of subclinical mastitis treatment strategies can 
be demonstrated on commercial dairy farms.   Furthermore, there is limited knowledge 
on the impact of such interventions on the population dynamics of specific bacterial 
strains.  Recent reports have suggested differences among S. aureus strain types in 
response to therapy (Barkema et al., 2006; Haveri et al., 2007), and in risk of 
transmission (Smith et al., 1998).  
  In this research a clinical field trial was designed to evaluate the potential direct 
and indirect effects of a diagnosis driven treatment program targeting subclinical mastitis. 
In this report we describe the results of targeted lactation therapy of chronic subclinical S. 
aureus mastitis, and include pulsed field gel electrophoresis (PFGE) typing to identify 
strain specific S. aureus infection dynamics. Outcomes evaluated in this study included 
infection prevalence and incidence, rates of clinical mastitis and mastitis associated 
culling, and impact on cow level somatic cell count (SCC). 
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Materials and Methods 
 
Study design 
The negative-controlled treatment trial was conducted for a period of 13 months 
in two commercial dairy herds (Herd 1 was located in New York and Herd 2 in 
Vermont). Herd size, average milk production, and bulk tank milk somatic cell counts 
(BTSCC) are shown in table 3.1. Groups of approximately 100 lactating cows were 
housed in separate pens in free-stall housing on each farm (table 3.1). Cows on each farm 
were milked 3 times per day in a milking parlor.  Criteria for participation included: 1) 
reliable individual cattle identification based on sequential identification numbers 
assigned at birth or entry into the lactating herd; 2) housing of lactating dairy cattle in two 
or more comparable groups (“strings”) of approximately 100 cows in separate pens 
(“free-stall housing”); 3) enrollment in a Dairy Herd Improvement Association (DHIA) 
monthly testing program including SCC; 4) an average monthly herd somatic cell count 
between 250,000 and 500,000 cells/ml; 5) accepted mastitis control practices applied to 
all cows, including use of pre- and post-milking teat disinfectant solutions, and blanket 
use of dry-cow therapy; 6) segregated housing for lactating cows receiving antibiotic 
treatments (i.e. a treated cow pen); 7) ability to keep written records on all cows, 
including events and dates of calving, entries and exits from lactating cow pen groups, 
clinical disease, treatment, and culling; and 8) ability and willingness to collect and store 
milk samples associated with these events. Herd owners were financially compensated 
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for participation. The study was conducted with approval of the University of Vermont 
Institutional Animal Care and Use Committee (IACUC).  
 The treatment unit was the group of lactating cows with treatment randomly 
allocated to one of 2 designated pens within herds. In the month preceding the start of the 
study, cows were systematically assigned to pens based on odd or even identification 
numbers. Cows that calved during the study were assigned to either the treatment or 
negative control groups (pens) based on odd-even identification number.  Within farms, 
no differences in mean parity, days in milk, or somatic cell count, were found among 
treatment and control groups at the start of the study by using this assignment method. 
Groups within herds were a dynamic population, with entries and exits of individuals into 
the study population following normal management cycles.  Dates of all entries and exits 
to treatment or control pens were recorded for each cow.  Pens of cows within each herd 
were milked in the following order at each milking session: fresh cow group, study 
treatment group, study control group, additional groups not enrolled in study. The 
milking system was washed and sanitized between each milking session.  There was no 
rinsing or disinfection of milking units after milking individual cows during a milking 
session, and neither farm used a back-flushing system.  
The farms applied accepted mastitis control practices to all cows including use of 
iodine based (0.5 to 1 %) pre- and post-milking teat disinfectant solutions, and blanket 
use of commercially available dry-cow therapy products (herd 1, cephapirin benzathine; 
herd 2, cloxacillin benzathine).  The use of somatic cell count or bacteriologic culture 
data to segregate chronically infected cows was not practiced on either farm.  The use of 
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bacteriologic culture to aid clinical mastitis treatment decisions was not practiced on 
either farm. No diagnosis and treatment of subclinical mastitis was practiced on either 
farm prior to the start of the study.  Cows with clinical mastitis were treated with 
commercially available intramammary formulations of amoxicillin, cephapirin sodium, or 
pirlimycin hydrochloride on farm 1 and amoxicillin or pirlimycin hydrochloride on farm 
2.  Lactating cows in herd 1 were bedded on mattresses with sawdust bedding, while in 
herd 2 lactating cow stalls were deep-bedded with sand. Stocking density of study pens 
on both farms exceeded number of stalls by 18 to 20%. In both herds dry cows were 
loose-housed in a separate covered facility on a chopped straw bedded pack.  
 
Milk sample collection and bacteriologic analysis 
Composite milk samples were collected monthly by DHIA technicians and 
processed through the regional commercial testing laboratories for SCC testing. 
Individual quarter milk samples were collected for microbiologic analysis from all cows 
in control and treatment groups at the start of the study, at monthly intervals for the 
duration of the study, and at the end of the study. These quarter samples were collected 
within 3 days of DHIA monthly composite sample collection. Quarter milk samples were 
also collected from all cows within 3 days following parturition (fresh sample), 
immediately following identification of clinical mastitis (clinical pre-treatment sample), 
immediately prior to treatment of subclinical mastitis (subclinical pre-treatment sample), 
at any time when cows were added to or removed from the study pens for greater than 24 
hours (entry/exit sample), immediately prior to exit from the herd (cull sample), and at 
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approximately 7, 14, 21, and 28 days following cessation of any antibiotic therapy 
(clinical or subclinical post-treatment samples).  Monthly sample collection was 
conducted by trained field technicians, while farm personnel were trained to collect all 
additional samples following established aseptic methods (Hogan et al., 1999).  Samples 
collected by farm personnel were immediately stored frozen at -20°C and transported 
frozen to the microbiology laboratory at two-week intervals. Monthly samples were held 
on ice immediately following collection and during transport to the laboratory, and were 
stored frozen at -20°C for 24 – 72 hours.  All samples were thawed over-night under 
refrigeration and aerobic bacteriologic culture and interpretation of results were 
performed according to established guidelines (Hogan et al., 1999). Samples with >3 
morphologically distinct colony types were considered contaminated and eliminated from 
analysis.  For all morphologically distinct colony types in uncontaminated samples, the 
number of colony forming units (cfu) per 0.01 ml was recorded as a one of four 
categories: 1 to 4, 5 to 9, 10 to 49, or ≥ 50 cfu (Dingwell et al., 2003). 
 
Infection status  
This study was intended to model a practical treatment program that might be 
applied on commercial farms where an elevated SCC is used to trigger bacteriologic 
culture and culture results are used to trigger a treatment decision. Sequential cow level 
SCC was evaluated to identify cases of chronic subclinical mastitis which was defined as 
SCC ≥ 200,000 cells/ml for 2 of the past 3 serial monthly composite milk samples 
(Schukken et al., 2003). Chronic subclinical mastitis based on composite SCC results was 
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used as a criterion for enrollment for treatment as described in the next section, and was 
distinguished from intramammary infection status based on serial bacteriologic culture of 
quarter milk samples. Bacteriologic culture was used to define intramammary infection 
status as previously described by Zadoks, et al. (Zadoks et al., 2002a). Briefly, individual 
quarters were categorized as infected when positive on bacteriologic culture for a single 
species based on at least one of the following criteria: 1) ≥1000 cfu/ml from a single 
sample, 2) ≥500 cfu/ml from two out of three consecutive samples, 3) ≥100 cfu/ml from 
3 of 3 consecutive samples, or 4) ≥100 cfu/ml from a clinical sample.  Samples with 
bacteria isolated that did not meet the above criteria were defined as incidental isolation 
events. An individual quarter was defined as having a subclinical IMI when meeting any 
one of the first three criteria and having no occurrence of clinical mastitis within the past 
14 days.   A quarter with a subclinical IMI was defined as spontaneously cured when the 
quarter was negative for the same pathogen on 2 consecutive samples taken over at least 
a 28 day interval (Zadoks et al., 2002a). This definition was used to limit the number of 
errors in defining a cure due to the potential of observing a single false negative culture 
result on serial samples (Morant et al., 1988; Sears et al., 1990). A subclinical IMI was 
defined as cured following therapy when culture negative for the pre-treatment species or 
strain type on 4 of 4 post treatment samples taken at 7 (± 2) day intervals (Gillespie et al., 
2002).  A clinical mastitis case was defined as an abnormality in appearance or 
consistency of milk, with or without either local and/or systemic signs associated with 
infection. A new clinical mastitis case or event was identified at the quarter level after 
that quarter was observed free of clinical signs for ≥ 14 days or if clinical mastitis 
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occurred within 14 days of a previous case but was caused by a different pathogen 
species or a different strain within species. A clinical IMI was classified as a 
bacteriological cure when culture negative for the pre-treatment species or strain on 4 of 
4 post treatment samples taken at 7 (± 2) day intervals.  The infection status following 
either spontaneous cure or therapeutic cure was monitored for the duration of the study or 
until an animal exited the study population. Data on infection status and cure was 
recorded for all aerobic bacterial species identified during the trial.  A re-infection of a 
quarter that was previously defined as cured followed the above IMI definitions. 
 
Treatment program   
Cows assigned to the treatment group that had chronic subclinical mastitis (i.e. an 
elevated composite SCC ≥200,000 in 2 of 3 of the recent months) in combination with a 
positive S. aureus culture in at least one quarter in the current month were eligible for 
subclinical mastitis lactation therapy.  Figure 1 outlines the implementation of the 
treatment program within the study design. All lactating quarters of eligible cows were 
treated with a commercially available intramammary formulation of the lincosamide 
antibiotic pirlimycin hydrochloride (Pirsue, Pfizer Animal Health, New York) at the 
labeled daily dosage (50 mg) for an extended (8 days) duration of therapy (extended 
therapy) (Gillespie et al., 2002; Oliver et al., 2003; Deluyker et al., 2005).  Cows in the 
treatment group identified with a subclinical IMI due to a gram-negative pathogen in the   
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Figure 3.1 Study design and sample collection procedures for a subclinical mastitis treatment trial 
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current month were not eligible for extended therapy due to the limited antimicrobial 
spectrum of pirlimycin. Cows that had received treatment for a case of clinical mastitis 
within the previous 14 days were not eligible for extended therapy.  No additional 
covariates that might influence treatment success (e.g. cow lactation number or number 
of infected quarters, or pathogen duration of infection or antimicrobial susceptibility 
phenotype) were used to select cows for treatment. Treated cows on both farms were 
segregated in a ‘sick cow’ pen during treatment and subsequent milk withhold periods.   
A maximum of approximately 6 cows could be enrolled for extended therapy at any 
particular time due to the small size and number of available stalls in the treated cow pen 
on each farm.  Cows in the control group diagnosed with subclinical IMI and determined 
eligible for treatment received no extended therapy, nor an excipient infusion. Cows 
experiencing clinical mastitis in either group were treated using the established practices 
on the participating farms and records were maintained on the type and duration of 
therapy.  There was a 3-month ‘pre-intervention’ observation period at the start of the 
study prior to a 10 month intervention period.  All data as described above were collected 
during both the initial 3 month observation and the subsequent 10 month intervention 
period. 
 
Species identification and S. aureus strain typing   
Representative presumptive Staphylococcus spp. colonies were identified based 
on growth characteristics, and were transferred to a blood agar plate for isolation and 
further identification.  All catalase-positive, hemolytic, gram-positive cocci were tested 
  80 
for coagulase activity by tube agglutination methods (Hogan et al., 1999). Following 
preliminary species identification and prior to further analysis, coagulase positive 
staphylococci isolates were transferred to broth culture and stored at -80°C on ceramic 
beads (CryoBank beads, Copan Diagnostics Inc., Murrieta, CA) in tryptone soy broth 
with 15% glycerol.  Bacterial growth from a quarter milk sample was examined for 
potential variability in hemolysis or pigmentation patterns of presumptive S. aureus 
colonies, and isolates representing any phenotypic variants were stored separately.  All 
stored coagulase-positive gram-positive cocci were tested by PCR amplification of the 
thermonuclease gene (nuc) using established methods to confirm species identity 
(Brakstad et al., 1992).  Within each quarter, representative S. aureus isolates were 
selected from each IMI for strain typing by PFGE.  All isolates from single isolation 
events were included. In quarters having more than one isolation event over time, isolates 
for strain typing were selected from early, middle, and late time points. In addition, pre- 
and post-treatment isolates were selected for strain typing for all cows receiving lactation 
therapy.   
PFGE typing was conducted as described by McDougal et al. (2003), with slight 
modifications. Isolates were grown overnight on trypticase soy agar plates containing 
sheep blood and 0.1% esculin. A single colony was inoculated into 5 ml Brain Heart 
Infusion broth (Becton-Dickinson, Sparks, MD) and incubated overnight at 37°C. 
Overnight cultures were adjusted to an optical density of 1.3 to 1.4 using a 
spectrophotometer (SmartSpec Plus, Bio-Rad, Hercules, CA) at 610 nm. Eight hundred 
µl of the adjusted cell suspension was centrifuged at 13,000 rpm for 5 minutes and the 
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supernatant was removed.  Pellets were re-suspended in 300 µl of Tris-EDTA (TE) buffer 
(1M Tris-HCL, pH8; 0.5M EDTA, pH8), equilibrated in a 37°C water bath for 10 min 
and mixed with 10 µl lysostaphin (1mg/mL in 20mM of sodium acetate, pH 4.5, Sigma-
Aldrich, St. Louis, MO). The suspension was then mixed with 300 µl of 1.8% SeaKem 
Gold agarose (Lonza, Rockland, MD) in TE buffer (equilibrated to 55°C) and dispensed 
into the wells of the large plug molds (Bio-Rad, Hercules, CA). Once solidified, plugs 
were transferred to tubes containing 3 ml of EC lysis buffer (6mM Tris HCl, 1M NaCl, 
100 mM EDTA, 0.5% Brij-58, 0.2% sodium deoxycholate, 0.5% sodium-lauroyl-
sarcosine) and incubated at 37°C overnight. Plugs were washed 5 times in TE buffer on 
an orbital rocker for 30 min at a time and stored in 4 ml TE Buffer at 4°C. The plug was 
sliced to 2 x 10mm and the slices were equilibrated in 1X restriction buffer (New 
England BioLabs, Ipswich, MA) for at least 30min.  After removal of the buffer, the 
restriction enzyme digestion was performed using 1.5 µl of SmaI (20U/µl, New England 
BioLabs, Ipswich, MA) in 1X buffer at 25°C overnight. Plugs were loaded into wells of a 
1% SeaKem gold agarose gel in 0.5X TBE buffer (0.9 M Tris base, 0.9 M Boric acid, 
0.02 M EDTA pH 8.0; Fisher Scientific, Fairlawn, NJ). The wells were sealed with 1% 
molten agarose.  Gels were run for 21 hours at 14°C using a CHEF-Mapper (Bio-Rad, 
Hercules, CA) at 6.0 V/cm with initial switch time 5 seconds, final switch time 40 
seconds, linear ramping and angle 120°.  After the electrophoresis was completed, the gel 
was stained in a 1µg/mL ethidium bromide solution (EMD Chemicals, San Diego, CA) 
for 30 min. and destained in fresh distilled water for 30 min.  Results were documented 
using the GelDoc 2000 (Bio-Rad, Hercules, CA).  PFGE types were identified by visual 
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examination of gels by two independent observers using established criteria (Tenover et 
al., 1995; Zadoks et al., 2002b), with different types identified by > 3 band differences on 
restriction digest patterns and indicated by an arbitrary numeric code. Isolates that 
differed by 1 to 3 bands were defined as a subtype and indicated by a lowercase letter 
following the type number designation.  
 
Duration of infection 
Duration of infection was calculated based on mid-point estimation method 
previously described by Zadoks et al. (Zadoks et al., 2003), where start of the IMI was 
defined as the middle of the time interval between a negative culture and the first positive 
culture event, and end of the IMI was defined as the middle of the time interval between 
the last positive culture and the first negative culture event for a quarter defined as cured. 
Quarters that entered the study infected, either at the start of the study or at the start of 
lactation, were considered left censored IMI and the start date was the date of first 
positive culture at time of entry. Infected quarters that exited the study were considered 
right censored and the IMI end date was the date of exit or the end date of the study for 
those lactating quarters still infected on the last monthly sample date. Quarter days 
infected (IMI prevalence days) in the study pens were calculated based on recorded dates 
of IMI start and end.  Quarter days susceptible (i.e. days at risk for new IMI among 
uninfected quarters) were calculated based on recorded dates of cow entry and exit from 
the study pens accounting for the date of changes in quarter infection status during each 
interval.  Non-lactating quarters in lactating cows were identified with the date of milking 
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cessation of the individual quarters (i.e. quarter ‘culling’) so that data on infected or 
susceptible quarter days accounted for any ‘blind’ or culled quarters within lactating 
cows.   
 
Statistical methods 
 All statistical analysis was conducted using SAS version 9 (SAS Institute, Inc., 
Cary, NC, USA). Pearson chi square or Fisher’s exact test were used to test for 
associations between treatment group and the proportion of quarters becoming re-infected 
following cure, or the proportion of quarters displaying at least one clinical mastitis 
event, or the proportion of quarters culled due to mastitis.  For the purpose of comparison 
of proportions and estimating odds ratios for clinical mastitis events only the first S. 
aureus clinical mastitis event was considered, although repeated clinical events within 
quarters were reported to quantify the total number of clinical mastitis events in treatment 
and control groups. The hypothesis that treatment affected duration of infection was 
tested using the Log-rank test to compare the Kaplan-Meier survival function for treated 
and control S. aureus IMI, while controlling for the effect of PFGE type. We also 
modeled the effect of treatment on duration of infection using a linear regression model 
including PFGE type as a covariate. Lactation duration for treated and control S. aureus 
IMI was also modeled using Kaplan-Meier survival methods accounting for censored 
events, using DHIA records of days in milk to define current lactation duration at either 
exit from the study or the end of the study. 
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Prevalence of S. aureus IMI (number of quarters days infected, PT ), and 
incidence of new S. aureus IMI (number of new IMI, IN ), were analyzed as outcomes 
using generalized linear models (PROC GENMOD, SAS) and model checking included 
examination of deviance and Pearson Chi-square for goodness of fit (Lam et al., 1996; 
Zadoks et al., 2002a).  Evidence of overdispersion was adjusted using Pearson Chi-square 
estimates divided by the degrees of freedom (Pscale option). Binomial, Poisson, or 
Negative Binomial error distributions were selected for final models after comparisons 
for goodness of fit.  Backward elimination of variables was used to select the final 
models with treatment group (Group), the effect of interest, forced into all final models 
and additional independent variables and their 2- and 3-way interactions included when 
the probability of significance was <0.10.  Additional variables included in the full 
models were farm, time period (Timep), and PFGE type (PFGEtype) where prevalence 
was the dependent variable, and these same variables plus prevalence (PT) where 
incidence was the dependent variable. Time period was modeled with 2 categories 
defining the pre-intervention (observation) period as 0 and the intervention period as 1.  
Because we observed differences in strain dynamics over time, we also modeled time 
period with 3 categories, by separating pre-intervention (earlytp, months 1-3), early 
(midtp, months 4-8) and late (latetp, months 9-13) intervention periods. In the final 
prevalence model, the impact of treatment group on the prevalence in each interval was 
modeled assuming a negative binomial distribution, a log link, and an offset of the total 
number of quarter days, 
                       [ ]ln( ) * ln( )TP intcpt Group Timep Group Timep Nε = + + + +                     [3.1], 
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where ε = expected value and ln(N)= offset. Comparison of least square means IMI 
quarter-days prevalence (PT) between treatment and control groups and across 
observation and intervention time periods was conducted separately for each farm using 
model 3.1 and accounting for multiple comparisons with Bonferroni methods.   
The impact of treatment on incidence in each interval was estimated in a Poisson 
regression model, with a Poisson error distribution, a log link, and an offset of the 
number of quarter days susceptible for new IMI (S),  
                        [ ]ln( ) * ln( )NI intcpt Group Timep Group Timep Sε = + + + +                       [3.2]. 
Since prevalence was affected by treatment, prevalence was not included as a covariate in 
model 3.2.  
            Somatic cell count data was log transformed (LSCC) and the effect of treatment 
on LSCC was estimated using a generalized linear model (PROC MIXED, SAS) with 
lactation number category (lactation 1, lactation ≥2), days in milk category (1-90, 91-180, 
>180), and post-treatment IMI species (none, major gram-positive, coliform) included as 
covariates.    
            Transmission parameters (βi) were estimated from a generalized linear model with 
number of new IMI events in each monthly interval (IN) as the outcome, a log link, 
assuming a Poisson distribution, and offset ln(S*I/N) (Lam et al., 1996; Zadoks et al., 
2002a),  
                           [ ]ln( ) * ln( * / )N iI S I Nε β= +                                                         [3.3], 
where β*= ln(β), S = quarter days susceptible, I = quarter days infected, and N = total 
quarter days in each interval. Separate transmission parameters (including 95% 
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confidence intervals) were estimated for the individual farms, as well as between 
treatment periods, groups, and for PFGE types. The univariate effect of farm, treatment 
group, time period, and PFGE type on transmission parameter estimates were estimated 




Intramammary infections eligible for therapy in treated and control groups  
A total of 31,761 quarter milk samples were collected from the two farms, with S. 
aureus isolated from 330 samples. On farm one, there were 14,467 quarter samples taken 
from 3675 sample events from 385 cows, with 209 (1.4%) samples identified as 
contaminated leaving 14258 quarter samples for analysis. Of these, S. aureus was 
isolated from 258 (1.8%) samples. On farm two, there were 17,294 quarter samples taken 
from 4387 sample events from 580 cows, with 787 (4.6%) samples identified as 
contaminated leaving 16,507 quarter samples for analysis. Of these, S. aureus was 
isolated from 72 (0.4%) samples. 
On farm 1 there were 217 S. aureus isolates associated with 48 IMI in 46 quarters 
of 41 cows, and 37 incidental isolates from 33 quarters of 28 cows that did not meet our 
definition of IMI. On farm 2 there were 59 S. aureus isolates associated with 13 IMI in 
12 quarters of 10 cows, and 2 incidental isolates from 2 quarters of 2 cows (table 3.1).  In 
addition, 13 IMI isolates and 2 incidental isolates were obtained from milk samples 
collected from cows sampled at the start of a lactation where either the IMI cured prior to 
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entry into a study pen or the cow did not enter a study pen during the course of the trial.  
The number of isolates associated with an IMI identified in quarters of cows in the 
treatment and control pens is shown in table 3.1.   
 
Table 3.1 Herd and study pen group size, production, and somatic cell count descriptive data from monthly 
Dairy Herd Improvement test records for study herds. Total quarter days for uninfected and infected 
quarters and number of Staphylococcus aureus isolates collected for the 13 month study period. 
 
 
On farm 1 there were 13 quarters in 11 cows in the treatment group that met the 
criteria for extended therapy, compared to 16 quarters in 12 cows in the control group 
(table 3.2).  On this farm 9 quarters and 7 cows cured following extended therapy 
compared to no quarters or cows observed to cure spontaneously in the control group.  
On farm 2 there were 9 quarters in 7 cows eligible for extended therapy in the treatment 
group. Two cows either exited the treatment group (1 cow with 3 infected quarters) or 
spontaneously cured (1 cow with 1 infected quarter) prior to the start of the intervention 
period.  Four of the 5 quarters that received extended therapy on this farm cured.  There 
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were no cows with S. aureus IMI that were identified with chronic subclinical mastitis 
and a S. aureus positive culture in the control group on farm 2 (table 3.2).  Data in table 
3.2 also summarizes the number of S. aureus clinical events and the extent to which exits 
from the study pens of existing IMI (e.g. right censored events) contributed to overall 
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Table 3.3 summarizes the number of clinical and asymptomatic IMI in each pen 
that did not meet the criteria for extended lactation therapy.  On farm 1 in the treatment 
and control pens these included short duration clinical episodes that cured following 
clinical therapy (n=3) or spontaneously cured (n=3), or were right censored (n=13).  On 
farm 2 this included 2 chronic IMI in 2 cows in the treatment pen that never demonstrated 
an elevated SCC, (one of which spontaneously cured and one which was right censored 
with the end of the study) and 1 IMI in 1 cow that appeared to spontaneously cure, 
although this cow was identified as a chronic S. aureus IMI beginning 4 months later. 
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Direct effect of treatment on IMI prevalence 
Differences between treatment groups were observed for the total number of 
infected quarter days on the two farms (table 3.1).  The monthly mean number of infected  
days per 10,000 quarter days in the treatment group on farm 1 was 101 (s.d. 71.6, range 
28 to 236), which was significantly less than the mean number of 175.8 (s.d. 100 days, 
range 71 to 309) infected days in control group (t value 2.55, p=0.018, figure 3.2). On 
farm 2 there were only 14 infected days observed in a single month in the control group, 
compared to a monthly mean of 113 (s.d. 98.7 days, range 0 to 251) infected days per 
10,000 cow days in the treatment group (figure 3.2).  On both farms changes in infection 
prevalence were observed over time within treatment and control groups (figure 3.2).  
On farm 1, the mean prevalence per 10,000 cow days for the pre-intervention time 
period (months 1 -3) did not differ between groups, however differences in the 
prevalence were evident in subsequent months in both groups (figures 3.2 and 3.3).   
The decline in prevalence in the treatment group on farm 1 from month 2 to 3 was 
attributed to mastitis associated culling of 2 infected quarters and dry-off of 1 infected 
quarter.  Subsequently in this group from months 4 to 9, four of 6 quarters treated with 
extended therapy were cured, and the constant low prevalence was due to a balance 
between emergence of new chronic IMI quarters and cure of existing IMI.  However in 
months 10 through 13, prevalence increased as 3 recovered susceptible and 9 other 
quarters became infected, which was only offset by cure of 5 of 7 quarters treated with 
extended therapy (figure 3.2 and table 3.4). 
 





Figure 3.2  Prevalence and incidence of Staphylococcus aureus intramammary infections (IMI) in treatment 
and control pens on two farms over 13 monthly intervals.  Total prevalence (data points on line) expressed 
as number of days infected per 10,000 quarter days (right axis).  Number new IMI from naïve susceptible 
quarters (S,  ) and number new IMI from recovered susceptible quarters (R,  ) per 10,000 quarter 
days at risk (left axis).  In treatment pens an initial observation period of months 1-3 was followed by the 
intervention period during months 4-13 when chronic subclinical IMI received extended therapy, while 
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Figure 3.3 Least square mean estimates of prevalence of Staphylococcus aureus IMI for three sequential 
time periods for treated and control groups on two farms.  Within a treatment group means with different 
letters differed between time periods on each farm, and between treatment groups means with different 





The observation that during months 10-13 there appeared to be an increased incidence of 
new IMI in the treatment group on farm 1 influenced our decision to consider these 4 
months as a separate time period for comparison to the observation period (months 1-3) 
and the early intervention period (months 4-9). In the late intervention period (months 10-
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13), new IMIs in the treatment group were approximately equally caused by 4 PFGE 
(sub)types (1, 1b, 2, and 2b) while in the earlier time periods subtype 2b was absent from 
both groups (table 3.4).  In comparison, in the control group on farm 1, prevalence of 
PFGE types 1, 1b, and 2 continued to steadily rise during months 4 through 9, where the 
least squares mean prevalence estimate for this time period (173.0 days) was significantly 
greater than the same time period for the treatment group (52.7 days, p=0.007, adjusted 
for multiple comparisons) (figure 3.3). The least square mean prevalence estimate for the 
control group for months 10 through 13 (306.8 days) was significantly greater than for 
months 4 through 9 within the same group (p=0.008, adjusted), but was not significantly 
greater than for months 10 through 13 in the treatment group (214.5 days, p=0.25; figure 
3.3).  
On farm 2 the change in prevalence over time was evident, with the least square 
mean prevalence estimate in months 10-13 (11.8 days) being significantly less than 
months 1 through 3 (178 days, p=0.0005, adjusted) and months 4 through 9 (128 days, 
p=0.003, adjusted; figure 3.3).  This difference was attributed to cure of 4 of 5 quarters, 
subsequent post-treatment spontaneous cure of the remaining treated quarter, and dry-off 
of one infected quarter during months 5 through 8.  In this group these cures were 
partially offset by a new IMI in month 9 and entry of an IMI in month 10. Both of these 
IMI’s were caused by a new PFGE type, and both spontaneously cured by month 12 
(figure 3.2 and table 3.4).  
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Table 3.4 Strain specific dynamics of Staphylococcus aureus IMI on two farms during a field trial of 
lactation therapy. Number of quarters with an IMI in each monthly sample interval are shown for three 
epidemiological classes for each PFGE type. 
Farm 1
treated pen control pen
sample interval (month) sample interval (month)
PFGE type IMI class1 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13
new 1 1 3* 5 1* 1 1* 2 1 2* 8
entry 1 1 1 1 2
prev 1 1 1 1 1 2 1 1 2 2 4 3 3* 6 1 2 1 1 2 2 3* 4** 1 2 2 4 3 10
new 0 1 1
entry 0 0
prev 0 1 1
new 1 2 2 5 1* 1 2
entry 1 1 1 1 2
prev 1 1* 1 1 2 1 3 3 6 1 1 1* 1* 3* 2 2 2* 2 3
new 2 1 3 1 2 1* 4
entry 1 1 2 1 1 2
prev 1 1* 1 1 1 2 3 2 5 2 2 1 1 1 3* 4 4 4 5 4 4 6
new 0 0
entry 1 1 0
prev 1 1 1 0
new 3* 3 1 1 2
entry 0 0
prev 3 3 1 1 3 1 1 2 2 2
new 0 0
entry 1 1 0
prev 1 1 1 1 0
new 0 0
entry 0 1 1
prev 0 1 1 1
new 0 1 1
entry 0 0
prev 0 1 1 1
new 0 0
entry 0 1* 1
prev 0 1 1 1 1 1 1 1 1* 1 1
new 1 1 1 1
entry 0 0
prev 1 1 1 1 1
Farm 2
treated pen control pen
sample interval (month) sample interval (month)
PFGE type IMI type 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13
new 0 1 1
entry 1 1 0
prev 1 1 1 1 1 1 1 1 1 1
new 2 1 3 0
entry 5 5 0
prev 5 7 6 6 6 4 4 8 0
new 0 0
entry 1 1 0
prev 1 1 0
new 1 1 0
entry 0 0
prev 1 1 1 1 0
new 1 1 0
entry 0 0













1. 'new', new IMI observed to begin in pen group; 'entry', left censored IMI observed prior to entry into pen group; 'prev', prevalence of IMI. *Number of IMI that are observed as a clinical event are 
















Because there were so few S. aureus infections in the control pen, comparison of 
treatments on farm 2 was not possible, and we subsequently modeled the effect of 
treatment on prevalence using only the subset of data for farm 1 and model 1.1 (table 
3.5).  In univariate analysis time period was a significant positive predictor, while 
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treatment group was a significant negative predictor of prevalence. In the final linear 
model the interaction between time period and treatment group was significant, and the 
effect of treatment within each intervention period was a reduction in the prevalence for 
the treated group (table 3.5).   
 
 
Table 3.5 Regression coefficients for the effect of treatment group on Staphylococcus aureus IMI 
prevalence and new IMI incidence in generalized linear regression models using data from farm 1. 
 
model variable1 estimate chi-square P DF dev.2
IMI prevalence = intercept + group + timep + group*timep intercept -4.6870 -5.1020 -4.2730 491.3 <0.0001 20 27
group -0.035 -0.631 0.561 0.01 0.9000
midtp 0.540 0.047 1.039 4.6 0.0319
latetp 1.060 0.533 1.591 15.46 <.0001
group*midtp -1.153 -1.869 -0.437 9.95 0.0016
group*latetp -0.322 -1.079 0.435 0.7 0.4043
IMI incidence = intercept + midtp + latetp + group*midtp + group*latetp intercept -10.646 -12.532 -8.760 122.4 <0.0001 21 24
midtp 1.985 0.015 3.955 3.9 0.0482
latetp 1.727 -0.310 3.764 2.76 0.0966
group*midtp -1.318 -2.546 -0.892 4.42 0.0355
group*latetp 0.415 -0.580 1.409 0.67 0.4137
95% CI limits





Direct effect of treatment on duration of S. aureus IMI 
The mean duration of chronic IMI calculated from the observed data using the 
midpoint estimation method was 135 and 86 days for the control and treatment groups 
respectively.  Least square mean estimates of duration from a generalized linear model 
accounting for the effect of treatment group, S. aureus strain, and the interaction between 
treatment and strain, yielded 165 and 85 days for control and treatment groups 
respectively, and the effect of treatment was significant (p=0.0072).   In a Kaplan-Meier 
estimate of the survival function of chronic IMI accounting for censored observations, the 
median duration of infection was estimated to be 256 and 93 days in the control (n=16) 
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and treatment (n=22) groups respectively, demonstrating a significant reduction in 
duration of infection in the groups of cows receiving the intervention while controlling 









Duration of infection (days) 




Figure 3.4  Kaplan-Meier survival function of chronic Staphylococcus aureus IMI from 2 commercial dairy 
herds accounting for right censored observations and including PFGE strain type as a covariate. The 
median duration of infection for 22 quarters in the treatment groups (dashed line) estimated to be 93 days 
was less than the 256 day median duration of infection estimate for 16 quarters in the control groups (solid 
line) demonstrating a reduction (log rank test p=0.0025) in duration of infection in the groups of cows 
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Effect of treatment on rates of S. aureus clinical mastitis and culling due to mastitis 
Differences were observed between the treatment and control pens in the 
incidence of clinical mastitis due to S. aureus, the incidence of mastitis associated culling 
among S. aureus infected quarters, and number of chronic S. aureus IMI at the end of the 
study (table 3.2).  No clinical S. aureus mastitis was observed on farm 2.  On farm 1, 2 of 
13 cows (2 of 13 quarters) with chronic S. aureus mastitis in the treatment group had at 
least one clinical mastitis event, while 7 of 12 cows (10 of 16 quarters) developed S. 
aureus clinical mastitis in the control group.  The odds of a cow with chronic S. aureus 
mastitis displaying at least one clinical mastitis episode among cows in the control group 
was 7 times that of cows in the treated group (p=0.025, Fischer exact test, exact 
confidence limits 0.09<OR< 93) while the odds of clinical mastitis among quarters in the 
control group was 10 times that of the treatment group (p=0.01, Fischer exact test, exact 
confidence limits 1.2<OR< 104).   On farm 1 there were 3 quarters in 2 cows that 
displayed > 1 clinical episode for a total of 11 clinical events in this group.  
There were fewer total right censored S. aureus IMI in the treatment compared to 
the control group, including fewer quarters with chronic mastitis that entered the dry 
period infected or that were still infected at the end of the study (table 3.2).  There was a 
numerical increase in the proportion of mastitis associated culling events from the 
treatment pen compared to the control pens, but this difference was not statistically 
significant (Fisher’s exact test, p=0.22).  Three cows with 3 S. aureus IMI were culled 
from the control group, 2 of these quarters with the primary reason for culling being 
mastitis. Four cows with 6 S. aureus IMI were culled from the treatment group, 5 of these 
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quarters with the primary reason for culling being mastitis.  Among the mastitis culls in 
the treatment group, 2 culling events were in recovered quarters that had previously 
received extended lactation therapy, with one of these culling events being associated 
with a gram-negative infection acquired after S. aureus cure.   
In a Kaplan-Meier estimate of the survival function, the mean lactation length 
among the quarters with chronic S. aureus IMI receiving extended therapy was 426 
(median 436, se 24) days, which did not differ from the mean lactation length for quarters 
with chronic IMI that did not receive extended lactation therapy (mean 420, median 456, 
se 27 days), suggesting that treatment was not associated with an increase or a decrease in 
lactation duration (log rank test p=0.29). 
 
Indirect effects of treatment on S. aureus IMI incidence 
There were a total of 42 new IMI per 501,774 quarter days at risk, with 36 new 
IMI observed on farm 1 and 6 new IMI on farm 2 (table 3.4).  A strongly favorable effect 
of treatment was observed in the early intervention period (midtp, months 4-9; table 3.5). 
In the late intervention period (latetp, months 10-13), the incidence rate for the treatment 
group was higher compared to the control group but the effect of treatment was not 
statistically significant (table 3.5).   
 
Strain typing 
Eight PFGE types differentiated by >3 band differences were recognized to cause 
S. aureus IMIs, and 1 to 2 additional subtypes were identified by 1 to 3 band differences 
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within 5 of these PFGE types (table 3.4).  On farm 1, two dominate PFGE types caused 
IMIs.  PFGE type 1 and its subtypes were associated with 25 (52%) IMI in 25 quarters of 
24 cows, and PFGE type 2 and its subtypes were associated with 17 (35%) IMI in 17 
quarters of 15 cows.  On farm 2 a single dominate pulso-type (PFGE type 3) was 
associated with 8 (62%) IMI in 8 quarters of 6 cows in the treatment group.  Among cows 
with multiple infected quarters, 5 cows had 2 quarters infected with either different PFGE 
types (n=3) or subtypes (n=2), compared to 1 cow which had 2 quarters infected with the 
same strain type, and 3 cows which had 3 quarters infected with the same strain type.  
Chronic infection due to a single strain type or subtype over time was common, with a 
change in a major strain type identified for 1 chronic IMI (2%), and 5 changes in PFGE 
sub-types identified in 4 chronic IMI. For the chronic IMI where a major strain type 
change was observed over time within a quarter, this event was associated with a shift in 
strain type following lactation therapy for subclinical mastitis.  Among the differences in 
subtypes observed over time within a quarter, 3 of these events were associated with a 
shift in strain type following lactation therapy for clinical mastitis, and in the other 2 
cases, there was no recorded treatment prior to the change in sub-type in the quarter.  
 
Influence of strain typing on determination of bacteriologic cure 
One quarter of one cow was observed to be culture negative for 3 weekly post 
treatment samples, and was subsequently S. aureus positive on 29 days post treatment, 
and PFGE typing of pretreatment and post treatment isolates demonstrated a type change.  
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This event was defined as treatment cure followed by re-infection in a recovered 
susceptible quarter.   
There were two IMI (one in each farm) defined as non-cure based on one or more 
positive cultures with the same PFGE type in the 4 weekly samples following extended 
therapy that were subsequently found to be culture negative for S. aureus in later months. 
We defined these events as post-treatment spontaneous cures. On farm 1 this was in a 
quarter that was positive for the same PFGE type on 7, 14, and 21 days post-treatment, 
but became S. aureus negative on day 28 and remained negative for 5 monthly samples 
over 130 days. On farm 2 this was a quarter that was positive for the same PFGE type on 
day 7 post-treatment but was S. aureus negative on the remaining 3 weekly post-
treatment samples and remained negative on 6 serial samples taken over 174 days.   
 
New IMI in recovered susceptible quarters 
In addition to the new S. aureus IMI identified by a PFGE type change following 
extended therapy described in the previous section, 2 quarters in 2 cows receiving 
extended therapy targeting a different bacterial species were also observed to become 
infected with S. aureus following extended therapy cure. Thus, we observed 4 new S. 
aureus IMI in recovered susceptible quarters following extended lactation therapy (figure 
3.1).  Similarly, among the 18 chronic S. aureus IMI receiving extended lactation 
therapy, we observed 8 post-treatment new clinical or subclinical IMI with a different 
species, including 3 acute clinical IMI due to E. coli, 2 acute clinical and 1 chronic 
subclinical IMI due to Klebsiella spp., 1 acute clinical Streptococcus dysgalactiae IMI, 
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and 1 acute clinical event with no bacterial growth detected.  Therefore, among 18 
quarters in 16 cows with chronic S. aureus mastitis that received extended therapy during 
lactation, 9 (50%) quarters and 8 (50%) cows became re-infected with a major mastitis 
pathogen. These post treatment IMI occurred either during the 8 days of therapy (n=1) 
between 3- 5 days after the last treatment 9 (n=4), or at least 16 days after the last 
treatment (n=4, range= 16 to 84 days). In 7 of these cases the S. aureus IMI targeted for 
therapy was observed to cure. In 2 quarters the S. aureus was cultured from the quarter 
following treatment up until the development of clinical mastitis caused by E. coli (at 30 
days post-treatment on farm 1) or Klebsiella (at 16 days post treatment on farm 2).  In 
comparison, among the 16 chronically infected quarters in the control group only 1 new 
clinical E. coli IMI was observed to emerge during the course of a chronic S. aureus 
infection.  The odds of developing acute clinical or chronic subclinical coliform mastitis 
among the 18 quarters with chronic S. aureus mastitis that received extended therapy 
during lactation were 7.5 times that of the 16 cows with chronic S. aureus mastitis that 
did not receive extended therapy (p=0.05, Fischer exact test, 95% exact confidence limits 
0.7<OR<367). 
 
Effect of extended therapy treatment on somatic cell count 
Pre- and 45 day post-treatment SCC data was available for 13 treated and 10 
control cows.  The mean LSCC at approximately 45 days post treatment (post sample 2) 
for the four treated cows that cured S. aureus IMIs and were culture negative for an IMI 
by any major pathogen in the 45 days post treatment was 170,000 (SCC estimate back-
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transformed from mean LSCC) cells/ml which was significantly less than the mean pre-
treatment 3 month average SCC of 557,000 cells/ml for these cows (paired t-test for 
difference of means, p=0.03).  All 10 cows in the control group were still S. aureus 
positive at 45 days following the first month of eligibility for treatment and had a mean 
45-day post treatment SCC of 746,000 cells/ml which was not different from the mean 
pre-treatment 3 month average SCC of 784,000 cells/ml. The mean 45-day post-treatment 
SCC of 876,000 cells/ml for cows with a post treatment IMI (either caused by a major 
gram-positive pathogen or a coliform species) did not differ significantly from their 
pretreatment SCC of  908,000 cells/ml.  In a generalized linear model only post-treatment 
pathogen category was a significant predictor of the 45-day post-treatment SCC. The 
least squares mean LSCC of cows with post-treatment major positive IMI or coliform 
IMI was significantly greater than the post-treatment SCC of cows with no post-treatment 
IMI and the effect of a post-treatment IMI was to increase the 45 day post-treatment SCC 
by approximately 800,000 cells/ml based on the difference of back-converted LSCC 
estimates (figure 3.5 and table 3.6). 
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Figure 3.5 Effect of treatment on somatic cell count (SCC). Least squares mean estimates of the natural 
logarithm of SCC (LSCC) for mean 3 month pre-treatment and 45-day post-treatment cow level SCC 
stratified pre-treatment by treatment group, and post-treatment by post-treatment infection status [Pre-
treatment IMI caused by Staphylococcus aureus; None = bacteriologic culture negative; Major Gram + = 
intramammary infection (IMI) casued by Staphylococcus aureus or a Streptococcus spp.; Coliform = IMI 
casued by Escherichia coli or Klebsiella spp.] 
 
 
Table 3. 6 Regression coefficients for the effect of treatment group on 45 day post treatment SCC.  
Model, LNPOST2 = TREATMENT + POST_IMI_PATH 
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S. aureus transmission parameter estimates 
Table 3.7 lists the transmission parameter (β) estimates for S. aureus from the full 
data set and for each individual farm. Covariates that were tested in this model included 
time period, treatment group, farm, and strain type but only strain type was statistically 
significant, with type 1 having a significantly increased log-odds effect estimate 
compared to the baseline reference type 3 in model 1.3.  Table 6 also lists the 
transmission parameter estimates for each of the three major PFGE types. The 
transmission parameter for PFGE type 1, which was isolated almost exclusively from 
farm 1, was significantly different from the transmission parameter for PFGE type 3, 
which was exclusively isolated from farm 2, showing that transmission parameters may 
be specific to herds or bacterial strains rather than to bacterial species. 
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Discussion 
 
This study demonstrated a positive direct effect of extended lactation therapy for 
chronic subclinical mastitis caused by S. aureus.  We observed a significant increase in 
proportion of quarters with bacteriologic cure among chronically infected subclinical IMI 
receiving 8-day pirlimycin therapy during lactation compared to the proportion of 
spontaneous cure in untreated quarters. The criteria for defining cure in our study were 
comparable to those of Gillespie et al. (2002) who observed 83% cure with 8-day 
pirlimycin therapy of S. aureus mastitis, comparable to 72% cure in our data.  Compared 
to our results, lower proportions of cure have been reported for other pirlimycin treatment 
regimens targeting subclinical S. aureus mastitis [e.g. ranging down to 13% for a 2-day 
duration of treatment (Gillespie et al., 2002)].  Sol et al. (1997) and Deluyker et al. (2005) 
have reported on host factors associated with cure after treatment of subclinical S. aureus 
mastitis (reviewed in Barkema et al., 2006). Deluyker et al. (2005) reported cure for S. 
aureus following an 8 day pirlimycin regimen to vary between 10 and 88% depending on 
host and laboratory covariates, although these authors did not report an overall cure 
proportion by bacterial species.  Previous studies have demonstrated S. aureus strain 
diversity between farms (Kapur et al., 1995; Zadoks et al., 2000; Rabello et al., 2007), 
and the large number of farms in the Deluyker study could have resulted in an increase in 
the diversity of S. aureus strains. This greater diversity may impact the overall cure rate 
observed; assuming probability of cure is associated with strain type (Haveri et al., 2007).  
The potential effect of herd (as a possible proxy for S. aureus strain type) was not 
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evaluated by Deluyker et al. (2005).   In our study 5 strain types were treated with 
extended pirlimycin therapy, and no isolates demonstrated lincosamide or macrolide 
resistance as measured by disc diffusion or microtiter plate broth dilution methods.   Of 
the 18 quarters treated, cure was observed for 5 of 8, 3 of 4, 4 of 4, 1 of 1, and 0 of 1 
quarters for PFGE types 1, 2, 3, 5, and 10 respectively. Interestingly, only PFGE types 3 
and 10 demonstrated either phenotypic or genetic evidence of penicillin resistance [based 
on disc diffusion, microtiter plate broth dilution, nitrocefin testing, and PCR-based 
detection of genes for 100 % (n = 19) of pre-treatment isolates examined from the 5 
cows].  For PFGE type 3 penicillin resistance did not appear to affect the probability of 
cure following pirlimycin treatment, although previous studies have suggested that beta-
lactamase resistance is associated with a decreased probability of cure even when non-
beta-lactam antimicrobials are used for treatment (reviewed in Barkema et al., 2006).   
The relatively small number of IMI caused by S. aureus on the two farms in our study 
and the high proportion of cure among treated quarters limited our ability to identify 
significant host or strain effects associated with cure (data not shown).   
On farm 1, treatment was strongly associated with a reduced incidence of S. 
aureus in the early intervention time period (incidence rate of the treatment group 
estimated to be approximately 27% of that of the control group in months 4 to 9). In this 
time period treatment was also associated with a reduction in S. aureus prevalence. In the 
later intervention time period, the incidence rate in the treatment group was estimated to 
be approximately 1.5 (95% CI 0.25 to 4.1) times that of the control group, which was not 
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significantly different. In this late time period prevalence in the treatment group was also 
not significantly different from the control.   
On farm 1 in the later intervention period (months 10-13) there were 2 times as 
many new IMI in the treatment group compared to the control group. In the treatment 
group at least 3 and up to 7 out of 10 new IMI emerged during months 10 and 11 in the 
absence of any existing IMI of the same PFGE-type in the current or previous months.  In 
comparison only 1 of 2 new IMI emerged with no prior existing prevalence in the control 
group during the same months.  Further, 4 of 7 new IMI in month 10 in herd 1 were 
caused by a previously unobserved PFGE sub-type.  Similarly, in herd 2 following 
elimination of the dominate PFGE-type by month 8, a new ‘sporadic’ IMI due to a 
previously unobserved PFGE type emerged in the treatment pen, and a single new IMI 
was observed in the control pen with no prior existing infections of this type.  These data 
suggests that new S. aureus IMI likely result from a combination of contagious 
transmission from existing intramammary infections and sporadic infections of extra-
mammary origin (Zadoks et al., 2002b).   
Although we can not completely eliminate the possibility of contagious 
transmission between cows in separate pens, the design of this study included control of 
pen milking order.  Milking systems were washed and sanitized between each milking 
session, and only the pen of fresh cows was milked prior to the treatment group and 
infection dynamics were monitored over the two week period that cows resided in the 
fresh pen. The possibility of spread of pathogens from the treatment group to cows in the 
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control group via contamination of the milking system can not be eliminated; however 
the reverse scenario was unlikely due to the pen milking order.  
The origin of sporadic cases may include the cow’s skin, the milking or housing 
environment, or milkers’ hands (Zadoks et al., 2002b; Smith et al., 2005b).  Because we 
only examined quarter milk samples, the epidemiology of any transmission from extra-
mammary sources could not be evaluated in this study. While strain typing can be 
sufficient to demonstrate that new infections were not the result of contagious 
transmission (Zadoks and Schukken, 2006), if extra-mammary sources of S. aureus are to 
be identified as a source of sporadic infections, future studies should include 
environmental surveillance. This may be especially valuable in low prevalence herds 
where sporadic infections may constitute a greater proportion of new IMI relative to 
those resulting from contagious transmission.  
An important observation from this study is the report of new S. aureus infections 
caused by a different strain type in previously cured quarters.  Unique to our study and 
that of Luby and Middleton (2005), strain typing of pre- and post-treatment S. aureus 
isolates provided improved estimates of cure and re-infection proportions.  In the absence 
of strain typing we would have under-estimated both the cure proportion observed and 
the re-infection rate.  Our ability to discriminate among strains led to the observation that 
a proportion of presumed non-cures based on bacteriologic culture alone (1 of 6 quarters 
found S. aureus positive post-treatment in this study), may actually be cure followed by a 
new post-cure infection with a different strain type. Based on routine bacteriology, the 
observed cure proportion in this study would have been 78% compared to 72% based on 
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strain typing.  Barkema et al. (Barkema et al., 2006) and Zadoks and Schukken (Zadoks 
and Schukken, 2006) have previously suggested that reports of cure rates in the absence 
of strain specific data may under-estimate true cure rates due to re-infection of cured 
quarters by contagious transmission from infected quarters in either the same cow or 
other cows in a herd. Luby and Middleton (2005) had previously shown this for 1 of 16 
quarters enrolled in a treatment trial. Our results provide further support of this concept, 
although we can not further distinguish between cure followed by re-infection and non-
cure for the 5 quarters infected with the same PFGE-type post-treatment.  In addition, we 
can not eliminate the possibility of genetic changes resulting in a change in PFGE type 
following treatment in a non-cure IMI (Goerke et al., 2004), which may explain the sub-
type changes observed in following both clinical and extended subclinical therapy during 
our study, although not all subtype changes occurred following antimicrobial therapy.  
Also, the possibility of carriage of more than one strain and isolation of different strains 
pre-treatment and post-treatment or across a chronic infection can not be eliminated 
(Smith et al., 2005a). 
The intervention did have a positive effect in reducing the rates of S. aureus 
clinical mastitis which we hypothesize is related to the effect of treatment reducing 
duration of infection of chronically infected quarters.  This is supported by the 
observation that the difference in S. aureus clinical mastitis rates between the treatment 
and control groups on farm 1 was primarily a result of a higher number of clinical flare-
ups among existing chronic infections in the control group.   Our finding of an effect of 
lactation therapy for subclinical mastitis being associated with a reduction in the number 
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of clinical mastitis cases is in agreement with St. Rose et al (St Rose et al., 2003), and 
may reduce the use of antibiotic treatments for clinical mastitis, offsetting the costs of 
treating subclinical mastitis (Swinkels et al., 2005a). This is currently controversial, as 
other authors have recently reported no difference in mastitis treatment rates following 
treatment of subclinical mastitis compared to an untreated control group (Sandgren et al., 
2008).   
These positive findings of an effect of treatment on S. aureus subclinical and 
clinical mastitis incidence are countered by the frequent occurrence of new IMI in cows 
receiving extended lactation therapy which were dominated by clinical coliform mastitis 
cases within a few days to more than 2 months following cure of the initial S. aureus 
infection. We also observed a numerically higher, but non-significant increase in the 
number of mastitis associated culling events for the treatment group compared to the 
control group.  Sandgren et al. (2008) also reported an increased rate of udder-health 
associated culling in cows receiving intramammary therapy for subclinical mastitis.  
Gillespie et al. (2002) and Middleton and Luby (2008) reported new gram-negative 
infections or clinical mastitis leading to early dry-off or death of cows following lactation 
therapy with pirlimycin. These authors suggested this was possibly due to a number of 
factors including introduction of pathogens during intramammary therapy, use of narrow-
spectrum antimicrobials, poor environmental hygiene, and seasonal effects of increased 
heat and humidity.  Introduction of pathogens during therapy was a possibility in a 
number of cases in our study. Five (56%) treated quarters developed a post-treatment  
IMI (4 coliform and 1 no growth clinical cases) within 5 days after the last extended 
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therapy infusion, and one of these quarters developed subclinical E. coli mastitis on the 
sixth day of treatment based on daily culture of cows during the 8 day treatment regimen.  
These are presumed to be 5 iatrogenic cases of mastitis, likely associated with a 
combination of poor hygiene practices during treatment and/or disruption or trauma of 
the teat canal leading to increased susceptibility, plus the limited antimicrobial spectrum 
of pirlimycin. One additional quarter developed clinical S. dysgalactiae mastitis on day 
16 following treatment.  Three (33%) quarters that cured of S. aureus following extended 
therapy were observed to become infected by a different S. aureus PFGE type (n=1, 30 
days post treatment) or a coliform (n=2, 33 and 84 days post treatment) after at least 3 
negative post-treatment samples. This may represent a subset of cows where factors in 
addition to any potential iatrogenic effects are responsible for re-infection.  For example, 
the role of host susceptibility (Lacy-Hulbert and Hillerton, 1995) may also contribute to 
the risk of post-treatment re-infections in agreement with observations of Zadoks et al. 
(2002a) who described an increased risk of infection among recovered susceptible 
quarters.   
Treatment clearly eliminated infections and reduced prevalence of S. aureus in 
both herds, however the association between prevalence and incidence could only be 
compared between treatment and control groups in herd 1.  For this herd, we suggest that 
the association between treatment and incidence was through the intermediate effect of 
prevalence.  This is consistent with a causal model for contagious disease transmission, 
where the effect of treatment is to reduce duration of infection and thus overall 
prevalence, which in turn results in a reduced force of infection for the susceptible 
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individuals.  The effect of treatment during the early intervention period (where 
contagious transmission appeared to dominate) suggests that lactation therapy may 
provide additional transmission control by lowering the force of infection. The observed 
‘outbreak’ in the treatment group on farm 1 during the late intervention period associated 
with new infections caused by both an existing strain and emergence of a new strain is 
worth further investigation.  This could either be a result of the impact of the treatment 
program selecting for the emergence of new contagious strain type(s), or may be 
unrelated to treatment and/or contagious transmission and simply be the result of the 
unrecognized introduction of an infected animal, or infections acquired from a common 
environmental source.  The small number of infections observed would be consistent 
with any of these possibilities.  Three (23%) of the new IMI that emerged in this late 
intervention period were in recovered susceptible quarters, indicating that culling or 
segregation should be considered as an additional control measure for infected quarters 
that become re-infected or that do not respond to therapy.  A comparison of the two herds 
in this study demonstrates the herd specific nature of S. aureus mastitis and possible 
differences among strains in transmission and response to interventions.  Modeling an 
effect of treatment on IMI prevalence in herd 2 was not reasonable due to lack of IMI 
caused by PFGE type 3 in the control group for comparison. Inferences regarding 
infection dynamics in the absence of treatment were restricted to only the first 3 months 
of the study for this herd and PFGE type.  
In a disease transmission model, Barlow et al. previously predicted that the 
indirect effect of therapy would approach zero under scenarios of very low transmission 
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parameter estimates (J. Barlow, unpublished data – manuscript submitted, Chapter 2 of 
this dissertation).  From a field trial conducted in the Netherlands, Lam et al. (1996) 
observed 13 new S. aureus IMI per 71,139 quarters days in quarters receiving post-
milking teat disinfection and obtained a point estimate of 0.0032 for the transmission 
parameter β.  In our current study we observed 36 new IMI per 260,238 quarter days at 
risk in herd 1, and using the same model predicted the ‘pooled’ transmission parameter β 
= 0.008, with a 95% confidence interval on this estimate that falls within the range of 
values where we have previously predicted the indirect effect of treatment to be positive 
(J. Barlow, unpublished data – manuscript submitted, Chapter 2 of this dissertation).  As 
expected, during the early intervention period we did observe a positive indirect effect of 
treatment.  The size of the indirect effect was in line with our model expectations.  Strain 
typing of isolates allowed estimation of strain specific transmission parameters, although 
in this study, as in a previous study of three herds (Zadoks et al., 2002a), it was difficult 
to separate strain effects from herd effects on transmission parameters because strains 
were largely herd-specific. Recognizing this limitation, potential differences in 
transmission among strains were identified, with PFGE type 3 appearing to have a lower 
transmission potential compared to PFGE type 1.  Transmission parameter estimates for 
PFGE types 1 and 2 were ‘pooled’ estimates including the respective sub-types.  
Differences in transmission have been described for two S. aureus strains that occurred 
during the same time period within a single herd (Smith et al., 1998). Other putative 
strain associated factors, such as persistency of infection (Haveri et al., 2005; Haveri et 
al., 2007), may impact the force of infection within a herd (Dodd and Neave, 1970). 
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Additional research is required to quantify differences in transmission probabilities 
among S. aureus strains associated with bovine mastitis, and the potential relevance of 
these differences to mastitis control practices.   
The decision to implement a subclinical mastitis treatment program during 
lactation is primarily economic although welfare concerns also exist (Hillerton and Berry, 
2003).  Swinkels et al. (2005a) have described a partial budget model for estimation of 
economic benefits of treating subclinical mastitis caused by S. aureus.  Their model was 
sensitive to estimates of transmission probability and probability of culling. In addition, 
the probability of clinical mastitis was a factor contributing to the economic benefits of 
lactation therapy. Results of our study provide additional information on the use of 
lactation therapy for control of subclinical mastitis in dairy herds. Key among our 
findings was the value of strain specific measures of infection and cure rates, and the 
observation that strain specific infection dynamics influence interpretation of direct and 
indirect treatment effect estimates. In addition, we demonstrated a reduced rate of clinical 
mastitis in the treated group on one farm, as well as elimination of IMI caused by a 
dominant strain in a second herd.  These benefits were offset by increased rates of clinical 
and subclinical mastitis in cured quarters following extended pirlimycin therapy, which 
appeared to influence the finding that there was no effect of treatment on post-treatment 
SCC. Alternative subclinical mastitis treatment regimens such as systemic therapy might 
be considered as a method to prevent potential iatrogenic mastitis associated with 
intramammary infusion, although it appears this would not eliminate all post treatment 
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re-infections (Sandgren et al., 2008). The balance of these potential effects needs further 




This research demonstrated a direct effect of lactation therapy in the overall 
reduction of duration of S. aureus infection on two commercial dairy herds.  A significant 
indirect effect of treatment was also observed, although differences between herds and 
over time within herds were present. These differences demonstrate the potential for 
strain and herd specific responses to lactation therapy programs.  Our data demonstrate 
potential benefits of subclinical mastitis treatment during lactation as a component of 
mastitis control programs on dairy farms, although the high rate of infection of recovered 
susceptible quarters and the occurrence of post-treatment coliform infections observed in 
these herds are two issues that would negate the potential benefits of extended pirlimycin 
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Abstract 
 
A split herd negative controlled field trial was conducted on 2 commercial dairy 
herds to evaluate the direct and indirect effects of a diagnosis and treatment program 
targeting subclinical mastitis caused by streptococcal species. Treatment of subclinical 
mastitis by extended (8 days) intramammary lactation therapy with pirlimycin 
hydrochloride was randomly allocated to a group of approximately 100 cows on each 
farm, and cows in the treatment group were determined eligible for treatment based on 
serial monthly somatic cell count (SCC) testing and individual quarter milk bacteriologic 
analysis. Extended therapy eliminated a greater proportion (71%) of chronic subclinical 
intramammary infections (IMI) caused by Streptococcus uberis and Streptococcus 
dysgalactiae compared to either spontaneous cure (50%) of chronic subclinical IMI or 
cure of clinical episodes (50%).  The direct effect of treatment at the cow level appeared 
to be limited, as there was a high proportion of spontaneous cure of chronic subclinical 
mastitis among cows that did not receive extended therapy in the negative control group 
and the overall duration of S.  uberis and S. dysgalactiae IMI was not different between 
treatment and control groups. Treatment affected the prevalence of S. uberis IMI in one 
herd. A significant reduction in S. uberis new IMI was associated with the time of 
reduced S. uberis prevalence in this herd, suggesting a potential herd level or indirect 
effect of treatment. In one herd there were a slightly greater number of infections due to 
S. dysgalactiae compared to S. uberis; while in the second, S. uberis was the dominant 
cause of chronic subclinical and clinical streptococcus mastitis.  Random amplified 
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polymorphic DNA (RAPD) testing demonstrated strain diversity among S. uberis isolates 
causing mastitis, consistent with environmental sources of exposure for this pathogen in 
both herds.  Differences in the extent of S. uberis strain diversity were observed between 
the 2 herds, with a single strain type associated with 52% of IMI in one herd, and 26% in 
the second herd. Species identification and strain typing improved estimates of cure 
proportions by distinguishing new streptococcus species infections from non-cure 
following treatment. Five (24%) of the treated quarters developed subclinical or clinical 
infections caused by gram-negative pathogens either during or within 16 days following 
the 8 days of treatment.  Macrolide-lincosamide-streptogramin (MLS) resistance was 
identified in 35% of S. uberis isolates tested and was associated with extended therapy 
treatment failures. Direct and indirect effects of lactation therapy in these herds were 
limited and suggest extended therapy of subclinical streptococcal mastitis provided 
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Introduction 
 
 The streptococcal species continue to be an important cause of mastitis in dairy 
cattle.  The adoption of the five-point mastitis control program including milking time 
hygiene, risk management, and treatment practices has resulted in the successful control 
of some contagious pathogens including Streptococcus agalactiae (Hillerton and Berry, 
2003). These practices seem to have been less successful in control of other (non-
agalactiae) streptococcal species, commonly described as the ‘environmental’ 
streptococci (Hillerton and Berry, 2003).  Despite 4 decades of research following 
development of the five-point control program, non-agalactiae streptococcal 
intramammary infections (IMI) remain a significant problem in modern dairy herds that 
have successfully implemented methods to control S. agalactiae, and environmental 
pathogens have increased in relative importance as a cause of mastitis (Hillerton and 
Berry, 2005). 
 The term ‘environmental streptococci’ has been used to describe a group of 
organisms, not all of the genus streptococcus, that are commonly associated with 
environmental sources of exposure.  Hillerton and Berry (2003) provide a list of the eight 
most common environmental streptococci.  These organisms may be isolated in pure or 
mixed culture either associated with intramammary infections or as milk sample 
contaminants. Among these species, Streptococcus uberis is the most frequently isolated 
major mastitis pathogen on many farms, and subclinical mastitis appears to be the 
dominant form associated with the environmental streptococci, including S. uberis 
(Bramley, 1984; Watt, 1999; Hillerton and Berry, 2003; Zadoks et al., 2003). Cases of 
  124 
subclinical mastitis may be of short (i.e. transient; e.g. < 30 days) or extended (i.e. 
chronic; e.g. > 30days) duration and may be characterized by the complete absence of 
clinical signs (i.e. fully asymptomatic), or by brief or extended asymptomatic periods 
with the occasional clinical episode(s) (i.e. a symptomatic period or clinical ‘flare-up’).  
Clinical episodes may occur at the start of or within chronic subclinical infections, or 
clinical cases may occur as new infection events with no evidence of an associated 
asymptomatic period (Dodd and Neave, 1970; Watt, 1999; Zadoks et al., 2003).  Chronic 
quarter level infections caused by the same pathogen may display repeated clinical 
episodes (Watt, 1999; Zadoks et al., 2003). 
Clinical mastitis is readily observed, and is frequently treated with the goal of 
returning milk to a normal marketable consistency (clinical cure) but often treatment is 
given without specific information on the cause of infection (Bramley and Dodd, 1984; 
Sawant et al., 2005; Pol and Ruegg, 2007). In comparison, subclinical mastitis, 
characterized by an elevated milk somatic cell count (SCC), frequently goes undetected 
or untreated by dairy producers for extended periods, and in many circumstances the 
reliance on observation of clinical signs will give a false impression of the extent of 
subclinical infections in a herd (Bramley and Dodd, 1984; Hillerton et al., 1995; Oliver et 
al., 2004). Increased somatic cell count is associated with reduced milk production, 
increased risk of antibiotic residue violations, reduced fluid milk quality, and reduced 
cheese yield and quality (Reneau, 1986; van Schaik et al., 2002; Santos et al., 2003). 
Reduced productivity and lost milk quality payments associated with subclinical mastitis 
represent more than half of the estimated $1.8 billion in costs attributed to mastitis for US 
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dairy producers annually (Ott and Novak, 2001). The association between the increased 
somatic cell count due to subclinical mastitis, and reduced productivity and milk quality 
presents a potential economic opportunity for dairy producers to implement control 
programs targeting subclinical mastitis.  Further, the introduction of cow level SCC 
testing at regular intervals provides information that can be used to identify infected cows 
(Bramley and Dodd, 1984).  A threshold of 200,000 cells per ml has been recommended 
to distinguish between uninfected and infected quarters or cows (Dohoo, 1991; Smith et 
al., 2001; Schukken et al., 2003; Hillerton and Berry, 2005), and results of sequential 
monthly SCC testing can be used to identify chronically infected cows (Schukken et al., 
2003).   
 It has long been recognized that control programs that target both the reduction of 
new infections and the reduction of duration of infection are able to achieve the greatest 
success (Dodd et al., 1977).  Thus the five-point mastitis plan is most effective as it 
controls new infection rates through use of teat hygiene, especially post milking teat 
disinfection, and reduces duration of infection though use of antimicrobial treatment at 
the end of each lactation (i.e. dry cow therapy), and to a more limited extent by treatment 
of clinical mastitis cases during lactation (Bramley, 1984; Bramley and Dodd, 1984).  
Success of this control program is likely in great part because farmers are able to 
implement the practices with limited increases in labor and no need to rely on diagnostic 
procedures (Dodd et al., 1977). The ability of this program to control streptococcal 
mastitis has been somewhat limited, suggesting additional measures may be required to 
control streptococcal mastitis (Bramley, 1984).  Recent work has suggested that diagnosis 
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and treatment of subclinical mastitis cases during lactation may be used as an adjunct to 
current control practices, and under some situations may be economically beneficial 
(Swinkels et al., 2005b; Salat et al., 2008). However, there are limited studies evaluating 
the effects of lactation therapy programs targeting subclinical streptococcal mastitis in 
commercial dairy herds as might be applied in North America, and additional data is 
needed to evaluate the potential value of treating subclinical infections during lactation 
(Hillerton and Berry, 2003). 
Measurements required to evaluate the effect of a control practice that reduces the 
duration of infection differ from those required to evaluate a practice that reduces the new 
infection rate (Dodd et al., 1977).  For example, prior studies that have evaluated the 
effect of lactation therapy for subclinical mastitis have typically limited their analysis to 
the direct effects of treatment by quantifying the proportion of cure in treated individuals 
(Sol et al., 1997; Shephard et al., 2000; Gillespie et al., 2002; St Rose et al., 2003; Oliver 
et al., 2004; Deluyker et al., 2005; Salat et al., 2008; Sandgren et al., 2008). Most of these 
studies have included comparisons to untreated control groups (Shephard et al., 2000; 
Gillespie et al., 2002; St Rose et al., 2003; Oliver et al., 2004; Salat et al., 2008; Sandgren 
et al., 2008), have included other measures such as response of SCC and milk production 
to the treatment (Shephard et al., 2000; St Rose et al., 2003; Deluyker et al., 2005; 
Sandgren et al., 2008), or have evaluated host or pathogen level risk factors associated 
with bacteriologic cure (St Rose et al., 2003; Oliver et al., 2004; Deluyker et al., 2005; 
Salat et al., 2008; Sandgren et al., 2008).   
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In comparison, studies that have evaluated control practices designed to reduce 
new infection rates (e.g. studies of teat-end disinfection) require measuring new infection 
rates, typically by sequential interval sampling of individuals within a herd (Dodd et al., 
1977; Lam et al., 1996; Lam et al., 1997b; White et al., 2006).  For pathogens that may 
spread from cow to cow, the direct effect of a successful treatment (i.e. reduction of 
duration of infection) is coupled to a potential positive indirect effect of treatment, in that 
eliminating infections reduces transmission risk or the infection pressure (i.e. force of 
infection) in the population (Zadoks et al., 2002a; Barkema et al., 2006; White et al., 
2006). A few prior studies have suggested this indirect component is of economic 
importance to the decision to implement lactation therapy programs targeting subclinical 
mastitis (Zadoks et al., 2002a; Swinkels et al., 2005a; Swinkels et al., 2005b). To the best 
of our knowledge, no negative controlled field studies of antimicrobial mastitis 
treatments have been designed to evaluate the indirect effect by including measurements 
of new infection rates in populations receiving the treatment intervention.  Studies of 
antimicrobial treatment programs designed to measure both direct and indirect effects 
require the most intensive sampling schemes and rarely appear in the literature, likely as 
a result of their expensive and labor intensive nature, but are necessary to describe the 
potential overall benefits and limitations of lactation therapy targeting subclinical mastitis 
control.    
Measurements of infection dynamics within dairy cattle populations may be 
improved by inclusion of methods to identify individual strains of pathogens (Luby and 
Middleton, 2005; Barkema et al., 2006; Zadoks and Schukken, 2006).  A bacterial strain 
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can be defined as “an isolate or a group of bacterial isolates exhibiting characteristics that 
set it apart from other isolates belonging to the same species” (Zadoks and Schukken, 
2006), and a number of molecular or DNA-based methods of genotyping can be used to 
discriminate among strains of mastitis pathogens within herds or larger populations 
(Phuektes et al., 2001b; Wieliczko et al., 2002; Zadoks et al., 2003). The ability to 
differentiate strains by molecular genotyping or fingerprinting may improve estimates of 
infection duration and the proportion of bacteriologic cure in studies of direct effects of 
mastitis therapy (Luby and Middleton, 2005; Barkema et al., 2006; Zadoks and 
Schukken, 2006).  In addition, the identification and enumeration of strain diversity 
within a population receiving an intervention may provide evidence of the potential 
source(s) of new infections, and thus improve indirect effect estimates for mastitis 
treatment programs.  
In an epidemiologic context, the finding of multiple bacterial strains of a single 
species causing mastitis in a population of cows suggests these infections arise from one 
or more sources of exposure that are populated with many strains. Such findings have 
been used to infer environmental sources of exposure for S. uberis mastitis in dairy herds 
where the environment is populated with a diverse number of S. uberis strain types 
(Phuektes et al., 2001b; Wieliczko et al., 2002; Zadoks et al., 2003; Pullinger et al., 2006; 
Pullinger et al., 2007).  In comparison, the finding of a limited number of strains within a 
herd experiencing a mastitis outbreak over a defined time period may be consistent with 
cow to cow transmission as has also been suggested for S. uberis in some herds or 
management scenarios (Phuektes et al., 2001b; Zadoks et al., 2001a). In these later cases 
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it is possible that clusters of infection with a limited number of strains in space or time 
can also arise from a common environmental source populated with a dominant strain, or 
from the enhanced virulence of some individual environmental strains (Phuektes et al., 
2001b; Munoz et al., 2007).  
 The objective of this negative controlled clinical field trial was to evaluate the 
direct and indirect effects of a diagnosis driven treatment program targeting chronic 
subclinical mastitis caused by Streptococcus spp.  We used PCR-based methods to 
identify the streptococcal species causing intramammary infections, and applied random 
amplified polymorphic DNA (RAPD) methods to discriminate among S. uberis strain 
types.  For S. uberis, S. dysgalactiae individually, and the other gram-positive catalase-
negative (GPCN) cocci collectively, we determined direct effects of the treatment 
program by measuring duration of infection and proportion of cure in treatment and 
control groups. In addition, we evaluated species and strain specific rates of new 




Materials and Methods 
 
Study design 
A negative-controlled treatment trial was conducted for 13 months on 2 
commercial dairy herds with free-stall housing and cows milked in parlor systems. Herds 
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1 and 2 were located in New York, and Vermont, USA, respectively. Enrolled cows 
within each herd were assigned to one of two pens, with pens randomly allocated to 
treatment and control groups on each farm.  In the month preceding the start of the study, 
cows were systematically assigned to pens based on odd or even identification numbers. 
Cows that calved during the study were assigned to either the treatment or negative 
control groups based on odd-even identification number.  Within farms, no differences in 
mean parity, days in milk, or somatic cell count, were found among treatment and control 
groups at the start of the study by using this assignment method. 
 The population of cows in the treatment and control pens was a dynamic group, 
with entries and exits of cows from these pens following normal management cycles. 
Generally, early lactation cows entered the study pens after being housed in a ‘fresh cow 
group’ for approximately 14 days postpartum.  Dates of all entries and exits to and from 
treatment or control pens were recorded for each cow.  The herds were milked 3 times 
per day, and pens of cows within each herd were milked in the following order at each 
milking session: fresh cow group, study treatment group, study control group, additional 
groups not enrolled in study. The milking system was washed and sanitized between each 
of ther 3 daily milking sessions. There was no rinsing or disinfection of milking units 
after milking individual cows during a milking session, and neither farm used a back-
flushing system.  
The farms applied accepted mastitis control practices to all cows including use of 
iodine based (0.5 to 1 %) pre- and post-milking teat disinfectant solutions, and blanket 
use of commercially available dry-cow therapy products (herd 1, cephapirin benzathine; 
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herd 2, cloxacillin benzathine). The use of somatic cell count or bacteriologic culture data 
to segregate chronically infected cows was not practiced on either farm. The use of 
bacteriologic culture to aid clinical mastitis treatment decisions was not practiced on 
either farm. No diagnosis and treatment of subclinical mastitis was practiced on either 
farm prior to the start of the study.  Products use to treat clinical mastitis included 
commercially available intramammary formulations of amoxicillin, cephapirin sodium, or 
pirlimycin hydrochloride, on both farms. Lactating cows in herd 1 were bedded on 
mattresses with sawdust bedding, while in herd 2 lactating cow stalls were deep-bedded 
with sand. Stocking density of study pens on both farms exceeded number of stalls by 18 
to 20%. In both herds dry cows were loose-housed in a separate covered facility on a 
chopped straw bedded pack. Herd owners were financially compensated for participation.   
The study was conducted with approval of the University of Vermont Institutional 
Animal Care and Use Committee (IACUC).  
 
Milk sample collection and bacteriologic analysis 
Composite milk samples were collected monthly by DHIA technicians and 
processed through the regional commercial testing laboratories for SCC testing. 
Individual quarter milk samples were collected for microbiologic analysis from all cows 
in control and treatment groups at the start of the study, at monthly intervals for the 
duration of the study, and at the end of the study. These quarter samples were collected 
within 3 days of DHIA monthly composite sample collection. Quarter milk samples were 
also collected from all cows within 3 days following parturition (fresh sample), 
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immediately following identification of clinical mastitis (clinical pre-treatment sample), 
immediately prior to treatment of subclinical mastitis (subclinical pre-treatment sample), 
at any time when cows were added to or removed from the study pens for greater than 24 
hours (entry/exit sample), immediately prior to exit from the herd (cull sample), and at 7, 
14, 21, and 28 (± 2) days following cessation of any antibiotic therapy (clinical or 
subclinical post-treatment samples).  Monthly sample collection was conducted by 
trained field technicians, while farm personnel were trained to collect all additional 
samples following established aseptic methods (Hogan et al., 1999).  Samples collected 
by farm personnel were immediately stored frozen at -20°C and transported frozen to the 
microbiology laboratory at two-week intervals. Monthly samples were held on ice 
immediately following collection and during transport to the laboratory, and were stored 
frozen at -20°C for 24 – 72 hours.  All samples were thawed over-night under 
refrigeration and aerobic bacteriologic culture and interpretation of results were 
performed according to established guidelines (Hogan et al., 1999). Briefly, 10 uL per 
sample was plated on to tryptic soy agar (TSA) containing 5% sheep blood and 0.1% 
esculin.  Samples with >3 morphologically distinct colony types were considered 
contaminated and eliminated from analysis.  For all morphologically distinct colony types 
in uncontaminated samples, the number of colony forming units (cfu) per 0.01 ml was 
recorded as a one of four categories: 1 to 4, 5 to 9, 10 to 49, or ≥ 50 cfu (Dingwell et al., 
2003).  Representative colonies of GPCN cocci were identified based on colony 
morphology, esculin hydrolysis, Gram staining, and catalase testing. Isolates were 
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transferred to a TSA plate for isolation and individual isolates were transferred to broth 
culture and stored at -80°C. 
 
Treatment program   
The intent of the study was to model a treatment program that might be applied on 
commercial farms where an elevated SCC is used to trigger one or more bacteriologic 
cultures and culture results are used to trigger a treatment decision. In this study, a 
prolonged elevated SCC and bacteriologic culture information were used to trigger a 
decision to treat a quarter with mastitis caused by CPCN cocci using a commercially 
available intramammary formulation of a narrow spectrum antimicrobial.  For this 
purpose, the monthly quarter milk sample taken by research personnel within 3 days of 
SCC testing was defined as the ‘enrollment’ sample, and was considered a proxy for a 
farmer collected milk sample taken following receipt of monthly SCC test results.  Cows 
assigned to the treatment group that had an elevated composite SCC (≥200,000 cells/ml) 
in the current month, plus an elevated SCC in one of the two previous months and a 
positive culture due to CPCN cocci in the current monthly enrollment sample were 
eligible for extended pirlimycin therapy during that month. Cows with the most recent 
monthly enrollment sample where a subclinical IMI due to a gram-negative pathogen was 
diagnosed were not enrolled for therapy because of the limited antimicrobial spectrum of 
pirlimycin. Cows with a clinical mastitis event within the previous 14 days of the 
enrollment sample were not eligible for extended therapy. Cows that had received 
extended therapy but had not cured were not re-enrolled for extended therapy in the 
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current lactation. No additional covariates that might influence treatment success (e.g. 
cow lactation number, number of infected quarters, duration of infection, or antimicrobial 
susceptibility phenotype) were used to select cows for treatment. Treated cows on both 
farms were segregated in a ‘treated-cow’ pen during treatment and subsequent milk 
withhold periods.  A maximum of approximately 6 cows could be enrolled for extended 
therapy at any particular time due to the small pen size and limited number of available 
stalls in the treated-cow holding pen on each farm. Cows in the control group were 
monitored for treatment eligibility based on monthly SCC and bacteriology but received 
neither extended therapy, nor an excipient infusion. All lactating quarters of an enrolled 
cow were infused once daily with a commercially available intramammary formulation of 
the lincosamide antibiotic pirlimycin hydrochloride (Pirsue, Pfizer Animal Health, 
New York) at the labeled daily dosage (50 mg) for an extended (8 days) duration of 
therapy (extended therapy) (Gillespie et al., 2002; Oliver et al., 2003; Deluyker et al., 
2005).  Farmers collected quarter milk samples from enrolled cows immediately prior to 
the initial extended therapy treatment. Cows experiencing clinical mastitis in either group 
were treated using the established practices on the participating farms and records were 
maintained on the type and duration of therapy.  In general, antimicrobials used for 
intramammary treatment of clinical mastitis were restricted to commercially available 
formulations, including amoxicillin, cephapirin sodium, and pirlimycin hydrochloride on 
farm 1, and amoxicillin and pirlimycin hydrochloride on farm 2. There was a 3-month 
‘pre-intervention’ observation period at the start of the study prior to a 10 month 
intervention period.  All data were collected during both the initial 3 month observation 
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and the subsequent 10 month intervention period. Figure 4.1 provides a summary of the 
study design and sample collection procedures. 
 
 




Infection status  
Infection status was defined at two levels.  First, as described in the previous 
section, using monthly SCC data to model treatment decisions as might be applied on 
commercial farms, chronic subclinical mastitis was defined as SCC ≥ 200,000 cells/ml 
for at least 2 of the past 3 serial monthly composite milk samples (Schukken et al., 2003). 
After identifying cows with chronic subclinical mastitis each month, the current month’s 
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bacteriologic results were used to identify cows that were eligible for treatment in that 
month. Extended therapy treatments were limited to cows in the treatment group with at 
least one quarter with a presumptive infection caused by GPCN cocci, and no concurrent 
isolation of a gram-negative pathogen, or clinical mastitis episode within the past 14 
days.  This assumes that whole herd serial monthly bacteriologic culture is not cost 
effective for routine use on commercial farms, but that monthly SCC test data is 
frequently available which can be used to select individual cows for culture and possible 
treatment based on culture results (Schukken et al., 2003).   
Second, IMI status was defined based on sequential culture results as previously 
described by Zadoks, et al. (2002a).  This data was used retrospectively to determine 
monthly infection prevalence and to evaluate the direct (bacteriologic cure proportions) 
and indirect (new infection rates) effects of the treatment program. These serial culture 
data were used to define the IMI status of individual quarters independent of the 
composite SCC results, and IMI status was not used as a trigger for extended therapy 
treatment of subclinical mastitis. Based on the previously published definitions of  
Zadoks, et al. (2002a), individual quarters were categorized as having an IMI when a 10 
uL milk sample was positive on bacteriologic culture based on at least one of the 
following criteria: 1) ≥1000 cfu/ml from a single sample, 2) ≥500 cfu/ml from two out of 
three consecutive samples, 3) ≥100 cfu/ml from 3 of 3 consecutive samples, or 4) ≥100 
cfu/ml from a clinical sample.  Samples with >3 morphologically distinct colony types 
were considered contaminated and eliminated from analysis. Samples with bacteria 
isolated that did not meet the above criteria were defined as incidental isolation events, 
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and were presumed to be unimportant isolates possibly associated with transient or 
extended colonization of teat skin or orifices or with fecal contamination of these 
surfaces or workers’ hands (Bramley, 1984; Erskine and Eberhart, 1988; Hillerton and 
Berry, 2003; Zadoks et al., 2003). 
At each sampling point, an IMI was defined as either subclinical (i.e. 
asymptomatic) or clinical (symptomatic). It was recognized that an IMI first observed as 
a subclinical case may show sporadic or occasional episodes of clinical mastitis (clinical 
‘flare-up’), and that an IMI first observed as a clinical case event may persist as a 
subclinical mastitis. A clinical mastitis case was defined as an abnormality in appearance 
or consistency of milk, with or without either local and/or systemic signs associated with 
infection. Clinical mastitis severity was not categorized. A new clinical mastitis case or 
event was identified at the quarter level after that quarter was observed free of clinical 
signs for ≥ 14 days or if clinical mastitis occurred within 14 days of a previous case but 
was caused by a different pathogen species or strain. An individual quarter was defined 
as having a subclinical IMI, when meeting any one of the first three bacteriologic criteria, 
and having no occurrence of clinical symptoms within the past 14 days.  Thus for the 
purpose of this study, and consistent with established epidemiologic concepts (Dodd and 
Neave, 1970), a single persistent infection could be characterized by extended periods of 
subclinical mastitis punctuated by one or more clinical episodes. 
By establishing two parallel definitions, it was recognized that a cow with a 
quarter level IMI may have either a high or low SCC and the IMI may be either persistent 
(chronic) or of short duration (transient), making the IMI categories used for analysis of 
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infection dynamics distinct from the SCC based subclinical mastitis categories used for 
initiating treatment decisions.  A chronic subclinical IMI was defined as a quarter with an 
IMI caused by the same species or strain on at least 2 of 3 sequential monthly (28 day) 
sample intervals.  A transient subclinical IMI was defined as an IMI observed from a 
single isolation event (e.g. culture of ≥1000 cfu/ml from a single sample), or two 
isolation events less than 28 days apart.  It was possible for a cow with chronic 
subclinical mastitis (based on SCC results) to be enrolled for extended therapy following 
isolation of GPCN cocci from the enrollment sample but in retrospect to be defined as not 
having an IMI based on results that include a culture negative pretreatment sample.  
These events were recorded as ‘false positive’ treatments and were not included in 
analysis of IMI cure proportions. 
A quarter with a subclinical IMI was defined as spontaneously cured when the 
quarter was negative for the same pathogen or strain on 2 subsequent consecutive 
samples (generally at 28 and 56 days following the last positive sample). This definition 
was used to limit the number of errors in defining a cure due to the potential of observing 
a single false negative culture result on serial samples (Morant et al., 1988). A subclinical 
IMI was defined as cured following extended therapy when culture negative for the pre-
treatment species or strain on 4 of 4 post treatment samples taken at 7 (± 2) day intervals 
(Gillespie et al., 2002), accounting for the possibility of post-treatment false negative 
culture results. A clinical IMI was defined as a bacteriological cure following treatment 
when culture negative for the pre-treatment species or strain on 4 of 4 post treatment 
samples taken at 7 (± 2) day intervals.  The infection status following either spontaneous 
  139 
cure or therapeutic cure was monitored for the duration of the study or until an animal 
exited the study population. Data on infection status and cure was recorded for all aerobic 
bacterial species identified during the trial.  A re-infection of a quarter that was 
previously defined as cured followed the above IMI definitions, after the observation of 
at least two bacteriologic negative samples. 
 
Duration of infection 
Duration of infection was calculated based on mid-point estimation method 
previously described by Zadoks et al. (2003), where start of the IMI was defined as the 
middle of the time interval between a negative culture and the first positive culture event, 
and end of the IMI was defined as the middle of the time interval between the last 
positive culture and the first negative culture event for a quarter defined as cured. 
Quarters that entered the study infected, either at the start of the study or at the start of 
lactation, were considered left censored IMI and the infection start date was the date of 
first positive culture at time of enrollment. Infected quarters that exited the study were 
considered right censored and the IMI end date was the date of exit or the end date of the 
study for those lactating quarters still infected on the last monthly sample date. Quarter 
days infected (IMI prevalence days) in the study pens were calculated based on recorded 
dates of cow entry and exit from the study pens for all lactating quarters.  Quarter days 
susceptible (i.e. days at risk for new IMI among uninfected quarters) were calculated 
based on recorded dates of cow entry and exit from the study pens accounting for the date 
of changes in quarter infection status during each interval.  Non-lactating quarters in 
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lactating cows were identified with the date of milking cessation of the individual 
quarters (i.e. quarter ‘culling’) so that data on infected or susceptible quarter days 
accounted for any ‘blind’ or culled quarters within lactating cows.   
 
Species identification and S. uberis strain typing   
Pure subcultures were obtained for species identification from selected isolates 
representing all IMI caused by GPCN cocci.  Isolates were selected from early, middle, 
and late time points. In addition, pre- and post-treatment isolates were selected for all 
cows receiving lactation therapy.  For initial identification, Streptococcus uberis and 
Streptococcus dysgalactiae were identified by multiplex PCR directly from bacterial 
suspensions (Martineau et al., 2000) using established methods (Phuektes et al., 2001a) 
with slight modifications. Briefly 3-5 colonies from a pure subculture were suspended in 
100 uL TE, and 1 uL of the bacterial suspension was transferred to a 50 uL final volume 
containing PCR reagents and S. uberis and S. dysgalactiae primers previously described 
by Phuektes et al. (2001a). Cell lysis was by extended heating during a prolonged initial 
denaturing step of 94°C for 15 min at the start of each thermocycler program, with 
amplification performed by 36 cycles of  95°C for 1 minute,  50°C for 30 seconds, and 
72°C for 30 seconds, followed by final extension at 72°C for 5 minutes. PCR product was 
resolved by electrophoresis through a 1.5% or 2% agarose gel stained with ethidium 
bromide and visualized under UV light. Species identity was based on amplification 
product size estimated by comparison with a 50-bp molecular size ladder and 
amplification products run in parrelel for S. uberis and S. dysgalactiae control strains. 
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Absence of an amplification product suggested identification of GPCN cocci other than 
S. uberis or S. dysgalactiae.  Selected isolates that were negative for S. uberis or S. 
dysgalactiae PCR were identified by amplification and sequencing of a 740 bp fragment 
of the rpoB gene (encoding the beta subunit of RNA polymerase) using previously 
described primers and methods (Drancourt et al., 2004).  
Isolates initially identified as S. uberis were confirmed by a second independent 
uni-plex PCR reaction with DNA template prepared from pure subculture by established 
methods (Furrer et al., 1991).   Strain typing of S. uberis isolates was performed by 
RAPD as previously described (Schmitt-Van de Leemput and Zadoks, 2007).  RAPD 
type was considered to be the same for isolates having the same number and size of DNA 
fragments, regardless of band intensity. Individual RAPD types were designated with an 
arbitrary numeric code, preceded by a letter designation for each of the two farms.  Two 
independent observers visually evaluated banding patterns to discriminate among RAPD 
types, and any discrepancies in RAPD type classification were resolved by joint re-
evaluation. Comparisons of banding patterns were limited to within an individual gel 
where sets of up to 18 isolates were processed simultaneously and run on a single gel for 
visualization.  Sufficient gels were run to make within quarter, within cow, and within 
farm comparisons of isolates in order to discriminate among potential strain differences at 
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Antimicrobial susceptibility testing 
 Antimicrobial susceptibility was determined retrospectively by broth dilution and 
disc diffusion methods for pretreatment isolates of IMI receiving extended pirlimycin 
therapy.  For each IMI, susceptibility test results were determined for a minimum of 2 
pre-treatment isolates obtained at separate time-points (e.g. the enrollment sample isolate 
and the subclinical pre-treatment sample isolate).  
Minimum inhibitory concentrations were determined by broth microdilution 
methods using commercially prepared micro-titer plates (Sensititre, Trek Diagnostics, 
Cleveland, Ohio), and performed in accordance with Clinical Laboratory Standards 
Institute guidelines (2008).  Briefly, bacterial suspensions in sterile demineralized water 
standardized to a 0.5 McFarland were made from pure subcultures and used to inoculate 
commercially prepared cation adjusted Mueller-Hinton broth with TES buffer (Trek 
Diagnostics, Cleveland, Ohio) per manufacturer instructions.  Aliquots (50 uL) of this 
broth were immediately dispensed into wells of  96-well plates containing two-fold serial 
dilutions of  ampicillin (0.12 to 8 ug/ml), penicillin(0.12 to 8 ug/ml), oxacillin (2 to 4 
ug/ml), erythromycin (0.25 to 4 ug/ml), pirlimycin (0.5 to 4 ug/ml),  
penicillin/novobiocin (1/2 to 8/16 ug/ml), tetracycline (1 to 8 ug/ml), cephalothin (2 to 16 
ug/ml), ceftiofur (0.5 to 4 ug/ml), and sulphadimethoxine (32 to 256 ug/ml). Plates were 
incubated for 18 to 24 hours at 37°C and MICs were determined visually using an 
inverted magnifying mirror.  Positive growth controls were included in each plate.  
Quality control organisms Staphylococcus aureus (ATCC strain 29213) and 
Enterococcus faecalis (ATCC strain 29212) were run in parallel with each series of 
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isolates tested.   Inoculum purity controls were examined by streaking aliquots of the 
inoculated Mueller-Hinton (M-H) broth to TSA with 5% sheep blood and incubating for 
48 hours at 37°C to detect mixed cultures due to contamination. Testing was repeated 
from a pure subculture if a mixed culture was suspected.  
 Agar disc diffusion susceptibility testing was conducted for ampicillin (10 ug), 
penicillin (10 IU), erythromycin (15 ug), pirlimycin (2 ug), penicillin/novobiocin (10 IU / 
30 ug), tetracycline (30 ug),cephalothin (30 ug), ceftiofur (30 ug), clindamycin (2 ug) and 
vancomycin (3 ug).  Colonies from pure subcultures were used to inoculate tryptic soy 
broth (TSB), which was incubated for 2 to 12 hours and when necessary diluted with 
saline to achieve a 0.5 McFarland turbidity suspension.  A sterile cotton swab was used to 
streak the suspension on Mueller-Hinton agar with 5% sheep blood to create a confluent 
bacterial lawn. Antimicrobial discs were applied within 15 minutes of streaking the lawn 
and zone diameters determined after plates were incubated for 18-20 hours at 37°C. 
Inoculum purity controls were performed from the TSB as described for M-H broth. For 
isolates demonstrating erythromycin resistance either by disc diffusion or broth dilution 
but appearing susceptible to either clindamycin or pirlimycin the D-test was performed in 
accordance with recommended methods to identify inducible lincosamide resistance 
(Steward et al., 2005; Schmitt-Van de Leemput and Zadoks, 2007).   
For each testing method, isolates were categorized as susceptible, intermediate or 
resistant based on criteria established for streptococci other than Streptococcus 
pneumoniae, for all antimicrobials examined, except for pirlimycin and 
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penicillin/novobiocin which were categorized based on criteria for streptococci causing 
bovine mastitis (CSLI, 2008).  
 
Statistical methods 
 All statistical analysis was conducted using SAS version 9 (SAS Institute, Inc., 
Cary, NC, USA). The effect of treatment on the natural logarithm of duration 
(LnIMIDUR) was tested in a generalized linear model including the effect of 
streptococcus species, farm and the interactions between farm and treatment group and 
species and treatment group. The effects of treatment on duration were also explored 
using a data set containing only IMI defined as chronic. The hypothesis that treatment 
affected duration of S. uberis and S. dysgalactiae infection was tested using the Log-rank 
test to compare the Kaplan-Meier survival function for treated and control groups, while 
controlling for the effect of farm and species, with mean [standard deviation (sd)], and 
median [ 95% confidence interval (CI)] estimates reported. 
Prevalence (number of quarters days infected, PT ) and incidence(number of new 
IMI, IN ) of S. uberis or S dusgalactiae IMI were analyzed as outcomes using generalized 
linear models (PROC GENMOD, SAS) and model checking included examination of 
deviance and Pearson Chi-square for goodness of fit (Lam et al., 1996; Zadoks et al., 
2002a).  Evidence of overdispersion was adjusted using Pearson Chi-square estimates 
divided by the degrees of freedom (Pscale option). Binomial, Poisson, or Negative 
Binomial error distributions were selected for final models after comparisons for 
goodness of fit.  Treatment group (Group) and time period (2 categories, pre-intervention 
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versus intervention periods) were included as dependent variables.  In the final 
prevalence model, the impact of treatment group on the prevalence in each interval was 
modeled assuming a negative binomial distribution, a log link, and an offset of the total 
number of quarter days, 
 [ ]ln( ) * ln( )TP intcpt Group Timep Group Timep Nε = + + + +                                   [4.1], 
where ε = expected value and ln(N)= offset. Comparison of least square means IMI 
quarter-days prevalence (PT) between treatment and control groups and across 
observation and intervention time periods was conducted separately for each farm using 
model 4.1 and accounting for multiple comparisons with Bonferroni methods.   
The impact of treatment on incidence in each interval was estimated in a Poisson 
regression model, with a Poisson error distribution, a log link, and an offset of the 
number of quarter days susceptible for new IMI (S),  
 [ ]ln( ) * ln( )NI intcpt Group Timep Group Timep Sε = + + + +                                   [4.2]. 
Since prevalence was affected by treatment, prevalence was not included as a covariate in 





On farms 1 and 2 there were a monthly average of 319 and 346 lactating cows, 
respectively. The monthly average number of cows in treatment and control pens at the 
time of monthly DHIA SCC testing was 95 and 98, respectively, on farm 1, and, 91 and 
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89, respectively on farm 2.  On farm 1 milk production averaged 69 and 72 lbs per day, 
while on farm 2 production averaged 93 and 91 pounds per day, in treatment and control 
pens, respectively.  The mean lactation number of cows in control pens and treatment 
pens did not differ on either farm, and the overall mean lactation number of cows 
enrolled in the study on farm 1 and 2 was 2.44 and 3.05, respectively. 
A total of 31,761 quarter milk samples were collected from the two farms. On 
farm 1 there were 14,467 quarter samples taken from 3675 sample events from 385 cows, 
with 209 (1.4%) samples identified as contaminated leaving 14258 quarter samples for 
analysis. Of these, GPCN cocci were isolated from 1313 (9.2%) samples. On farm two 
there were 17,294 quarter samples taken from 4387 sample events from 580 cows, with 
787 (4.6%) samples identified as contaminated leaving 16507 quarter samples for 
analysis. Of these, GPCN cocci were isolated from 1340 (8.1%) samples. 
 
Intramammary infection cure proportions in treated and control groups 
Farm 1.  On farm 1, eight Streptococcus spp. IMI in 8 quarters of 8 cows were 
treated by extended therapy.  Six (75%) IMI were defined as cures including 3 of 3 S. 
dysgalactiae, 0 of 2 S. uberis, and 3 of 3 other GPCN cocci (S. parauberis, S. 
pluranimalium, and one species not determined). The frequency of IMI events including 
treatments within each monthly interval for S. dysgalactiae and S. uberis for treatment 
and control groups on farm 1 are shown in tables 4.1 and 4.2. 
A total of 16 S. dysgalactiae IMI in 14 quarters of 12 cows, and 12 S. uberis IMI 
in 12 quarters of 6 cows, were identified in the treatment pen on farm 1. Of the S. 
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dysgalactiae IMI in the treatment pen, 3 IMI cured following extended therapy of 
subclinical mastitis and 2 cured following treatment of a clinical episode. Of the 6 
chronic IMI that received no treatment of clinical or subclinical mastitis in this pen, 2 
cured spontaneously. No S. uberis IMI were defined as cures following extended therapy 
of subclinical mastitis, however both quarters subsequently cured spontaneously. 
Bacteriologic cure was observed for 2 of 7 S. uberis IMI that were treated because of 
clnical episodes. In the treatment pen on farm 1 there were 6 S. uberis IMI that were not 
treated with extended therapy or for clinical mastitis, including 3 transient IMI that cured 
spontaneously, and 3 chronic IMI that left the study population infected.  
Seven S. dysgalactiae IMI in 6 quarters of 6 cows, and 5 S. uberis IMI in 5 
quarters of 5 cows, were identified in the control pen on this farm. Of the S. dysgalactiae 
IMI in the control pen, 2 cured following treatment of a clinical episode, and 3 of 5 
chronic subclinical IMI cured spontaneously.  Five S. uberis IMI in 5 quarters of 5 cows 
were identified in the control pen on farm 1. Two of 3 clinical S. uberis episodes in 2 
quarter level IMI cured following treatment in the control pen. In the control pen on farm 
1 there were 2 spontaneous cures of 3 chronic S. uberis IMI that were not treated for 
clinical mastitis (tables 4.1 and 4.2).  
Overall, the proportion of chronic subclinical IMI that cured spontaneously on 
farm 1 (including IMI in the treatment and control pens that did not receive any lactation 
therapy) was 45% (5/11) for S. dysgalactiae and 33% (2/6) for S. uberis. Streptococci 
were cultured from 22 clinical episodes in 16 quarters of 13 cows in herd 1 caused by S 
uberis (n=10), S. dysgalactiae (n=11), and other GPCN cocci (not typed n=1). Cure 
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following clinical therapy was observed for 8 (36%) of these cases including, 4 S. 
dysgalactiae and 4 S. uberis IMI.  
Farm 2.  On farm 2, eighteen GPCN cocci IMI in 18 quarters of 15 cows were 
treated by extended therapy.  One cow was culled due to clinical mastitis caused by 
Escherichia coli 3 days following the eighth day of treatment and was considered a 
treatment failure in the analysis of cure proportions. The frequency of IMI events 
including treatments within each monthly interval for S. dysgalactiae and S. uberis for 
treatment and control groups on farm 2 are shown in tables 4.3 and 4.4. 
Three S. dysgalactiae IMI in 3 quarters of 3 cows, and 41 S. uberis IMI in 21 
quarters of 17 cows, were identified in the treatment pen on farm 2. Of the S. 
dysgalactiae IMI in the treatment pen, one IMI each cured following extended therapy of 
subclinical mastitis and treatment of clinical IMI, and one spontaneously cured. Of the S. 
uberis IMI in the treatment pen, 11 of 15 cured following extended therapy of subclinical 
mastitis, while 2 of 4 IMI cured following a clinical episode. Two of the 4 chronic 
subclinical IMI that did not cure following extended therapy subsequently cured 
spontaneously. In the treatment pen on farm 2 there were 16 spontaneous cures of 22 S. 
uberis IMI that were not treated with extended therapy or for clinical mastitis, including 7 
transient IMI, and 15 chronic IMI.  
Six S. dysgalactiae IMI in 5 quarters of 5 cows, and 32 S. uberis IMI in 22 
quarters of 14 cows, were identified in the control pen on farm 2. Of the S. dysgalactiae 
IMI in the control pen, two IMI cured following treatment of a clinical episode, and 2 of 
4 chronic subclinical IMI cured spontaneously.  Five of 11 clinical S. uberis episodes in 7 
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quarter level IMI cured following treatment in the control pen on farm 2. In the control 
pen on farm 2 there were 13 spontaneous cures of 25 S. uberis IMI that were not treated 
for clinical mastitis, including 3 transient IMI, and 22 chronic IMI (table 4.3 and 4.4).  
Overall, the proportion of chronic subclinical IMI that cured spontaneously on 
farm 2 (including IMI in the treatment and control pens that did not receive any lactation 
therapy) was 54% (19/35) for S. uberis and 60% (3/5) for S. dysgalactiae. Streptococci 
were cultured from 23 clinical episodes in 19 quarters of 17 cows in herd 2 caused by S. 
uberis (n=15), S. dysgalactiae (n=5), Lactococcus lactis (n=1), and Enterococcus faecium 
(n=2).  Cure following clinical therapy was observed for 10 (43%) of these episodes 
including, 3 S. dysgalactiae and 7 S. uberis IMI.     
 The overall proportion of quarters with chronic subclinical IMI that cured 
following extended therapy was 65% (11/17) and 100% (4/4) for S. uberis and S. 
dysgalactiae, respectively; while 51% (21/41) and 50% (8/16) of chronic subclinical IMI 
spontaneously cured for S. uberis and S. dysgalactiae, respectively. In a logistic model, 
extended lactation therapy was not a significant predictor of the probability of cure 
among cases of chronic subclinical mastitis, accounting for the effects of IMI species (S. 
uberis vs. S dysgalactiae), farm, and the 2 way interaction between farm and species. 
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Table 4.1 Frequency of Streptococcus uberis intramammary infections in treatment and control groups on 








Table 4.2 Frequency of Streptococcus dysgalactiae intramammary infections in treatment and control 
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Table 4.3 Frequency of Streptococcus uberis intramammary infections in treatment and control groups on 
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Table 4.4 Frequency of Streptococcus dysgalactiae intramammary infections in treatment and control 
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Effect of treatment on duration of S. uberis and S. dysgalactiae mastitis 
The mean (s.d.) and median duration of all S. uberis and S. dysgalactiae IMI are 
shown in table 4.5 and the frequency distribution of IMI duration categories demonstrates 
that the majority of IMI for both species had a duration of infection < 60 days (figure 4.2) 
which likely influences overall estimates of the effect of treatment on duration of 
infection for all infected quarters within a treatment group. Overall a numerical reduction 
in the duration of infection was observed for all S. uberis and S. dysgalactiae IMI in the 
treatment pens compared to control pens (table 4.5).  
 
 
Figure 4.2 Frequency distribution of Streptococcus dysgalactiae and Streptococcus uberis intramammary 
infections by duration of infection categories. 
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In a generalized linear model treatment was not a significant predictor of 
LnIMIDUR when accounting for the affect of farm and the treatment by farm interaction, 
with least square means estimates of  22 and 36 days duration (back-transformed from the 
natural logarithm) for the treatment and control groups respectively. 
 
 
Table 4.5 Duration of infection estimates for Streptococcus uberis and Streptococcus dysgalactiae 





In a Kaplan-Meier estimate of the survival function of all IMI accounting for right 
censored observations, the median (95% CI; mean, s.d.) duration of infection was 
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estimated to be 38 (25-64; 77, 12) and 63 (55-129; 100, 14) days in the treatment and 
control groups respectively, but the overall survival curves were not different at the 




Figure 4.3 Kaplan-Meier survival function of Streptococcus dysgalactiae and Streptococcus uberis 
intramammary infections (IMI) from 2 commercial dairy herds accounting for right censored observations, 
including farm and bacterial species as covariates, and stratified by treatment groups (Treatment group = 





Effect of treatment on IMI prevalence and incidence 
There were a total of 23 new S. dysgalactiae IMI per 500,653 quarter days at risk, 
with 17 new IMI observed on farm 1 and 6 new IMI on farm 2.  There were 40 new S. 
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uberis IMI per 496,991 quarter days at risk, with 12 new IMI on farm 1 and 28 new IMI 
on farm 2.  Figures 4.4 and 4.5 shows the relationship between prevalence and incidence 





Figure 4.4 Incidence and Prevalence of Streptococcus uberis intramammary infections (IMI) stratified by 
farm and treatment group.  Prevalence in quarter days infected is graphed on the right axis and represent by 
a line, while incidence of new IMI (quarters per 10,000 quarter days at risk) in naïve susceptible quarters 
(solid bars) and recovered susceptible quarters (open bars) are graphed on the left axis.  
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Figure 4.5 Incidence and Prevalence of Streptococcus dysgalactiae intramammary infections (IMI) 
stratified by farm and treatment group.  Prevalence in quarter days infected is graphed on the right axis and 
represent by a line, while incidence of new IMI (quarters per 10,000 quarter days at risk) in naïve 




When data on S. uberis and S. dysgalactiae prevalence was pooled there was a strong 
effect of prevalence on incidence of new mastitis cases caused by these pathogens, which 
was also observed for S. uberis on farm 2, but not for any other subset of the data (i.e S. 
dysgalactiae on farms 1 and 2, and S. uberis on farm 1).  Treatment was not a significant 
predictor of either prevalence or incidence when the models were applied to either the 
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complete data set, or subsets of data stratified by pathogen and farm.  For incidence of S. 
uberis on farm 2, time period was a significant predictor of incidence but the effects of 
treatment, or a treatment by time period interaction were not significant. 
 
New IMI in recovered susceptible quarters following extended therapy 
 On Farm 1, there was one new IMI due to S. uberis identified in a quarter with a 
prior S. dysgalactiae IMI that cured following extended therapy, and one quarter with a 
pre-treatment S. parauberis IMI that had a post treatment IMI caused by L. lactis. No 
Streptococcal IMI were observed in recovered susceptible quarters on farm 2. 
 Five IMI caused by other major mastitis pathogens were observed either during 
therapy or following the last day of treatment.  On farm 2, four IMI caused by E. coli 
(n=2) or Klebsiella (n=2) were identified in 4 quarters of 3 cows during treatment by 
analysis of daily quarter milk samples taken prior to antimicrobial infusion on each of the 
8 days of treatment.  Positive sequential samples were observed for 2 or more days 
beginning on days 4, 6, 6, 7 for each of these 4 quarters respectively. Two of these 
quarters in one cow cured spontaneously by the first post treatment sample (pen move 
samples taken at 2 days post treatment), and one of these quarters in another cow was still 
positive for a Klebsiella at 16 days following the last treatment before becoming negative 
on culture.  Neither of these 2 cows showed clinical signs.  In comparison one cow with 
E. coli IMI that was first diagnosed on the sixth day of treatment was culled due to E. coli 
mastitis within the week following treatment. On farm 1, a cow developed clinical 
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mastitis in two quarters at 16 days following extended therapy for streptococcal mastitis 
and a Proteus spp. was isolated from both quarters.   
 
Diversity of S. uberis strains 
 Eight RAPD types were identified among 40 isolates examined from 21 quarters 
of 15 cows with S. uberis IMI on farm 1, and were arbitrarily numbered types M-1 
through M-8.  Of these, 7 different RAPD types were found to cause 10 IMI in 10 
quarters of 9 cows, with each RAPD type only infecting up to 2 cows.  In comparison 
RAPD type M-5 was associated with 11 IMI in 11 (52%) quarters of 7 (47%) cows on 
farm 1. 
 On farm 2, 30 RAPD types were identified among 104 isolates examined from 30 
IMI in 27 quarters of 21 cows.  Again, most RAPD types were isolated from only one or 
two quarters of one or two cows, but one RAPD type (S-9) was associated with 7 IMI in 
7 (26%) quarters in 5 (24%) cows. 
 
Influence of speciation and strain typing on determination of IMI definition and 
bacteriologic cure 
 There were two cases in two cows where GPCN cocci IMI were identified in pre- 
and post treatment samples, suggesting no cure following extended therapy, which were 
defined as cures because a different species was identified in the post treatment sample.  
These included a quarter with S. dysgalactiae pre-treatment that developed a new S. 
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uberis IMI post treatment (figure 4.4), and a quarter with a pre-treatment S. parauberis 
IMI that had a post treatment IMI caused by L. lactis. 
Strain typing of a series of S. uberis isolates collected from individual quarters 
over time allowed the IMI definitions to be refined for 5 quarters of 5 cows. In two cases 
of a series of isolates, RAPD typing found different strain types in sequential samples 
with < 1000 cfu/ml resulting in a reclassification of the IMI status for theses quarter to 
negative.  In another series of isolates from a quarter with a chronic IMI, RAPD typing 
identified a different strain type at the earliest positive sample with 100 cfu/ml resulting 
in a reduction in the duration of infection estimate for that IMI. In one quarter, a series of 
4 IMIs caused by different strains was identified. These separate IMI included an initial 
clinical event at 19 days in milk, followed by 3 separate subclinical IMI based on pairs of 
sequential samples each caused by a different strain over a 240 day period. Interestingly, 
this same cow had chronic IMI with recurrent clinical mastitis in two other quarters with 
each quarter IMI caused by a single but different strain type.  The remaining cases were 
IMI that were redefined from a single quarter level IMI of long duration with ≥ 4 positive 
monthly samples, to 2 IMI of shorter duration caused by different strains in the same 
quarter at different time periods. 
 
Association between antimicrobial susceptibility and bacteriologic cure 
Antimicrobial susceptibility was examined for pairs of isolates taken at two 
separate time points (e.g. enrollment isolate and subclinical pre-treatment isolate) prior to 
extended therapy. For each testing method, there was agreement in susceptibility 
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classification within each pair of pre-treatment samples.  Minor differences in either the 
zone diameter (1-2 mm) or the MIC (1 dilution) were observed for most pairs of isolates 
from the same IMI. In only one pair of S. uberis isolates did a difference in measurements 
of a disc diffusion diameter for pirlimycin result in a different susceptibility classification 
(12 mm for 1 isolate shown in figure 1 versus 20 mm for the other not included in figure 
4.6).  The smaller observed zone diameter was subsequently confirmed by repeated 
testing of these two isolates. Four pairs of S. uberis pre-treatment isolates were classified 
as pirlimycin resistant by MIC and susceptible by disc diffusion (figure 4.6). Thornsberry 
et al. (1993) had previous defined falsely susceptible isolates (i.e. resistance by MIC and 
susceptible by disc diffusion) as “very major errors”, and falsely resistant isolates (i.e. 
susceptible by MIC and resistant by disc diffusion) as “major errors”.   Using these 
definitions we observed no major errors and 4 very major errors.  None of these four S. 
uberis IMI cured in the 4 weeks following therapy, although all appeared to 
spontaneously cure after 30 days post treatment. Two out of 8 isolates classified as 
pirlimycin resistant by MIC ≥ 4 ug/ml cured following extended therapy.  These were 
identified as Enterococcus faecalis and Lactococcus lactis.  In comparison, 5 of the 6 
isolates with an MIC ≥ 4 ug/ml that did not cure following extended therapy were S. 
uberis representing a single RAPD type (M-5) from farm 1 and 2 RAPD types (S-1 and 
S-9) from farm 2.  The additional isolate with a pirlimycin resistant MIC that did not cure 
was Lactococcus lactis.  One out of 17 isolates classified as pirlimycin susceptible by 
MIC ≤ 2 ug/ml did not cure following extended therapy.  This isolate was a S. uberis 
(RAPD type S-21) that demonstrated erythromycin resistance (MIC ≥ 8 ug/ml and no 
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zone of inhibition by disk diffusion) and was D-test positive for pirlimycin and 
clindamycin, but appeared sensitive to lincosamides in the absence of erythromycin 
induction. 
 
Figure 4.6 Scatter plot for pirlimycin MICs and zone diameters observed for representative pre-treatment 
isolates of gram-positive catalase-negative cocci causing IMI that were treated with 8 days intramammary 
pirlimycin.  Results of one isolate per IMI are shown. Open symbols = cure following 8 days therapy, Solid 
symbols = no cure following 8 days therapy, □ or ■ = Streptococcus uberis (n=17), ◊ or ♦  = Streptococcus 
dygalactiae (n=4), ∆ or▲ = other ‘streptococci’ [Lactococcus lactis (n=2), Enterococcus faecalis (n=1), 
Streptococcus parauberis (n=1), Streptococcus pluranimalium (n=1), and Aerococcus spp. (n=1)]. 
Horizontal line represents the MIC breakpoint (≤ 2 ug/ml) is susceptible, and the vertical line represents the 
disk diffusion breakpoint (≥ 13 mm is susceptible) as recommended for gram-positive pathogens causing 
mastitis (CSLI, 2004). Isolates with footnotes: 1 = D-test positive S. uberis isolate, zone diameter in 
absence of Erythromycin induction = 21 mm, in presence of erythromycin induction = 10 mm; L= 
Lactococcus lactis; Ef= Enterococcus faecalis. 
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Therefore after reclassifying the S. uberis isolate with inducible pirlimycin resistance as 
resistant, in this study 11 of 11 pirlimycin susceptible S. uberis isolates cured, while 0 of 
6 pirlimycin resistant S. uberis isolates cured.  In contrast among the other streptococcal 
species, 5 of 5 susceptible isolates cured and 2 of 3 resistant isolates cured.   
Pirlimycin resistance was identified in 6 S. uberis isolates from 4 different RAPD 
types, and was consistently associated with clindamycin resistance.  In RAPD types M-5 
and S-9, lincosamide resistance was associated with tetracycline resistance, while 
tetracycline resistance was not found in the remaining S. uberis isolates.  S. uberis RAPD 
type 26 demonstrated intermediate resistance to ampicillin and penicillin, while the 
remaining S. uberis isolates appeared susceptible to all other antimicrobials tested (table 
4.6). 
Table 4.6 Antimicrobial susceptibility profile of Streptococcus spp. isolates obtained pre-treatment.  
 





 The direct and indirect effects of lactation therapy of subclinical mastitis due to S. 
uberis and S. dysgalactiae were not significant in the herds in this study.  While the 
proportion of subclinically infected quarters that cured following intramammary 
treatment was in the range observed for S. uberis and S. dysgalactiae in previous studies 
(Gillespie et al., 2002; Deluyker et al., 2005; Sandgren et al., 2008) the spontaneous cure 
rate observed in this study was increased compared to other reports (Cattell et al., 2001; 
Gillespie et al., 2002; St Rose et al., 2003; Oliver et al., 2004; Salat et al., 2008; Sandgren 
et al., 2008).  Differences in study design, specifically the longitudinal design of this 
study compared to other treatment trials that followed IMI for a shorter time period, 
likely contributed to our observation of a high spontaneous cure rate.  Similar 
spontaneous cure proportions for the environmental streptococci have been observed in 
other longitudinal studies (Todhunter et al., 1995; Zadoks et al., 2003; McDougall et al., 
2004) and in one treatment trial (McDougall, 1998).  
To the best of our knowledge this is the first subclinical mastitis treatment trial 
that used duration of infection as an outcome measure.  The durations of subclinical S. 
uberis infections observed in this trial did not differ from previous reports (Watt, 1999; 
Zadoks et al., 2003; McDougall et al., 2004).  The finding of no difference between 
treatment and control groups in duration of subclinical IMI was likely influenced by the 
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large proportion of subclinical S. uberis and S. dysgalactiae IMI identified that 
spontaneously cured in less than 60 days.  However, limiting analysis to only those 
quarters with IMI of greater than 30 days duration still resulted in no evidence of a 
treatment effect on duration of infection. It was clear that approximately 25% of S. uberis 
IMI have a duration of infection greater than 100 days and the majority of these are 
strictly subclinical in presentation, similar to what was reported previously (Zadoks et al., 
2003). Targeting this group of infections for treatment would seem logical and would 
reduce overall duration of S. uberis infection in a population of dairy cattle.  Further, 
treatment of the short duration infections is likely an imprudent use of antimicrobials and 
not cost effective (Hillerton and Berry, 2003). However, the challenge remains in 
distinguishing those infections that are destined to spontaneously cure within one to three 
months from those that are likely to survive for more than 90 days.  It appears the 
enrollment criteria used in this study were insufficient in making that distinction.  Further 
studies on the association between host or pathogen factors and duration of infection   
may provide prognostic markers that can be used in treatment decisions similar to has 
been suggested for Staphylococcus aureus infections (Barkema et al., 2006). Data from 
the current studies may be used to evaluate pathogen factors based on results of RAPD 
typing. 
The use of antimicrobial susceptibility profiles to select therapies and infections 
for treatment remains controversial with differences of opinion among researchers 
(Constable and Morin, 2003; Barkema et al., 2006).  Results of pre-treatment 
susceptibility testing of isolates indicated a strong association between MLS 
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susceptibility and probability of cure following extended pirlimycin therapy, with 
treatment failures in 6 of 6 pirlimycin resistant S. uberis isolates and 0 of 11 susceptible 
S. uberis isolates. Further work should be conducted to evaluate the potential value of 
including susceptibility testing as a treatment criterion. These results can not be expanded 
to other streptococcal species as response to therapy may not be completely associated 
with susceptibility profiles but may be driven by other virulence factors in other species 
(Haveri et al., 2007), thus explaining some of the conflicting results regarding use of 
susceptibility profiles. The potential association between strain type and susceptibility 
profile should also be considered in future studies as specific strains may differ in the 
ability to acquire mobile genetic elements encoding for resistance (Waldron and Lindsay, 
2006; Sung and Lindsay, 2007). 
A further constraint in this study could have been the ability to only enroll a 
limited number of cows for therapy within a given month.  This may have allowed the 
continued presence of infected individuals within the herd contributing to transmission.  
Based on results obtained for herd 2 this potential limitation may be inconsequential in 
many herds as we were able to eliminate the majority of S. uberis IMI over a 3 month 
period.  
The observation of potential iatrogenic IMIs association with extended 
intramammary pirlimycin therapy appears to be consistent (Gillespie et al., 2002; 
Middleton and Luby, 2008) and has led to the recent inclusion of a precautionary 
statement on the product insert for the commercial product. Prevention of these infections 
is critical to the successful implementation of lactation therapy and may be accomplished 
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to some degree by careful aseptic technique during intramammary infusion, or by the use 
of systemic therapy (Salat et al., 2008; Sandgren et al., 2008), although there are 
currently no systemic products approved for treatment of subclinical mastitis in the 
United States.  A possible additional value of systemic therapy for subclinical mastitis 
may be that it provides simultaneous treatment of all four quarters and may eliminate 
minor mastitis pathogens infecting other quarters of a cow with a major pathogen in one 
or more quarters. However the effect of eliminating minor mastitis on the risk of new 
infections associated with major pathogens needs to be evaluated further (Lam et al., 
1997a; White et al., 2006). The increased risk of new infections following elimination of 
minor infections may explain the observation that the risk of new mastitis treatments 
following treatment of subclinical mastitis did not differ among cows treated by an 
intramammary or systemic route(Sandgren et al., 2008).  
While S. uberis is commonly described as an environmental pathogen, a few 
recent reports have provided evidence of contagious transmission of a dominant strain 
within some dairy cattle populations under specific management conditions (Phuektes et 
al., 2001b; Zadoks et al., 2001a).  While these contagious outbreak scenarios may be 
infrequent among reports of mastitis epidemiology for the environmental streptococci, 
they do reinforce the concept that cow to cow transmission of mastitis pathogens is 
possible and contributes to the total infection pressure or force of infection experienced 
within a herd.  Under most scenarios it appears the infection pressure associated with 
environmental sources of infection may exceed the pressure due to contagious sources for 
the ‘environmental’ streptococci including S. uberis.  This appears to be the case for S. 
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uberis infections in herd 1 as incidence of new S. uberis IMI appeared to be unrelated to 
prevalence, despite finding approximately 50% of quarters infected with the same strain 
in this herd.  An environmetal source of exposure would be predicted based on the high 
degree of S. uberis strain diversity observed in herd 2, however this appears to conflict 
with the observation that incidence was associated with prevalence in this herd, and that 
in the treatment group elimination of infections over a 3 month period eliminated new S. 
uberis IMI in the subsequent months.  It is unclear if other management factors may have 
played a role in this finding; however there were no observed changes in bedding 
management or environmental hygiene practices during the 13 months of the study on 
this farm.   
 
Conclusion 
 This study found no significant direct or indirect effect of subclinical treatment 
targeting S. uberis and S. dysgalactiae mastitis although the proportion of infected 
quarters that cured following 8-day treatment was similar to that of other studies where a 
significant effect was observed.  The observation that a large proportion of subclinical 
IMI that cured spontaneously during lactation in untreated cows contributed to the lack of 
a significant effect of treatment on the proportion of quarters that cured and the duration 
of infection.  In one herd, incidence of new S. uberis infections was associated with 
prevalence and new S. uberis IMI were eliminated following successful treatment of 
existing S. uberis IMI in one group of cattle, suggesting contagious S. uberis transmission 
may have been a factor in this population.  Antimicrobial susceptibility profiles 
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indicating erythromycin and pirlimycin resistance of pre-treatment S. uberis isolates was 
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The objective of this research was to explore the potential association between 
Coxiella burnetii shedding in milk and chronic subclinical mastitis in dairy cattle.  In two 
separate studies, we identified an association between PCR-based detection of C. burnetii 
in milk and chronic subclinical mastitis in lactating dairy cows.  These studies were 
conducted in a commercial dairy herd where there was ongoing intensive monitoring of 
subclinical mastitis by aerobic bacteriology, but no prior knowledge or management of C. 
burnetii infections.  In a case-control study, quarter level C. burnetii status determined by 
real-time quantitative PCR (RT-qPCR) was strongly associated with chronic subclinical 
mastitis as measured by milk somatic cell counts.  In a subsequent cross sectional study, 
147 (45%) of 325 lactating cows were positive for C. burnetii by RT-qPCR of composite 
milk samples.  In a generalized linear model, accounting for the effect of covariates 
including aerobic intramammary infection status, C. burnetii PCR status was a significant 
predictor of linear somatic cell count score. In agreement with a small number of 
previous reports, this research provides evidence that there may be mammary gland 










 Coxiella burnetii is an obligate intracellular zoonotic pathogen and the etiologic 
agent of Q fever in humans (Marrie and Raoult, 1997; Maurin and Raoult, 1999; 
McQuiston and Childs, 2002; Arricau-Bouvery and Rodolakis, 2005).  Domestic 
ruminants (cattle, sheep and goats) are described as the primary reservoir species for 
exposure of humans (Marrie and Raoult, 1997; Maurin and Raoult, 1999; McQuiston and 
Childs, 2002; Arricau-Bouvery and Rodolakis, 2005).  In dairy cattle C. burnetii 
infections may be under-recognized (McQuiston and Childs, 2002; McQuiston et al., 
2006) and there is incomplete understanding of infection dynamics and disease 
manifestations.  In the United States there are currently no approved C. burnetii 
veterinary diagnostic tests or vaccines, and no state or national coxiellosis surveillance or 
control programs for ruminant species, although recent publications have suggested that 
C. burnetii is enzootic in US dairy herds (McQuiston and Childs, 2002; Arricau-Bouvery 
and Rodolakis, 2005; Kim et al., 2005).  
C. burnetii infections of domestic ruminants are generally described as subclinical 
(i.e. asymptomatic) and persistent (Marrie and Raoult, 1997; Maurin and Raoult, 1999; 
McQuiston and Childs, 2002; Arricau-Bouvery and Rodolakis, 2005). Where clinical 
signs have been reported, they are most frequently described in sheep and goats and are 
related to reproductive disease (Maurin and Raoult, 1999; Arricau-Bouvery and 
Rodolakis, 2005; Arricau-Bouvery et al., 2005; Berri et al., 2005a; Berri et al., 2005b). 
Results of studies investigating the relationship between herd level seroprevalence and 
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reproductive health in dairy cattle are inconsistent (Literak and Kroupa, 1998; To et al., 
1998; Bildfell et al., 2000). In past studies, a major limitation may have been the reliance 
on serology to define C. burnetii infection status, as serology is poor indicator of active 
C. burnetii shedding in individual animals (Maurin and Raoult, 1999; Arricau-Bouvery 
and Rodolakis, 2005; Berri et al., 2005a; Berri et al., 2005b; Guatteo et al., 2006). 
Classically, confirmation of active infection in cattle required isolation of the organism 
either by laboratory animal or cell culture inoculation (Jellison et al., 1948; Bell et al., 
1949; Biberstein et al., 1974; Lorenz et al., 1998; Arricau-Bouvery and Rodolakis, 2005), 
and currently few laboratories carry out isolation due to legal limitations, risk of human 
exposure and lack of sensitivity of the technique (Maurin and Raoult, 1999; Arricau-
Bouvery and Rodolakis, 2005; Guatteo et al., 2006). A small number of recent studies 
have described PCR-based DNA detection to identify shedding of C. burnetii in 
ruminants, including dairy cattle with reproductive disorders (To et al., 1998; Berri et al., 
2005a; Berri et al., 2005b; Guatteo et al., 2006). 
While C. burnetii is shed for extended periods in the milk of dairy cattle, and has 
been shown to be immunogenic in dairy cattle, potential associations with clinical or 
subclinical mastitis have only rarely been examined (Jellison et al., 1948; Bell et al., 
1949; Biberstein et al., 1974; Marrie and Raoult, 1997; Maurin and Raoult, 1999; 
Arricau-Bouvery and Rodolakis, 2005).  In reviews of mastitis etiologies, most authors 
recognize the potential public health significance of C. burnetii excretion in milk without 
describing the organism as a cause of mastitis (Heidrich and Renk, 1967; Rebhun, 1995). 
Some reviews have included C. burnetii among ‘the lesser known organisms that may 
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cause mastitis’ (Philpot and Pankey, 1975), while others did not include the organism 
among a broad review of bacterial etiologic agents of mastitis (Watts, 1988).  In 1948 and 
1949 respectively, a case of chronic focal mastitis in a cow naturally infected with C. 
burnetii (Jellison et al., 1948), and severe acute mastitis following experimental 
intramammary inoculation of dairy cattle (Bell et al., 1949) were described. A more 
recent report suggested that the prevalence of C. burnetii infections was higher among 
dairy cattle with reproductive problems including mastitis (To et al., 1998).   
PCR has been described as the only veterinary diagnostic method to allow 
detection of specific C. burnetii clinical manifestations such as metritis and as the ‘most 
sensitive and rapid means to identify shedders’ (Arricau-Bouvery and Rodolakis, 2005).   
PCR has been used to identify shedding patterns of C. burnetii DNA in ruminant milk 
(Arricau-Bouvery and Rodolakis, 2005; Arricau-Bouvery et al., 2005; Berri et al., 2005b; 
Guatteo et al., 2006), although it is currently unclear whether shedding in milk is related 
to mammary specific manifestations of infection. 
 
 The objective of this work was to explore the potential association between C. 
burnetii detection in milk by RT-qPCR and chronic subclinical mastitis in a commercial 
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Materials and methods 
 
Herd description   
This study was conducted on a commercial dairy herd in north-central New York, 
USA. The study herd consisted of approximately 350 lactating Holstein cattle housed in a 
free-stall confinement barn and milked in a double-6 parallel-stall parlor.  Pregnant non-
lactating cows were housed in two group pens, and small groups (≤ 4cows) of 
periparturient cows were managed in a separate maternity pen with straw bedding 
cleaned regularly and replaced monthly. C. burnetii infection status of the herd was 
unknown prior to this study and there was no established surveillance or management 
targeting C. burnetii control. Sporadic and incidental metritis, infertility, and abortion 
events were recorded in the two years prior to this study, but no diagnostics of individual 
reproductive problems were completed, and no definitive causes of abortions were 
identified.  The herd was demonstrated to be free of intramammary infections caused by 
Streptococcus agalactiae and Mycoplasma spp. based on extensive individual cow and 
bulk tank milk cultures over the proceeding 13 months. 
 
Coxiella burnetii PCR      
 Prevalence of C. burnetii DNA sequence in milk was assayed by RT-qPCR of 
quarter or composite (all quarters within a cow) milk samples collected from individual 
cows using previously reported methods (Kim et al., 2005).   Briefly, DNA from milk 
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was isolated using the DNeasy Tissue kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions. Isolated DNA samples were tested using primers and a probe 
targeting the repetitive transposon-like region (1S1111a) of the C. burnetii genome 
(Hoover et al., 1992). Real-time PCR was performed with an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). Template DNA (5 µl) 
was added to a reaction mixture containing 0.3 µM each primer, 0.1 µM probe, 12.5 µl of 
TaqMan Universal PCR Master Mix (Applied Biosystems) in a final volume of 25 µl. 
The cycle profile of real-time PCR was as follows: 1 cycle of 95°C for 10 min and 40 
cycles of 95°C for 15 s and 60°C for 60s. A standard curve was constructed using a series 
of 10-fold dilutions of total genomic DNA (106 to 101 C. burnetii genome copies/ml) 
isolated from C. burnetii Nine Mile, phase II (RSA 493). DNase free water was used as 
the negative control (Hoover et al., 1992).  
 
Milk sampling, aerobic mastitis microbiology and somatic cell count analysis  
For three months prior to C. burnetii testing, monthly quarter milk samples were 
obtained aseptically for aerobic bacteriologic culture from all cows and held at 4 °C until 
processing for bacteriologic culture within 24 hours.  In addition, quarter milk samples 
from all cows at calving, dry-off, and all cases of clinical mastitis, including pre- and 
post-treatment were collected and held frozen at -20 °C for a maximum of two weeks 
until processing for bacteriologic culture.  Microbiological analysis of milk samples was 
conducted using established methods for identification of aerobic mastitis pathogens 
(Sears et al., 1993; Hogan et al., 1999).  Composite milk samples were obtained for 
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determination of milk somatic cell count (SCC) by electronic counting within 3 days 
prior to monthly sampling for bacteriology.   
 
Definitions   
Aerobic bacteriologic status of quarters was defined based on culture results from 
milk taken at the time of sampling for C. burnetii PCR. For cows and quarters where at 
least 3 months serial culture results were available, aerobic intramammary infection (A-
IMI) status was defined using definitions of Zadoks et al. (Zadoks et al., 2001a) with a 
slightly more restricted definition for uninfected quarters, which were defined as a 
quarters with no growth of a major mastitis pathogen on 3 of 3 consecutive samples, or 
no growth of a minor pathogen on at least 2 of 3 consecutive samples.  Major mastitis 
pathogens included isolation of Staphylococcus aureus, Streptococcus spp., 
Arcanobacterium pyogenes or coliform species, while minor mastitis pathogens were 
defined as coagulase negative staphylococci, or Corynebacterium species.  For analysis 
of the association between C. burnetii status and aerobic culture results, quarter level 
observations for aerobic culture were merged within cow to define a cow level aerobic 
bacteriologic or A-IMI status.   
Subclinical mastitis status was defined as an elevated milk somatic cell count 
(SCC) ≥200,000 cells/ml for a single monthly observation, where no clinical event was 
observed in the 14 days preceding or following the SCC test date. Chronic subclinical 
mastitis was defined as elevated SCC for at least 2 consecutive months.  All somatic cell 
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count measures were transformed to the industry standard logarithmic linear somatic cell 
count score (LSCS) for statistical analysis where LSCS = (ln(SCC/100)/0.693147)+3. 
 
 Study design and statistical analysis  
 Data were recorded in spreadsheet format (Microsoft Excel, Microsoft 
Corporation), and the data file was imported to a statistical software program for 
subsequent data management and analysis (SAS version 9.1, SAS Institute). Descriptive 
statistical analysis, including tests for normality, was completed for all variables (PROC 
UNIVARIATE or SAS/INSIGHT, SAS 9.1, SAS Institute Inc.).  Two separate studies 
were conducted.   
 
Study 1   
 A preliminary case-control study was conducted to explore the association 
between subclinical mastitis and C. burnetii shedding among A-IMI negative cows.  C. 
burnetii RT-qPCR status of quarter milk samples was compared for 39 quarter milk 
samples from 10 cows with culture negative chronic subclinical mastitis (SCC ≥ 200,000 
cells/ml and no major pathogen isolated for 2 consecutive months; cases) and 39 quarter 
milk samples from 10 cows with culture negative continuous low SCC (SCC < 200,000 
cells/ml and no major pathogen isolated for 2 consecutive months; controls). Case and 
control cows were matched on lactation number and days in milk.  The association 
between the number of Coxiella burnetii RT-qPCR (CbPCR) positive quarters within 
cows and cow level subclinical mastitis status was examined using contingency tables 
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and Cochran-Mantel-Haenszel statistics, with significance of association set at p<0.05.  A 
generalized linear model was used to test for differences in the mean average somatic cell 
count score among cows stratified by number of CbPCR positive quarters, with 
significance set at p<0.05. 
 
Study 2   
 Data from a cross sectional study of all lactating cows in the herd was used to test 
for an association between C. burnetii shedding in milk and subclinical mastitis in a 
series of hierarchical linear and logistic regression models (PROC MIXED and PROC 
GENMOD, SAS 9.1, SAS Institute Inc.) that included up to 7 individual predictors and 
any 2-way interaction significant at the p≤0.05 level.  The full linear regression model 
using the 3 month average LSCS (AVLS) as the outcome variable was AVLS = β0 + β1 
CbPCR + β2 A-IMI + β3 LACTGRP + β4 DIMCAT + β5 CLIN +  β6 MILK + β7 ME305 + βi Xi*βi 
Xi   + …., where CbPCR is C. burnetii infection status as measured by RT-qPCR, A-IMI is 
the aerobic bacterial intramammary infection status, LACTGRP is the lactation group 
number, DIMCAT is the days in milk category, MILK is the pounds of milk produced at 
the most recent test, ME305 is the predicted 305 day mature equivalent milk production, 
and CLIN is clinical mastitis status, of each individual cow.  A-IMI status was a 
categorical variable describing the pathogen specific infection status of the cow for 
common species and groups of mastitis pathogens (i.e. Staphylococcus aureus, 
Streptococcus spp., other major pathogens (OMP), coagulase negative Staphylococci 
(CNS), other minor pathogens (OTHMINOR), and aerobic culture negative samples 
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(NEG)).  Lactation group reflects the age of the cow and was a categorical variable with 
3 categories defined as lactation 1 (primiparous cows), lactation 2 (cows in second 
lactation), and lactation 3 or greater.  Days in milk is the number of days currently 
lactating, and 10 categories were defined by 30 day intervals from 1 day post partum to 
270 days, with the final category defined as ≥ 270 days in milk. Clinical status was a 
binary categorical variable defined as 1 for cows that had a clinical mastitis event in the 
14 days prior to or following milk sampling for RT-qPCR testing. Final model selection 
was based on goodness of fit tests including change in deviance observed for the two 
hierarchical models being compared, as well as comparison of Akaike’s information 
criteria (AIC) and Bayesian information criteria (BIC) fit statistics, with CbPCR forced 
into all models.  The potential association between C. burnetii shedding in milk and 
subclinical mastitis was also evaluated using logistic regression models developed in the 
same manner, but where the dependent variable was a binary variable defining a cow as 
having a persistent high SCC for 3 of 3 sequential test dates prior to CbPCR testing.  For 
all independent variables included in the final models, Pearson correlation coefficients 
and tests of multicollinearity were explored using the PROC CORR and PROC REG 
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Results 
 
Bacteriologic culture and somatic cell counts   
Quarter milk samples were collected for aerobic bacteriologic culture from 351 
cows. Three consecutive months of serial aerobic culture results were available to define 
A-IMI status for 222 cows, and one, two, and three months of SCC data were available 
for 195, 189, and 185 of these cows, respectively.  At the cow level, 21 cows had IMI 
caused by a major pathogen , 84 cows had IMI caused by a minor pathogen, and 23 cows 
had quarters with IMI caused by two pathogen types (mixed IMI) being predominately 
Streptococcus spp. plus either Corynebacterium spp. or coagulase negative staphylococci.  
 
Study one - Case-control study results   
There were 31 CbPCR positive and 8 CbPCR negative quarters among cows with 
culture negative chronic subclinical mastitis, and 11 CbPCR positive and 28 CbPCR 
negative quarters among culture negative cows with persistent low SCC.  Eight cows 
with chronic subclinical mastitis were CbPCR positive in all four quarters, and 2 cows 
with chronic subclinical mastitis were CbPCR negative in all four quarters.  In 
comparison, 5, 3, and 2 cows with persistent low SCC had 0, 3, and 4 CbPCR positive 
quarters, respectively. The number of CbPCR positive quarters within cows was 
positively associated with chronic subclinical mastitis status of cows (Cochran-Mantel-
Haenzel statistic p=0.0236, on two degrees of freedom).   The mean LSCS (s.d) of the 10 
cows with four CbPCR positive quarters was 4.82 (1.95), compared to means of 1.20 
(0.56) and 2.72 (2.23) for cows with 1 and 0 positive quarters respectively.   
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Study two – cross sectional survey results  
One-hundred-forty-seven (45%) of 325 cows tested were positive for C. burnetii 
and cows later in lactation at the time of testing were more likely to be found CbPCR 
positive (table 5.1).   
C. burnetii PCR status was a significant predictor of AVLS in all linear models 
regardless of number of covariates included. All covariates except ME305 were 
significant predictors of AVLS in multivariate models, and no 2-way interactions were 
significant or found to improve model fit.  Table 5.2 includes results of the final linear 
regression model indicating CbPCR was a significant predictor of somatic cell count after 
correcting for the effect of 5 significant covariates.  The mean somatic cell count of 
CbPCR positive cows was numerically higher than CbPCR negative cows regardless of 
infection status, but the difference was greatest among A-IMI negative cows (figure 5.1). 
For example, among cows with an A-IMI caused by S. aureus the 3 month average LSCS 
of CbPCR positive and negative cows were 5.93 and 5.33, respectively.  In comparison, 
the least squares mean 3 month average LSCS of A-IMI negative CbPCR positive cows 
was 4.25 compared to 2.51 for A-IMI negative CbPCR negative cows (figure 5.1).   The 
median somatic cell counts calculated from the raw data for CbPCR positive and negative 
cows with an IMI caused by a major mastitis pathogen were 762,000 and 528,000 cells   
per ml, respectively, and for CbPCR positive and negative cows with an A-IMI caused by 
a minor mastitis pathogen were 233,000 and 203,000 cells per ml, respectively.  In      
comparison, the median SCC of cows with no evidence of an intramammary infection 
caused by aerobic pathogens was 229,000 and 82,000 cells per ml, for CbPCR positive 
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Table 5.2  Parameter estimates for the multivariate model of the association between QPCR status and the 3 
month average linear somatic cell count score in 181 lactating dairy cattle.  
Model  AVLS = CbPCR + A-IMI + CLINICAL + DIMCAT + LACTGRP + MILK 
 
 
and negative cows, respectively. From the final multivariate logistic model, the odds of a 
chronic high cell count among CbPCR positive cows are 3.92 (95 % CI, 1.63 <OR<9.39) 
times that of CbPCR negative cows, after accounting for the effect of other variables.  In 
both linear and logistic multivariate models, CbPCR status was also a significant 
predictor of either AVLS or chronic subclinical mastitis when aerobic bacteriologic 
culture status (based on a single milk culture at the time of PCR testing) was substituted 
for A-IMI status (data not shown). Significant correlations were found between CbPCR 
status and DIMCAT (correlation coefficient = 0.255, p<0.001), MILK and DIMCAT (-
0.393, p<0.001), CLIN and MILK (-0.145, p=0.009), and A-IMI status and DIMCAT 
(0.138, p=0.049); all remaining correlation coefficients were < 0.08.  Further, no problem 
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of collinearity was identified as all variance inflation factor values were < 1.5, and the 





Figure 5.1  Least square mean 3 month average linear somatic cell count score for CbPCR positive and 
negative cows stratified by aerobic intramammary infection (A-IMI) status where A-IMI status was based 
on at least 3 monthly serial aerobic bacteriologic culture results (error bars indicate standard error, number 
above bars = number of cows, A-IMI categories defined in text). * Among cows that were defined as A-
IMI negative (n=73) the mean 3 month average LSCS of CbPCR positive cows was significantly greater 
(p=0.002) then that of CbPCR negative cows. 
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Discussion 
 
In comparison to previous studies suggesting C. burnetii is associated with bovine 
mastitis, a major strength of our studies is that they were conducted in a herd where there 
was ongoing intensive monitoring of subclinical mastitis infection dynamics. A key 
finding was that C. burnetii shedding in milk was associated with chronic subclinical 
mastitis in cows demonstrated to be free of infection caused by common aerobic mastitis 
pathogens.  This is in contrast to three previous reports of mastitis associated with C. 
burnetii infection that did not appear to investigate the possibility of mastitis caused by 
common aerobic mammary pathogens (Jellison et al., 1948; Bell et al., 1949; To et al., 
1998). Although we were able to account for the potential effect of bacterial mastitis 
pathogens identified by routine aerobic culture, we could not eliminate the possible role 
of other less common bacterial or viral pathogens that might be associated with 
subclinical mastitis (Philpot and Pankey, 1975; Watts, 1988; Wellenberg et al., 2002).  
Despite this limitation, our finding that A-IMI negative CbPCR positive cows had a 
median SCC of > 200,000 cells/ml compared to <100,000 cells/ml for A-IMI negative 
CbPCR negative cows is of particular interest from the perspective of mastitis control, as 
SCC is used as a diagnostic screening test in mastitis control programs (Sears et al., 
1993).  Further, the observation that the SCC of cows with both C. burnetii positive milk 
and A-IMI was increased relative to CbPCR negative A-IMI positive cows, suggests a 
possible effect of co-infection of C. burnetii and common mastitis pathogens, although 
the nature and clinical relevance of this potential interaction is unknown.  Other 
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associations observed in this study that warrant further analysis include the finding that 
CbPCR positive status increased with increasing days in milk.  Because the history and 
true prevalence of C. burnetii infections in this herd was unknown it is unclear how our 
observations may have been affected by duration of C. burnetii infection in the herd or 
individual animals.  Further, because the organism was not isolated and the strain type 
was not identified it is unknown if the mammary specific disease manifestations observed 
in this herd could have been influenced by the involved strain(s) (Arricau-Bouvery et al., 
2006). 
These studies were limited to PCR-based detection of C. burnetii DNA sequence 
in milk samples, so we are unable to speculate on the viability of organisms in milk of 
cows in this commercial herd, or on the sensitivity and specificity of the PCR relative to 
other diagnostic methods.  Current alternatives to diagnosis of C. burnetii infection in 
ruminants include serological analysis, organism isolation by either cell culture (e.g. shell 
vial culture) or live animal inoculation, immunohistochemical and PCR-based detection 
(Marrie and Raoult, 1997; Maurin and Raoult, 1999; Bildfell et al., 2000; Arricau-
Bouvery and Rodolakis, 2005).  Previous reports have demonstrated that viable 
organisms may be variably shed in the milk of dairy cattle for extended periods of greater 
then 1 year and across multiple lactations (Biberstein et al., 1974; Marrie and Raoult, 
1997; Arricau-Bouvery and Rodolakis, 2005), and that within a herd the proportion of 
cows shedding in milk may range from 15 to 62% (Biberstein et al., 1974; Guatteo et al., 
2006).  Our finding that 45% of cows in this commercial herd were CbPCR positive in 
milk samples is consistent with these previous reports. To the best of our knowledge, 
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only two studies have compared results of PCR detection of C. burnetii in milk with 
bacteria viability assays by mouse inoculation (To et al., 1998; Arricau-Bouvery et al., 
2005).  While these two studies demonstrate PCR positive milk samples contain viable 
organisms, additional studies are needed to determine how PCR based detection relates to 
the potential infectiousness of C. burnetii in milk samples, or the sensitivity and 
specificity of PCR relative to inoculation or antigen detection assays.  The ability to 
obtain such data is likely restricted to a relatively small number of research laboratories, 
as isolation must be conducted in biosafety-level 3 laboratories (Arricau-Bouvery and 
Rodolakis, 2005), and may be legally restricted in the United States where the organism 
is classified as a category B bioterrorism agent by Centers for Disease Control and 
Prevention (CDC).   
Coxiella burnetii infections of dairy cattle have received relatively little attention 
in North America (Bildfell et al., 2000). Shedding of the organism from other tissue sites 
and other potential disease manifestations were not explored in this herd. While our 
studies were limited to a single commercial dairy herd and focused on mammary specific 
detection of C. burnetii to evaluate a potential association with subclinical mastitis, the 
finding that C. burnetii PCR status in milk is associated with increased SCC, an 
economically important milk quality measure and diagnostic tool for mastitis control, 
suggests that additional research is justified to evaluate the consequences of C. burnetii 
infections in dairy cattle.  
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- Chapter 6 - 
 





The objective of this research was to evaluate the effects of lactation antibiotic 
therapy for the treatment of subclinical mastitis caused by the major gram-positive 
mastitis pathogens Staphylococcus aureus, Streptococcus uberis, and Streptococcus 
dysgalactiae.  This was addressed in a three-tiered approach that integrated a 
mathematical epidemiologic model, a randomly controlled clinical field trial, and 
molecular and microbiologic epidemiologic diagnostics. 
 
Through the development of a deterministic model of mastitis transmission 
dynamics it was predicted that lactation therapy of subclinical mastitis could have strong 
positive herd level effects by reducing the size of the infected pool and thus indirectly 
affecting the risk of new infections for contagious pathogens. These findings are 
consistent with established concepts of infectious disease transmission but are unique in 
that they demonstrate the effect of a targeted antibiotic based intervention applied at the 
level of the individual for mastitis control in a population.  Only a handful of studies have 
previously used predictive models to evaluate the impact of mastitis control interventions 
(Lam et al., 1996; Allore and Erb, 1999; White et al., 2001a; White et al., 2001b; White 
et al., 2002; Zadoks et al., 2002a; White et al., 2006), and none have modeled the impact 
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of a targeted intervention.  Similarly, in human infectious disease predictive models most 
interventions evaluated are applied broadly across a population (Anderson and May, 
1991; Halloran et al., 1991; Bonhoeffer et al., 1997; Pourbohloul et al., 2003).   
Perhaps the most interesting finding from the simulations was the prediction that 
under high transmission scenarios the indirect effect of therapy becomes negative and the 
overall effect of therapy approaches zero. In this model structure, successful treatment of 
an infected individual resulted in a state shift to the recovered susceptible state which, 
under high transmission scenarios quickly returns to the infected state. For many diseases 
where there is strong host immunity this would seem paradoxical.  However because 
there seems to be little protective effect of humoral immunity on risk of new mastitis 
infections for many pathogens including S. aureus and S. uberis, other host factors may 
govern the risk of infection. Therefore it is conceivable that a host that has been cured 
might be at increased susceptibility compared to previously uninfected animals that have 
been under the same level of exposure. For example, differences in host innate immunity 
may manifest as an a priori increased susceptibility which increases risk of infection for 
the life of that individual (Burvenich et al., 2004; Rainard and Riollet, 2006).  Also, 
physical differences in teat end shape or sphincter length may lead to heterogeneity of 
infection risk within a population (Lacy-Hulbert and Hillerton, 1995).  The assumption 
that drives the prediction of increased rates of infection from the recovered susceptible 
state is based on prior research demonstrating increased risk of new infections for 
quarters in the recovered susceptible state compared to the naïve susceptible state 
(Zadoks et al., 2002a).  These results were further supported by observations of 
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reinfections during the field trial described in chapter 3.  There are two practical 
implications that arise from these predictions.   First, producers and their advisors would 
be wise to address factors that affect mastitis transmission before adopting lactation 
therapy as a component of mastitis control. This is consistent with early 
recommendations (Dodd et al., 1969; Dodd and Neave, 1970; Kingwill et al., 1970; Dodd 
et al., 1977) and recent predictive models (White et al., 2006).  Second this highlights the 
potential value of culling as an important component of mastitis control (Dodd et al., 
1977). 
 Our research suggests that prior economic models might be reformulated to 
incorporate the apparent non-linear relationship between transmission rates and the 
indirect effect of lactation therapy. In economic models Swinkels et al. (Swinkels et al., 
2005a; Swinkels et al., 2005b) estimated the indirect effect of treatment as a constant 
function across two transmission scenarios.  Data from our current study would suggest 
the proportion of prevented infections associated with treatment is not constant, but a 
complex function of cure rates, transmission rates, and the difference in the force of 
infection for naïve susceptible and recovered susceptible quarters.   Our results suggest 
that there may be a range of transmission rates where the indirect effect of lactation 
therapy of subclinical mastitis may be positive; however in high transmission scenarios 
the indirect benefit of treating chronic subclinical mastitis may be limited, and the 
economic assumptions underlying previous models may not be constant. Additional 
research is needed to integrate our results into an economic model.   
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 Another consideration to include in the economic models of lactation therapy 
should be the pathogen specific impact of the diagnostic component.  Additional research 
is needed to evaluate the diagnostic component of targeted treatment for subclinical 
mastitis.  The hypothesis would be that S. aureus treatment based on serial cow level 
SCC results and a single bacteriologic culture would result in few false negative or 
inappropriate treatment delays (high sensitivity for identifying a true S. aureus IMI) and 
few false positive inappropriate treatments (high specificity for identifying true negative 
S. aureus IMI).  The risk of delayed treatment may be a reduced probability of cure, 
although false negative culture results in true S. aureus IMI appear to be infrequent 
enough that treatment would not be delayed for more than 1 to 2 months under a monthly 
surveillance system (Erskine and Eberhart, 1988; Sears et al., 1990).  The cost of these 
false negatives would be an increase in the number of cultures needed prior to initiating 
treatment. The costs of false positive S. aureus diagnoses may be greater as this would 
lead to an inappropriate use of antimicrobials and an inappropriate increase in amount of 
discarded milk. The data from a series of previous field trials, including the one in this 
research, could be pooled to evaluate the diagnostic criteria used in this study for 
identification of specific pathogens causing subclinical mastitis. Studies similar to this 
have been conducted for evaluation of the California mastitis test as a component of a 
mastitis treatment program (Wallace et al., 2004).  This may be especially important as 
managers of herds with bulk tank somatic cell counts in a moderately high to high range 
(e.g. > 250,000 cells/ml) may be considering lactation therapy as an adjunct to their 
current control practices and additional information on the use of sequential monthly 
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SCC results and bacteriologic culture is needed to implement such programs (Middleton 
et al., 2004). 
 A major limitation identified in this research and previously reported (Gillespie et 
al., 2002; Middleton and Luby, 2008)was the occurrence of new clinical or subclinical 
IMI due to coliform organisms following extended therapy.  This has been previously 
attributed to a number of non-host associated factors including introduction of pathogens 
during intramammary therapy, use of narrow-spectrum antimicrobials, poor 
environmental hygiene, and seasonal effects of increased heat and humidity.  Regardless 
of the cause, these infections severely impacted the response to therapy including the 
potential for a post-treatment reduction of SCC, and in a few cases resulted in the culling 
of a quarter or cow following treatment.  The risk of these post-treatment infections 
should be included in future economic models unless they can be prevented.  Strict 
attention to aseptic methods during infusion might significantly reduce the risk of these 
infections, however it is not clear that this is the only contributing factor.  Systemic 
therapy might be considered as an alternative to intramammary infusion and would 
eliminate either the possibility of iatrogenic cases due to contamination of infusion 
products or the constant manipulation and potential irritation of the teat end and canal.  
However, Sangren et al. (2008) reported the same number of new mastitis treatments 
following systemic or intramammary treatment of subclinical mastitis suggesting host or 
environmental factors may also affect the risk of post-treatment infections. 
 In this research host factors associated with bacteriologic cure following treatment 
of subclinical mastitis were not addressed but might be used to select cows for treatment 
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as has been previously suggested (Sol et al., 1997; Deluyker et al., 2005; Barkema et al., 
2006).  However, at a population level this would suggest that some infected cows would 
be left in the herd unless they are removed or segregated based on culture status.  
Selective lactation therapy is an alternative strategy that would need to be tested in 
epidemiologic and economic models as the indirect effect is likely to be reduced and  
may not off-set the reduced income associated with lost milk.   
 Pathogen factors associated with cure were examined in this research although 
they were limited to antimicrobial susceptibility testing.   Antimicrobial resistance 
appeared to be associated with strain type in the herds in this study for both S. aureus and 
S. uberis. An interesting finding was the difference in response to treatment seen for the 
resistant strains of the two species.  For S. uberis treatment failures were observed for 
100% (n=6) of the isolates expressing resistance in vitro, and resistance was restricted to 
5 of the 12 RAPD types tested.  In comparison, among S. aureus isolates, treatment 
success was observed for 89% (8/9) of isolates carrying beta-lactam resistance. In these 
isolates the phenotype was limited to penicillin and ampicillin resistance out of 8 classes 
of antimicrobials examined.  The lack of lincosamide and macrolide resistance in these 
isolates may explain treatment success, however it has been reported that penicillin 
resistance is a predictor for treatment failure to other classes of antimicrobials (Barkema 
et al., 2006).  For either pathogen, in vitro resistance may be associated with other 
virulence factors that limit probability of cure (Haveri et al., 2005; Dingwell et al., 2006).  
It is hypothesized that there is an association between strain type and carriage of 
resistance among bovine mastitis pathogens.  In the context of the broader hypothesis of 
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host-adapted and non-host-adapted strains of mastitis pathogens, a positive association 
between non-host-adapted strains and antimicrobial resistance gene carriage in S. aureus 
would explain observations of limited changes in the proportion of susceptible S. aureus 
mastitis isolates over the past decades (Erskine et al., 2002; Makovec and Ruegg, 2003). 
An association between strain-type and antimicrobial resistance may also explain the 
limited extent of differences in antimicrobial susceptibility of S. aureus on organic and 
conventional dairy farms (Tikofsky et al., 2003; Sato et al., 2004).  The resistant 
phenotypes and genotypes of isolates obtained in this study were restricted to 2 of 11 
PFGE types, consistent with other reports describing an association between PFGE type 
and susceptibility profiles (Anderson et al., 2006).  Further analysis of the isolates from 
this study indicate that the resistant isolates are limited to multilocus sequence types 
(MLST) 8, 25, and 87 (table 6.1).  ST 8 and 25 were found only on farm 2 and were 
associated with intramammary infections.  MLST type 8 caused 8 IMI in 8 quarters of 6 
cows, all of which cured following extended pirlimycin therapy. MLST type 25 was 
found in 1 quarter of 1 cow which did not cure immediately following therapy, but had 
cured by day 21 post-treatment.  On farm 1 a single isolate of MLST type 87 was 
obtained from a milk sample of a cow with no evidence of mastitis and was classified as 
an incidental isolation presumed to be a contaminant. This isolate expressed methicillin 
resistance and was positive on a mecA gene PCR.  These five strain types are unique 
among MLST types that have been isolated from dairy cattle and are not associated with 
bovine S. aureus clonal complexes but cluster with human clonal complexes. 
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Table 6.1 Frequency of Staphylococcus aureus strain types isolated from 2 dairy herds including pulsed-
field gel electrophoresis (PFGE) type and multilocus strain type (MLST) groupings. 
 
 
Further research appears justified to test the hypothesis that antimicrobial resistant S. 
aureus isolates associated with mastitis belong to human associated clonal complexes 
(non-host-adapted) while bovine mastitis isolates associated with host-adapted clonal 
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complexes have rarely acquired antimicrobial resistance.  These differences might be 
explained by differences in the ability of specific strains to acquire mobile genetic 
elements encoding resistance (Waldron and Lindsay, 2006; Sung and Lindsay, 2007), or 
may be related to the concept that there is no selective advantage for the acquisition of 
antimicrobial resistance genes among bovine host-adapted mastitis ecotypes. 
 In potential contrast, a unique finding of these studies was the unexpected high 
frequency of macrolide-lincosamide resistance among S. uberis isolates.  At the time 
these studies were initiated there was limted evidence of either erythromycin or 
pirlimycin resistance among streptococcal mastitis isolates, but in recent years an 
increase in the proportion of GPCN cocci expressing antimicrobial resistance has been 
observed (Erskine et al., 2002; Rossitto et al., 2002; Makovec and Ruegg, 2003; Loch et 
al., 2005; Schmitt-Van de Leemput and Zadoks, 2007).  To the best of our knowledge 
this is the first study that has shown a clear relationship between antimicrobial 
susceptibility to pirlimycin and treatment outcome for subclinical S. uberis mastitis. 
Previous studies that have no demonstrated no predictive relationship between 
antimicrobial susceptibility and treatment outcome for Streptococcus spp. have been 
limted to treatment of clinical mastitis and have either pooled results across all GPCN 
species (Hoe and Ruegg, 2005) or had included a limited number of resistant isolates 
(Constable and Morin, 2002). Further, we have identified a relationship between RAPD 
type and resistance phenotype.  Additional research is justified to explore the potential 
associations between S. uberis strain type, carriage of antimicrobial resistance genes, and 
response to treatment.  Further, data from these studies and that of Schmitt-Van de 
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leemput and Zadoks (2007) suggest that the disc diffusion breakpoints for pirlimycin 





This research provides data that may be used to inform decisions on the adoption 
of lactation therapy as a component of a mastitis control program. While there may be a 
number of individual herds that can successfully implement use of lactation therapy as a 
part of their mastitis control program, under current dairy herd management and 
economic conditions in North America it seems unwarranted to broadly recommend 
blanket adoption of this practice.   
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